Alcohol-Associated Liver Disease

Complex MONDO:0043693 Pathograph 21 Show in embeddings browser Hepatic Disease

Alcohol-associated liver disease (ALD) is a heterogeneous spectrum of liver injury associated with harmful alcohol use. Hepatic ethanol metabolism shifts redox balance and generates acetaldehyde and reactive oxygen species, while intestinal-barrier disruption exposes the liver to microbial products. These processes can produce steatosis and converge on hepatocyte and Kupffer-cell inflammatory injury, stellate-cell activation, extracellular-matrix deposition, fibrosis, cirrhosis, portal hypertension, and impaired liver function. Alcohol-associated hepatitis is an acute clinical phenotype that can arise on chronic liver disease; it is not an obligatory stage between steatosis and fibrosis. Sustained abstinence is central to long-term management, with integrated addiction treatment when alcohol use disorder is present.

Ask OpenScientist

Ask a research question about Alcohol-Associated Liver Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

11
Pathophys.
6
Phenotypes
4
Hypotheses
1
Gaps
21
Pathograph
1
Genes
3
Medical Actions
1
Datasets
29
References
4
Deep Research
1
Hyp. Reports
◈

Mechanistic Hypotheses

4
Canonical multi-hit alcohol-injury model
canonical_multihit_alcohol_injury CANONICAL
Evidence balance 1 support
Harmful alcohol exposure drives hepatic ethanol metabolism, redox and oxidative stress, lipid accumulation, and intestinal-barrier dysfunction. Hepatocyte stress and gut-derived endotoxin converge on inflammatory injury and, with persistent injury, stellate-cell activation and fibrosis.
Pathograph links
Chronic Ethanol Exposure -> Hepatic Ethanol Metabolism and Redox-Oxidative Stress DIRECT Hepatic ADH and inducible CYP2E1 oxidize ethanol to acetaldehyde while altering redox balance and generating reactive oxygen species.
Chronic Ethanol Exposure -> Intestinal Barrier Dysfunction and Endotoxin Translocation INDIRECT KNOWN INTERMEDIATES Chronic alcohol exposure promotes intestinal CYP2E1-dependent oxidative stress and barrier hyperpermeability, permitting microbial products to reach the portal circulation. Intermediates: Intestinal CYP2E1-dependent oxidative stress and tight-junction disruption
Hepatic Ethanol Metabolism and Redox-Oxidative Stress -> Hepatocyte Lipid Overload INDIRECT KNOWN INTERMEDIATES Increased NADH promotes fatty-acid synthesis and opposes fatty-acid oxidation, favoring triglyceride accumulation in hepatocytes. Intermediates: NADH-driven stimulation of fatty-acid synthesis and inhibition of fatty-acid oxidation
Hepatic Ethanol Metabolism and Redox-Oxidative Stress -> Lipotoxic and Oxidative Hepatocyte Stress DIRECT Acetaldehyde and CYP2E1-derived oxidants directly impair mitochondria, glutathione-dependent defenses, membranes, and cellular redox homeostasis.
Hepatocyte Lipid Overload -> Hepatic steatosis DIRECT Intracellular triglyceride and lipid-droplet accumulation manifests as hepatic steatosis.
Hepatocyte Lipid Overload -> Lipotoxic and Oxidative Hepatocyte Stress INDIRECT KNOWN INTERMEDIATES Excess fatty acids enter oxidative pathways that generate free radicals and lipid peroxidation, damaging hepatocyte membranes and cellular homeostasis. Intermediates: Fatty-acid-driven radical generation, lipid peroxidation, and membrane damage
Lipotoxic and Oxidative Hepatocyte Stress -> Kupffer-Cell and Hepatocyte Inflammatory Injury INDIRECT KNOWN INTERMEDIATES Oxidative and membrane injury produces inflammatory signals, while Kupffer-cell cytokines amplify hepatocyte injury. Intermediates: Damage-associated signaling and Kupffer-cell tumor-necrosis-factor production
Intestinal Barrier Dysfunction and Endotoxin Translocation -> Kupffer-Cell and Hepatocyte Inflammatory Injury INDIRECT KNOWN INTERMEDIATES Portal endotoxin activates hepatic TLR4-dependent signaling in Kupffer cells and other liver cells, increasing inflammatory mediators and liver injury. Intermediates: Hepatic TLR4-dependent, MyD88-independent inflammatory signaling
Kupffer-Cell and Hepatocyte Inflammatory Injury -> Alcohol-associated hepatitis INDIRECT UNKNOWN INTERMEDIATES Severe inflammatory hepatocellular injury can present clinically as rapidly worsening jaundice and acute-on-chronic liver failure, but AH is not an obligatory stage in every ALD trajectory.
Kupffer-Cell and Hepatocyte Inflammatory Injury -> Hepatic Stellate Cell Activation INDIRECT KNOWN INTERMEDIATES Persistent inflammatory and oxidative signals activate TGF-beta and other profibrotic pathways that transform quiescent stellate cells into matrix-producing myofibroblasts. Intermediates: TGF-beta, reactive-oxygen-species, PDGF, and CTGF signaling
Hepatic Stellate Cell Activation -> Excessive Hepatic Extracellular Matrix Deposition DIRECT Activated HSC-derived myofibroblasts synthesize collagen and other scar-matrix proteins.
Excessive Hepatic Extracellular Matrix Deposition -> Hepatic fibrosis DIRECT Accumulated fibrillar scar matrix manifests as hepatic fibrosis.
Excessive Hepatic Extracellular Matrix Deposition -> Cirrhotic Architectural Distortion and Functional Failure INDIRECT KNOWN INTERMEDIATES Persistent matrix deposition and scar remodeling distort hepatic architecture, alter sinusoidal flow, and progressively impair organ function. Intermediates: Bridging fibrosis, regenerative nodules, vascular remodeling, and sinusoidal resistance
Cirrhotic Architectural Distortion and Functional Failure -> Cirrhosis DIRECT Advanced architectural distortion and nodular remodeling manifest clinically as cirrhosis.
Cirrhotic Architectural Distortion and Functional Failure -> Portal hypertension INDIRECT KNOWN INTERMEDIATES Fibrotic and vascular architectural remodeling increases intrahepatic resistance and portal pressure. Intermediates: Increased intrahepatic vascular resistance and portal pressure
Cirrhotic Architectural Distortion and Functional Failure -> Decreased liver function INDIRECT KNOWN INTERMEDIATES Loss of functional parenchyma and distorted hepatic architecture impair liver function. Intermediates: Reduced functional hepatocyte mass and disrupted hepatic perfusion
Show evidence (1 reference)
PMID:39362713 SUPPORT Other
"Alcohol metabolism, cellular stress, and gut-derived factors contribute to hepatocyte and immune cell injury leading to cytokine and chemokine production."
This review summarizes the convergent intracellular, hepatic, and extrahepatic components of the canonical ALD mechanism.
LSEC CYP2E1-Hsp90-eNOS dysfunction axis
lsec_hsp90_enos_axis EMERGING
Evidence balance 1 support
Liver sinusoidal endothelial-cell ethanol metabolism may reduce nitric-oxide production through CYP2E1-dependent Hsp90 acetylation and impaired Hsp90-eNOS interaction. The evidence is primarily cellular and mouse-model based, so this axis is modeled as an emerging amplifier rather than an established universal driver in human ALD.
Pathograph links
Hepatic Ethanol Metabolism and Redox-Oxidative Stress -> Liver Sinusoidal Endothelial Dysfunction DIRECT CYP2E1-dependent ethanol metabolism in LSECs increases Hsp90 acetylation, weakens Hsp90-eNOS interaction, and decreases nitric-oxide production.
Liver Sinusoidal Endothelial Dysfunction -> Kupffer-Cell and Hepatocyte Inflammatory Injury INDIRECT UNKNOWN INTERMEDIATES Reduced endothelial nitric-oxide signaling may amplify hepatic injury and inflammatory crosstalk, but the omitted human intermediates are not yet resolved.
Show evidence (1 reference)
PMID:33675874 SUPPORT Model Organism
"AAV8-driven HDAC6 overexpression specifically in liver ECs deacetylated Hsp90, restored Hsp90's interaction with eNOS and ameliorated alcohol-induced liver injury in mice."
Rescue of the proposed endothelial axis in ethanol-fed mice supports the mechanism while defining its preclinical evidence boundary.
PNPLA3-alcohol gene-environment susceptibility
pnpla3_gene_environment_susceptibility EMERGING
Evidence balance 1 support
PNPLA3 rs738409 is a robust susceptibility locus for alcohol-related cirrhosis, and alcohol exposure amplifies its disease association. The molecular route between this gene-environment interaction and advanced disease is not resolved well enough to treat PNPLA3 as a direct lipid-overload mechanism.
Pathograph links
Chronic Ethanol Exposure -> PNPLA3-Linked Gene-Environment Susceptibility INDIRECT UNKNOWN INTERMEDIATES Alcohol exposure amplifies the liver-disease association of PNPLA3 rs738409, although the molecular intermediates and stage specificity remain unresolved.
PNPLA3-Linked Gene-Environment Susceptibility -> Cirrhotic Architectural Distortion and Functional Failure INDIRECT UNKNOWN INTERMEDIATES PNPLA3 rs738409 increases susceptibility to alcohol-related cirrhosis, but the molecular path from the locus to advanced architectural disease is unresolved.
Show evidence (1 reference)
PMID:39679853 SUPPORT Other
"The PNPLA3 rs738409 variant stands as a paradigmatic example of gene-environment interaction, where its effect on liver disease is dramatically amplified by alcohol consumption, obesity and type 2 diabetes."
This review supports a gene-environment susceptibility overlay while leaving its causal intermediates explicitly unresolved.
Baijiu-extract microbiota-lactate mediation model
baijiu_extract_microbiota_lactate_mediation_model EMERGING
Evidence balance 3 support
In the specific ethanol-exposed mouse model studied, one or more non-ethanol Baijiu constituents may reduce liver injury primarily by changing intestinal microbial function, lowering gut-derived lactate flux, and thereby improving hepatic redox balance and oxidative stress. Whole-extract treatment changed microbial composition, lactate, hepatic NADH/NAD+ balance, and injury concurrently, while lactate worsened oxidative stress in cultured cells. Candidate constituents were identified in the extract by GC-MS, but no individual constituent or combination was causally assigned to protection. These observations do not establish a Ligilactobacillus strain as the relevant lactate source or prove mediation. Other alcohol-fed mouse models show strain- and model-dependent Lactobacillaceae effects, while severe human ALD data associate circulating lactate with prognosis without establishing its source or causal direction. None of these findings supports a protective effect of Baijiu in humans.
Deep research
OpenScientist citations 19 citations 2026-07-26T05:31:55.730715
Show evidence (3 references)
PMID:42300615 SUPPORT Model Organism
"Concurrently, they remodeled the gut microbial structure, restored the Firmicutes/Bacteroidetes (F/B) ratio, inhibited the abnormal proliferation of g_Ligilactobacillus, and reduced lactate production."
The mouse study links whole-extract exposure to concurrent microbiota and lactate changes, but does not establish that either change mediates hepatic protection.
PMID:42300615 SUPPORT In Vitro
"Cellular experiments confirmed that excessive lactate exacerbated oxidative stress."
The cell assay supports lactate as a sufficient oxidative-stress amplifier, but not its microbial source, in-vivo flux, or necessity for extract-mediated protection.
PMID:42300615 SUPPORT Other
"multiple active chemical constituents were identified in this extract via GC-MS."
GC-MS nominates chemical candidates in the extract, but does not causally assign the whole-extract protection to an individual constituent or combination.
?

Discussions and Knowledge Gaps

1
Which of the GC-MS-identified candidate non-ethanol Baijiu constituents, or which combination, accounts for the protection observed in ethanol-exposed mice, and is that protection mediated by a species-resolved microbial lactate route, an intrahepatic glycolytic-lactate route, a lactate-independent intestinal-barrier/endotoxin route, a microbial tryptophan-metabolite/AhR route, a direct hepatic effect, or a combination of these routes?
KNOWLEDGE GAP OPEN gap_baijiu_nonethanol_active_constituent_and_mediation
Attached to
mechanistic_hypotheses#baijiu_extract_microbiota_lactate_mediation_model pathophysiology#Hepatic Ethanol Metabolism and Redox-Oxidative Stress pathophysiology#Intestinal Barrier Dysfunction and Endotoxin Translocation pathophysiology#Kupffer-Cell and Hepatocyte Inflammatory Injury
The source study compared a chemically complex non-ethanol extract with ethanol and measured microbiota composition, metabolites, redox markers, and liver injury concurrently. GC-MS identified candidate constituents, but those candidates were not individually or combinatorially perturbed to assign the whole-extract effect. The co-moving endpoints also do not establish causal order, and co-moving permeability, endotoxin, and inflammatory endpoints alone cannot establish barrier-pathway mediation. Genus-level 16S data and the Firmicutes/Bacteroidetes ratio cannot show that the expanded Ligilactobacillus population produced the lactate reaching the liver, while the cell assay shows only that excess lactate can worsen oxidative stress. A separate chronic liquor-fed mouse study found alcohol-associated depletion of broad Lactobacillus and Bifidobacterium populations and protection after Lactiplantibacillus plantarum treatment, so taxon direction is strain- and model-dependent rather than a general refutation or validation of the Ligilactobacillus observation. A causal pectin study in human-microbiota-associated alcohol-fed mice associated higher bacterial tryptophan-metabolite production with improvement and causally implicated AhR signaling: an AhR agonist reduced injury and Ahr loss abolished the prebiotic benefit. This competing route was not measured in the seed study. In severe human alcohol-related acute-on-chronic liver failure, serum lactate predicts mortality but does not establish a microbial source or causal direction. Even if lactate contributes, hepatocyte-derived glycolytic lactate rather than gut-derived flux could explain the hepatic signal. A changed community could instead protect through intestinal-barrier integrity, reduced portal endotoxin, and lower hepatic TLR4/Kupffer-cell activation without lactate mediation. Moreover, complete microbiota removal can itself alter ethanol metabolism and worsen acute liver injury in mice, so a global depletion comparison would not isolate either microbial route. Independent in-vivo and hepatocyte fraction screens, species- and strain-resolved transfer, pathway-specific readouts for endotoxin/TLR4 and tryptophan-metabolite/AhR alternatives, source-resolved metabolic tracing, and controlled rescue and pathway-interaction experiments are needed before this model-specific signal can be added to the causal graph. Two subsequent non-ALD mouse studies now directly demonstrate a gut-to-portal-vein-to-liver D-lactate route that the seed study could not establish on its own: commensal-derived D-lactate reaching the liver via the portal vein programs Kupffer-cell-mediated pathogen clearance in a sepsis model, and gut microbiota is reported as the dominant source of circulating D-lactate that raises hepatic glycogen, triglycerides, and inflammation in obese mice with fatty liver disease. Both studies overturn the narrow claim that no gut-to-liver lactate route has been shown, but neither exposes ethanol, tests the Baijiu extract, or resolves whether the (R)-lactate (D-lactate) or (S)-lactate (L-lactate) stereoisomer is the species reaching the liver in the ethanol-exposed model; they sharpen rather than validate the microbiota-lactate hypothesis and should be read as external plausibility for a route, not as evidence for this intervention. A distinct finding in a direct alcohol-associated liver disease mouse model complicates rather than supports the microbiota-lactate model: ethyl lactate, a lactate ester and non-ethanol distilled-liquor ingredient chemically distinct from free D- or L-lactate, ameliorates ethanol-induced hepatosteatosis and acute-on-chronic injury through hepatocyte SIRT1-FGF21 signaling, independent of any demonstrated microbial lactate flux; this ester must not be conflated with the microbial-lactate route and is itself a plausible, mechanistically direct candidate among the seed study's GC-MS-identified constituents. A separate Baijiu-versus-ethanol comparison in mice adds a further competing route: a non-alcoholic Baijiu-compound formula attenuated ethanol-induced liver injury and intestinal barrier leakage by opposing deoxycholic-acid-driven barrier disruption, implicating bile-acid signaling alongside the tryptophan-metabolite/AhR pathway already noted above (deoxycholic acid/deoxycholate should not be confused with the unrelated drug dichloroacetate, which shares the same DCA abbreviation). The finding does not establish that Baijiu is safer than other alcohol exposure or protective in humans.
Proposed experiments
Bioassay-guided fractionation with gnotobiotic pathway mediation testing
bioassay-guided fractionation and gnotobiotic mediation experiment Relation: this experiment is of type this experiment type This experiment is of type bioassay-guided fractionation and gnotobiotic mediation experiment.
exp_baijiu_fraction_gnotobiotic_pathway_mediation
Fractionate the study's non-ethanol extract and run two independent bioactivity screens: an ethanol-dose-matched, isocaloric, pair-fed mouse screen for in-vivo protection and microbial/barrier effects, and a primary hepatocyte screen for microbiota-independent direct effects. Advance every reproducibly in-vivo-active fraction into conventional and gnotobiotic pathway testing regardless of its hepatocyte result; retain hepatocyte-active fractions separately as direct-effect candidates. In gnotobiotic recipients colonized with microbiota from ethanol-only or fraction-treated donors, resolve the Ligilactobacillus signal to cultured species and strains, quantify lactate production, and compare reconstitution with the wild-type isolate versus a lactate-production-deficient derivative. Use stable-isotope tracing and lactate add-back to test the lactate route, alongside intestinal permeability, portal endotoxin, tight-junction, and hepatic TLR4/Kupffer-cell measurements for a lactate-independent barrier route. For the barrier route, restore the portal lipopolysaccharide exposure of protected mice to the ethanol-only range without changing lactate, and cross the fraction or community intervention with Kupffer-cell-specific Tlr4 loss or validated Kupffer-targeted TLR4 inhibition to test phenocopy, occlusion, and add-back interaction. In parallel, quantify microbial tryptophan metabolites and AhR target engagement, then use AhR inhibition and agonist rescue to test whether this competing microbial-metabolite pathway is necessary or sufficient. Throughout, quantify D-lactate and L-lactate separately by chiral chromatography in intestinal contents, portal blood, systemic blood, and liver rather than assuming a single achiral lactate pool. Add a parallel arm testing the distinct non-ethanol constituent ethyl lactate against equimolar free D-/L-lactate, with SIRT1 inhibition and hepatocyte-specific Fgf21 loss, to isolate this ester-specific direct-hepatic route from microbial lactate flux. Add a further arm restoring deoxycholic acid in protected animals to the ethanol-only range to test a bile-acid/barrier route distinct from lipopolysaccharide-driven endotoxin signaling. Measure ethanol pharmacokinetics in every arm.
Model systems
Ethanol-exposed conventional and gnotobiotic C57BL/6J mice
Pair-fed female and male mice receiving identical ethanol doses, with defined donor communities or strain-level reconstitution in gnotobiotic recipients.
OTHER
mouse NCBITaxon:10090 NCBI Taxonomy (NCBITaxon) Relation: this experimental model is built in this organism This experimental model is built in mouse, annotated with Mus musculus (NCBITaxon:10090). NCBITaxon:10090 is an organism from the NCBI Taxonomy.
Primary mouse hepatocyte direct-effect assay
Primary hepatocytes exposed to matched ethanol and extract fractions, with or without lactate, to test protection that does not require a microbial community.
PRIMARY CELL CULTURE
mouse NCBITaxon:10090 NCBI Taxonomy (NCBITaxon) Relation: this experimental model is built in this organism This experimental model is built in mouse, annotated with Mus musculus (NCBITaxon:10090). NCBITaxon:10090 is an organism from the NCBI Taxonomy.
hepatocyte CL:0000182 Cell Ontology (CL) Relation: this experimental model uses this cell type This experimental model uses hepatocyte (CL:0000182). CL:0000182 is a cell type from the Cell Ontology.
Perturbations
Chemically defined non-ethanol extract fractions
pathophysiology#Hepatic Ethanol Metabolism and Redox-Oxidative Stress
Compare the whole extract, orthogonal chemical fractions, and identified constituent combinations at exposure-matched doses.
Donor-community transfer and Ligilactobacillus strain reconstitution
lactate biosynthetic process
Transfer complete donor communities, then add a cultured candidate Ligilactobacillus strain or a lactate-production-deficient derivative to test strain and metabolic-function dependence.
lactate biosynthetic process GO:0019249 Gene Ontology (GO) Relation: this perturbation acts on this biological process This perturbation acts on lactate biosynthetic process (GO:0019249). GO:0019249 is a biological process from the Gene Ontology.
Stable-isotope lactate tracing and lactate add-back
pathophysiology#Lipotoxic and Oxidative Hepatocyte Stress
Trace intestinal-to-portal-to-hepatic lactate flux with stereospecific (chiral) separation of D-lactate from L-lactate, and restore each stereoisomer's exposure separately in protected animals to test whether lowering a specific stereoisomer, rather than total lactate, is necessary for protection.
lactate CHEBI:24996 Chemical Entities of Biological Interest (CHEBI) Relation: this perturbation uses this chemical entity This perturbation uses lactate (CHEBI:24996). CHEBI:24996 is a chemical entity from Chemical Entities of Biological Interest. D-lactate CHEBI:16004 Chemical Entities of Biological Interest (CHEBI) Relation: this perturbation uses this chemical entity This perturbation uses D-lactate, annotated with (R)-lactate (CHEBI:16004). CHEBI:16004 is a chemical entity from Chemical Entities of Biological Interest. L-lactate CHEBI:16651 Chemical Entities of Biological Interest (CHEBI) Relation: this perturbation uses this chemical entity This perturbation uses L-lactate, annotated with (S)-lactate (CHEBI:16651). CHEBI:16651 is a chemical entity from Chemical Entities of Biological Interest.
Controlled portal-endotoxin add-back
pathophysiology#Intestinal Barrier Dysfunction and Endotoxin Translocation
In the protected fraction or donor-community arm, use titrated low-dose mesenteric-vein infusion of ultrapure lipopolysaccharide to restore the portal endotoxin time course and exposure to the ethanol-only range without exceeding its systemic endotoxin exposure, while confirming unchanged species-resolved lactate flux, ethanol pharmacokinetics, and community composition. This bypass rescue tests whether reduced hepatic endotoxin exposure is necessary for protection rather than merely co-moving with it.
lipopolysaccharide CHEBI:16412 Chemical Entities of Biological Interest (CHEBI) Relation: this perturbation uses this chemical entity This perturbation uses lipopolysaccharide (CHEBI:16412). CHEBI:16412 is a chemical entity from Chemical Entities of Biological Interest.
Kupffer-cell TLR4 pathway interaction
pathophysiology#Kupffer-Cell and Hepatocyte Inflammatory Injury
Cross ethanol-only and protected fraction or donor-community arms with lineage-validated Kupffer-cell-specific Tlr4 loss or a validated Kupffer-targeted TLR4 inhibitor. Test whether pathway blockade phenocopies protection in ethanol-only mice, occludes additional protection by the fraction or community, and prevents portal-endotoxin add-back from restoring hepatic inflammation and injury.
AhR pathway necessity and sufficiency
aryl hydrocarbon receptor signaling
Cross ethanol-only and protected fraction or donor-community arms with Ahr-deficient recipients or a validated AhR antagonist, and administer the AhR agonist FICZ in a matched ethanol-only arm. Test whether AhR loss or inhibition abolishes protection and whether agonism phenocopies and occludes the fraction or community effect.
Ethyl lactate SIRT1-FGF21 pathway testing
pathophysiology#Lipotoxic and Oxidative Hepatocyte Stress
Administer purified ethyl lactate, at doses matched to its concentration in the whole extract, against equimolar free D-/L-lactate in ethanol-fed mice, with SIRT1 inhibition (EX527) and hepatocyte-specific Fgf21 loss in parallel arms. Tests whether the seed extract's activity depends on this distinct, microbiota-independent ester rather than on microbial lactate flux.
ethyl lactate CHEBI:78321 Chemical Entities of Biological Interest (CHEBI) Relation: this perturbation uses this chemical entity This perturbation uses ethyl lactate, annotated with ethyl 2-hydroxypropanoate (CHEBI:78321). CHEBI:78321 is a chemical entity from Chemical Entities of Biological Interest.
Deoxycholate-dependent intestinal barrier testing
pathophysiology#Intestinal Barrier Dysfunction and Endotoxin Translocation
Compare exogenous deoxycholic-acid supplementation with a non-alcoholic Baijiu-compound formula in ethanol-fed mice to test whether extract protection acts by suppressing deoxycholic-acid-driven barrier disruption, distinct from the lipopolysaccharide/TLR4 and lactate routes tested above.
deoxycholic acid CHEBI:28834 Chemical Entities of Biological Interest (CHEBI) Relation: this perturbation uses this chemical entity This perturbation uses deoxycholic acid (CHEBI:28834). CHEBI:28834 is a chemical entity from Chemical Entities of Biological Interest.
Readouts
Species-resolved microbial lactate flux
lactate biosynthetic process
Shotgun metagenomics, isolate genomics, and isotope-resolved fecal, portal, and hepatic lactate quantify the organism and metabolic flux rather than relying on a genus abundance or phylum ratio. Chiral separation resolves D-lactate from L-lactate at each site so that a stereospecific route is not collapsed into a single achiral pool.
lactate biosynthetic process GO:0019249 Gene Ontology (GO) Relation: this readout reports on this biological process This readout reports on lactate biosynthetic process (GO:0019249). GO:0019249 is a biological process from the Gene Ontology.
shotgun metagenomic sequencing Relation: this readout is measured by this assay This readout is measured by shotgun metagenomic sequencing. targeted metabolomics Relation: this readout is measured by this assay This readout is measured by targeted metabolomics. stable-isotope metabolic flux analysis Relation: this readout is measured by this assay This readout is measured by stable-isotope metabolic flux analysis. chiral chromatography Relation: this readout is measured by this assay This readout is measured by chiral chromatography.
Direction: POSITIVE
Intestinal permeability and portal endotoxin
pathophysiology#Intestinal Barrier Dysfunction and Endotoxin Translocation
Serial FITC-dextran permeability and portal endotoxin measurements quantify barrier failure and microbial-product translocation independently of lactate and determine whether barrier improvement precedes hepatic pathway and injury changes.
FITC-dextran intestinal permeability assay Relation: this readout is measured by this assay This readout is measured by FITC-dextran intestinal permeability assay. portal endotoxin assay Relation: this readout is measured by this assay This readout is measured by portal endotoxin assay.
Direction: POSITIVE
Intestinal tight-junction integrity
pathophysiology#Intestinal Barrier Dysfunction and Endotoxin Translocation
Intestinal epithelial ZO-1, occludin, and claudin localization and abundance provide an inverse readout of barrier dysfunction.
tight-junction protein immunostaining Relation: this readout is measured by this assay This readout is measured by tight-junction protein immunostaining. tight-junction protein quantification Relation: this readout is measured by this assay This readout is measured by tight-junction protein quantification.
Direction: NEGATIVE
Hepatic TLR4 and Kupffer-cell activation
pathophysiology#Kupffer-Cell and Hepatocyte Inflammatory Injury
Time-resolved hepatic TLR4-pathway activity, Kupffer-cell activation, and inflammatory cytokines test the sequence and interaction of a lactate-independent endotoxin route from community remodeling to liver injury.
hepatic TLR4 signaling assay Relation: this readout is measured by this assay This readout is measured by hepatic TLR4 signaling assay. Kupffer-cell activation assay Relation: this readout is measured by this assay This readout is measured by Kupffer-cell activation assay. inflammatory cytokine quantification Relation: this readout is measured by this assay This readout is measured by inflammatory cytokine quantification.
Direction: POSITIVE
Microbial tryptophan metabolites and AhR target engagement
aryl hydrocarbon receptor signaling
Time-resolved fecal, portal, and hepatic tryptophan and indole metabolite profiles, together with intestinal and hepatic AhR reporter activity and Cyp1a1 and Nqo1 expression, test a causal microbial-metabolite route independently of lactate and endotoxin.
targeted metabolomics Relation: this readout is measured by this assay This readout is measured by targeted metabolomics. AhR reporter assay Relation: this readout is measured by this assay This readout is measured by AhR reporter assay. gene expression assay Relation: this readout is measured by this assay This readout is measured by gene expression assay.
Direction: POSITIVE
Hepatic reductive redox shift and oxidative damage
pathophysiology#Hepatic Ethanol Metabolism and Redox-Oxidative Stress
Hepatic NADH/NAD+ ratio and MDA are measured before and after microbiota transfer, strain reconstitution, and lactate add-back.
NADH to NAD+ ratio assay Relation: this readout is measured by this assay This readout is measured by NADH to NAD+ ratio assay. lipid peroxidation assay Relation: this readout is measured by this assay This readout is measured by lipid peroxidation assay.
Direction: POSITIVE
Hepatic antioxidant capacity
pathophysiology#Hepatic Ethanol Metabolism and Redox-Oxidative Stress
SOD2 activity and the reduced-to-oxidized glutathione ratio provide inverse readouts of oxidative stress without bundling their direction with NADH/NAD+ and MDA.
antioxidant enzyme activity assay Relation: this readout is measured by this assay This readout is measured by antioxidant enzyme activity assay. glutathione redox ratio assay Relation: this readout is measured by this assay This readout is measured by glutathione redox ratio assay.
Direction: NEGATIVE
Hepatic injury and steatosis
pathophysiology#Lipotoxic and Oxidative Hepatocyte Stress
Blinded histopathology, hepatic triglycerides, serum ALT and AST, and inflammatory markers establish whether a change in lactate flux precedes and mediates tissue protection.
liver histopathology Relation: this readout is measured by this assay This readout is measured by liver histopathology. serum aminotransferase assay Relation: this readout is measured by this assay This readout is measured by serum aminotransferase assay. hepatic triglyceride assay Relation: this readout is measured by this assay This readout is measured by hepatic triglyceride assay.
Direction: POSITIVE
Hepatic SIRT1-FGF21 pathway activity
pathophysiology#Lipotoxic and Oxidative Hepatocyte Stress
Hepatic SIRT1 activity and serum/hepatic FGF21 induction test whether an ester-specific, microbiota-independent route accounts for protection when ethyl lactate is isolated from the whole extract.
fibroblast growth factor receptor signaling pathway GO:0008543 Gene Ontology (GO) Relation: this readout reports on this biological process This readout reports on fibroblast growth factor receptor signaling pathway (GO:0008543). GO:0008543 is a biological process from the Gene Ontology.
sirtuin activity assay Relation: this readout is measured by this assay This readout is measured by sirtuin activity assay. enzyme-linked immunosorbent assay Relation: this readout is measured by this assay This readout is measured by enzyme-linked immunosorbent assay. gene expression assay Relation: this readout is measured by this assay This readout is measured by gene expression assay.
Direction: POSITIVE
Serum and hepatic bile acid profiling
pathophysiology#Intestinal Barrier Dysfunction and Endotoxin Translocation
Targeted bile-acid metabolomics quantifying deoxycholic acid and related secondary bile acids tests whether the extract or its fractions blunt ethanol-induced bile-acid elevation ahead of barrier and injury improvement.
targeted metabolomics Relation: this readout is measured by this assay This readout is measured by targeted metabolomics.
Direction: POSITIVE
Controls
Ethanol-only and vehicle controls
Isocaloric pair-fed controls receiving identical ethanol doses, plus a non-ethanol vehicle or matrix control for every fraction.
Community, strain, and metabolite rescue controls
Reciprocal donor-community transfers, heat-killed strain controls, wild-type versus lactate-deficient strain reconstitution, and osmolality- and pH-matched lactate vehicle controls.
Ethanol pharmacokinetic control
Serial blood ethanol and acetaldehyde measurements to exclude altered ethanol absorption or clearance as the explanation for reduced injury.
Portal-endotoxin add-back controls
Compare protected animals receiving exposure-matched lipopolysaccharide with protected vehicle-infused, ethanol-only vehicle-infused, and pair-fed sham-procedure controls. Verify the portal and systemic endotoxin time courses and confirm that add-back does not alter lactate flux, community composition, or ethanol and acetaldehyde exposure.
Kupffer-cell TLR4 interaction controls
Use Cre-negative Tlr4-floxed littermates and validate Kupffer-cell targeting and TLR4 loss; for a pharmacologic replication, include matched inhibitor vehicle and target-engagement controls. Apply the same fraction, community, endotoxin-add-back, and pair-feeding assignments across TLR4-intact and TLR4-blocked groups.
AhR pathway interaction controls
Use matched AhR-competent littermates, antagonist and agonist vehicle controls, equivalent donor-community engraftment, and intestinal and hepatic target-engagement measurements. Confirm that AhR perturbation does not change ethanol or acetaldehyde exposure.
Ethyl lactate and bile-acid pathway interaction controls
Include dose-matched free D-/L-lactate and ester-vehicle controls for the ethyl lactate arm, EX527 vehicle and hepatocyte-specific Fgf21-intact littermates for the SIRT1-FGF21 cross, and deoxycholic-acid vehicle plus Baijiu-compound-formula-vehicle controls for the bile-acid arm. Confirm none of these perturbations alter ethanol or acetaldehyde exposure or species-resolved lactate flux.
Decision criterion
The microbiota-lactate model is supported only if a chemically defined fraction lowers species- and strain-resolved microbial lactate flux before hepatic improvement, the donor community transfers protection, and wild-type strain or lactate add-back reverses protection whereas a lactate-production-deficient strain does not, without changing ethanol exposure. A lactate-independent barrier/endotoxin model is favored if an in-vivo-active fraction or its donor community first improves permeability and tight-junction integrity, then lowers portal endotoxin, and only subsequently lowers hepatic TLR4/Kupffer-cell activation and injury despite unchanged species-resolved lactate flux and failure of lactate add-back to reverse protection. That temporal sequence must be accompanied by at least one causal interaction: exposure-matched portal-endotoxin add-back reverses hepatic pathway and injury protection without changing lactate or ethanol exposure, or Kupffer-cell TLR4 blockade phenocopies protection in ethanol-only mice and occludes the fraction or community effect, with blockade also preventing endotoxin add-back reversal. Co-moving barrier, endotoxin, inflammatory, and injury endpoints without add-back reversal or pathway occlusion are insufficient to support barrier mediation. A tryptophan-metabolite/AhR model is favored if a fraction or its donor community raises microbial indole ligands before protection, produces intestinal or hepatic AhR target engagement, and loses protection under AhR deficiency or antagonism, while FICZ phenocopies and occludes the effect without a necessary change in species-resolved lactate flux. A hepatocyte-derived glycolytic-lactate model is favored if hepatic lactate production changes before injury despite unchanged portal microbial lactate flux, and donor-community transfer, strain reconstitution, and intestinal lactate add-back do not account for protection. A direct hepatic model is favored if a fraction is active in the independent hepatocyte screen and protects in vivo while donor community transfer, lactate manipulation, barrier/endotoxin perturbations, and AhR interaction do not account for the effect. An ethyl-lactate/SIRT1-FGF21 model is favored if the isolated ester, independent of the whole extract, reduces steatosis and injury via hepatocyte FGF21 induction, that effect is abolished by SIRT1 inhibition or hepatocyte Fgf21 loss, and protection does not require microbial lactate manipulation or donor-community transfer. A deoxycholate-barrier model is favored if the extract or its fractions blunt ethanol-induced elevation of deoxycholic acid before injury improves, and exogenous deoxycholic-acid restoration in protected animals reverses barrier and injury protection without changing species-resolved lactate flux or ethanol exposure. Partial pathway-specific effects support combined mediation. The proposed microbiota-lactate hypothesis is refuted in this model if no species-resolved lactate flux is necessary for protection, even if a barrier/endotoxin, tryptophan-metabolite/AhR, ethyl-lactate/SIRT1-FGF21, deoxycholate-barrier, or direct hepatic route remains.
Would support
mechanistic_hypotheses#baijiu_extract_microbiota_lactate_mediation_model
Would refute
mechanistic_hypotheses#baijiu_extract_microbiota_lactate_mediation_model
Show evidence (10 references)
PMID:42300615 SUPPORT Model Organism
"The results showed that non-ethanol components of Baijiu significantly alleviated ethanol-induced body weight loss and hepatic pathological damage in mice, reduced serum AST and ALT activities as well as hepatic MDA levels, and enhanced the activity of the mitochondrial antioxidant enzyme SOD2."
The whole extract improved injury and oxidative-stress endpoints in mice, motivating constituent identification while remaining model-specific.
PMID:27890791 SUPPORT Model Organism
"Both methods prevented steatosis, liver inflammation, and restored gut homeostasis."
Fecal transfer and pectin intervention provide animal-model precedent that manipulating an intestinal community can modify alcohol-induced liver injury, but do not establish the Baijiu constituent or lactate route.
PMID:33004548 SUPPORT Model Organism
"The AhR agonist Ficz (6-formylindolo (3,2-b) carbazole) reduced liver lesions, similarly to prebiotic treatment. Conversely, inactivation of the ahr gene in alcohol-fed AhR knock-out mice abrogated the beneficial effects of the prebiotic."
Pharmacologic agonism and genetic loss establish AhR as a causal competing mediator of microbiota-targeted protection in human-microbiota-associated alcohol-fed mice, without testing the Baijiu extract or a lactate route.
+ 7 more references
⚙

Pathophysiology

11
Chronic Ethanol Exposure
Repeated harmful alcohol exposure is the initiating exposure for ALD, but it is not sufficient by itself to determine who develops advanced disease. Drinking pattern, cumulative exposure, metabolic context, sex, and host susceptibility influence risk.
Canonical multi-hit alcohol-injury model PNPLA3-alcohol gene-environment susceptibility
Downstream
Hepatic Ethanol Metabolism and Redox-Oxidative Stress Hepatic ADH and inducible CYP2E1 oxidize ethanol to acetaldehyde while altering redox balance and generating reactive oxygen species. Canonical multi-hit alcohol-injury model
Intestinal Barrier Dysfunction and Endotoxin Translocation Chronic alcohol exposure promotes intestinal CYP2E1-dependent oxidative stress and barrier hyperpermeability, permitting microbial products to reach the portal circulation. Canonical multi-hit alcohol-injury model
PNPLA3-Linked Gene-Environment Susceptibility Alcohol exposure amplifies the liver-disease association of PNPLA3 rs738409, although the molecular intermediates and stage specificity remain unresolved. PNPLA3-alcohol gene-environment susceptibility
Show evidence (2 references)
PMID:38174913 SUPPORT Other
"With harmful alcohol use as the primary risk factor, increasing alcohol use over the past decade has resulted in rapid growth of the ALD-related healthcare burden."
The guideline identifies harmful alcohol use as the primary ALD risk factor.
PMID:25634330 SUPPORT Human Clinical
"In men, daily drinking was associated with an increased risk of alcoholic cirrhosis."
This prospective Danish cohort supports a pattern-dependent association while not implying that exposure is sufficient or deterministic.
Hepatic Ethanol Metabolism and Redox-Oxidative Stress
ADH-mediated ethanol oxidation raises NADH and shifts hepatocyte redox balance, while CYP2E1 metabolism generates acetaldehyde and reactive oxygen species. These products alter lipid handling and injure multiple hepatic cell types.
Canonical multi-hit alcohol-injury model LSEC CYP2E1-Hsp90-eNOS dysfunction axis
hepatocyte CL:0000182 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves hepatocyte (CL:0000182). CL:0000182 is a cell type from the Cell Ontology.
ethanol catabolic process GO:0006068 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased ethanol catabolic process (GO:0006068). GO:0006068 is a biological process from the Gene Ontology. ↑ INCREASED cell redox homeostasis GO:0045454 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal cell redox homeostasis (GO:0045454). GO:0045454 is a biological process from the Gene Ontology. ⚠ ABNORMAL response to oxidative stress GO:0006979 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased response to oxidative stress (GO:0006979). GO:0006979 is a biological process from the Gene Ontology. ↑ INCREASED
liver UBERON:0002107 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in liver (UBERON:0002107). UBERON:0002107 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Hepatocyte Lipid Overload Increased NADH promotes fatty-acid synthesis and opposes fatty-acid oxidation, favoring triglyceride accumulation in hepatocytes. Canonical multi-hit alcohol-injury model
Liver Sinusoidal Endothelial Dysfunction CYP2E1-dependent ethanol metabolism in LSECs increases Hsp90 acetylation, weakens Hsp90-eNOS interaction, and decreases nitric-oxide production. LSEC CYP2E1-Hsp90-eNOS dysfunction axis
Lipotoxic and Oxidative Hepatocyte Stress Acetaldehyde and CYP2E1-derived oxidants directly impair mitochondria, glutathione-dependent defenses, membranes, and cellular redox homeostasis. Canonical multi-hit alcohol-injury model
Show evidence (1 reference)
PMID:30424581 SUPPORT Other
"MEOS induction accelerates the metabolism of ethanol to acetaldehyde that facilitates organ injury including the liver, and it produces via CYP 2E1 many reactive oxygen species (ROS)"
This review supports CYP2E1-dependent acetaldehyde and ROS generation.
Hepatocyte Lipid Overload
Redox-driven fatty-acid synthesis and impaired oxidation increase hepatocyte triglyceride synthesis and lipid-droplet storage, producing steatosis.
Canonical multi-hit alcohol-injury model
hepatocyte CL:0000182 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves hepatocyte (CL:0000182). CL:0000182 is a cell type from the Cell Ontology.
triglyceride biosynthetic process GO:0019432 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased triglyceride biosynthetic process (GO:0019432). GO:0019432 is a biological process from the Gene Ontology. ↑ INCREASED lipid storage GO:0019915 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased lipid storage (GO:0019915). GO:0019915 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Hepatic steatosis Intracellular triglyceride and lipid-droplet accumulation manifests as hepatic steatosis. Canonical multi-hit alcohol-injury model
Lipotoxic and Oxidative Hepatocyte Stress Excess fatty acids enter oxidative pathways that generate free radicals and lipid peroxidation, damaging hepatocyte membranes and cellular homeostasis. Canonical multi-hit alcohol-injury model
Show evidence (1 reference)
PMID:15670660 SUPPORT Other
"alcohol dehydrogenase-mediated ethanol metabolism generates the reduced form of nicotinamide adenine dinucleotide (NADH), which promotes steatosis by stimulating the synthesis of fatty acids and opposing their oxidation."
The review supports hepatocyte lipid accumulation as a redox-linked ALD mechanism.
Lipotoxic and Oxidative Hepatocyte Stress
Lipid peroxidation, acetaldehyde adducts, mitochondrial injury, endoplasmic reticulum stress, and oxidative stress impair hepatocyte homeostasis and promote injury signals that recruit and activate hepatic immune cells.
Canonical multi-hit alcohol-injury model
hepatocyte CL:0000182 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves hepatocyte (CL:0000182). CL:0000182 is a cell type from the Cell Ontology.
response to oxidative stress GO:0006979 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased response to oxidative stress (GO:0006979). GO:0006979 is a biological process from the Gene Ontology. ↑ INCREASED response to endoplasmic reticulum stress GO:0034976 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased response to endoplasmic reticulum stress (GO:0034976). GO:0034976 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Kupffer-Cell and Hepatocyte Inflammatory Injury Oxidative and membrane injury produces inflammatory signals, while Kupffer-cell cytokines amplify hepatocyte injury. Canonical multi-hit alcohol-injury model
Show evidence (1 reference)
PMID:37143126 SUPPORT Other
"the underlying mechanisms of ALD are complex, involving inflammation, mitochondrial damage, endoplasmic reticulum stress, nitrification, and oxidative stress."
The review supports the combined organelle and oxidative-stress node.
Intestinal Barrier Dysfunction and Endotoxin Translocation
Alcohol-associated intestinal oxidative stress and tight-junction dysfunction increase permeability to bacterial products, including lipopolysaccharide, which reach and stimulate the liver through the gut-liver axis.
Canonical multi-hit alcohol-injury model
intestinal epithelial cell CL:0002563 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves intestinal epithelial cell (CL:0002563). CL:0002563 is a cell type from the Cell Ontology.
tight junction assembly GO:0120192 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased tight junction assembly (GO:0120192). GO:0120192 is a biological process from the Gene Ontology. ↓ DECREASED
small intestine UBERON:0002108 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in small intestine (UBERON:0002108). UBERON:0002108 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Kupffer-Cell and Hepatocyte Inflammatory Injury Portal endotoxin activates hepatic TLR4-dependent signaling in Kupffer cells and other liver cells, increasing inflammatory mediators and liver injury. Canonical multi-hit alcohol-injury model
Show evidence (1 reference)
PMID:37143126 SUPPORT Other
"ethanol damages the intestinal barrier, resulting in the release of endotoxins and alterations in intestinal flora content and bile acid metabolism."
The review directly supports alcohol-associated intestinal-barrier damage and endotoxin release.
Liver Sinusoidal Endothelial Dysfunction
CYP2E1-dependent Hsp90 acetylation in LSECs reduces eNOS-derived nitric oxide and impairs sinusoidal endothelial function. This is an emerging preclinical mechanism whose prevalence and causal weight in human ALD remain uncertain.
LSEC CYP2E1-Hsp90-eNOS dysfunction axis
endothelial cell of hepatic sinusoid CL:1000398 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves endothelial cell of hepatic sinusoid (CL:1000398). CL:1000398 is a cell type from the Cell Ontology.
liver UBERON:0002107 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in liver (UBERON:0002107). UBERON:0002107 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Kupffer-Cell and Hepatocyte Inflammatory Injury Reduced endothelial nitric-oxide signaling may amplify hepatic injury and inflammatory crosstalk, but the omitted human intermediates are not yet resolved. LSEC CYP2E1-Hsp90-eNOS dysfunction axis
Show evidence (1 reference)
PMID:33675874 SUPPORT In Vitro
"LSECs expressed CYP2E1 and alcohol dehydrogenase 1 (ADH1) and metabolized alcohol."
Primary human, rat, and mouse LSECs demonstrated local ethanol-metabolizing capacity.
Kupffer-Cell and Hepatocyte Inflammatory Injury
Oxidative hepatocyte injury and gut-derived microbial signals converge on Kupffer cells and hepatocytes, increasing TLR4-linked inflammatory signaling, cytokine production, and hepatocyte death. Human single-cell data show immune remodeling in established ALD but are associative rather than proof of causal direction.
Canonical multi-hit alcohol-injury model
hepatocyte CL:0000182 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves hepatocyte (CL:0000182). CL:0000182 is a cell type from the Cell Ontology. Kupffer cell CL:0000091 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Kupffer cell (CL:0000091). CL:0000091 is a cell type from the Cell Ontology.
inflammatory response GO:0006954 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased inflammatory response (GO:0006954). GO:0006954 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Alcohol-associated hepatitis Severe inflammatory hepatocellular injury can present clinically as rapidly worsening jaundice and acute-on-chronic liver failure, but AH is not an obligatory stage in every ALD trajectory. Canonical multi-hit alcohol-injury model
Hepatic Stellate Cell Activation Persistent inflammatory and oxidative signals activate TGF-beta and other profibrotic pathways that transform quiescent stellate cells into matrix-producing myofibroblasts. Canonical multi-hit alcohol-injury model
Show evidence (2 references)
PMID:18792393 SUPPORT Model Organism
"Expression of inflammatory mediators (tumor necrosis factor-alpha and interleukin-6) and TLR4 coreceptors (CD14 and MD2) was significantly higher in livers of alcohol-fed WT, TLR2-KO, or MyD88-KO, but not in TLR4-KO mice, compared to controls."
Ethanol-fed knockout mice support a TLR4-dependent inflammatory liver-injury node.
PMID:39349248 SUPPORT Human Clinical
"Additionally, we noted shifts in myeloid populations, with expanded APOE+ macrophage and FCGR3B+ monocyte subsets in ALD samples relative to MASLD and healthy tissues."
Human liver single-cell data support immune-cell remodeling but not causal direction.
Hepatic Stellate Cell Activation
TGF-beta and cooperating injury signals activate hepatic stellate cells and promote their transition toward proliferative, contractile, collagen-producing myofibroblasts.
Canonical multi-hit alcohol-injury model
hepatic stellate cell CL:0000632 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves hepatic stellate cell (CL:0000632). CL:0000632 is a cell type from the Cell Ontology. myofibroblast cell CL:0000186 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves myofibroblast cell (CL:0000186). CL:0000186 is a cell type from the Cell Ontology.
transforming growth factor beta receptor signaling pathway GO:0007179 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased transforming growth factor beta receptor signaling pathway (GO:0007179). GO:0007179 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Excessive Hepatic Extracellular Matrix Deposition Activated HSC-derived myofibroblasts synthesize collagen and other scar-matrix proteins. Canonical multi-hit alcohol-injury model
Show evidence (1 reference)
PMID:31718044 SUPPORT Other
"there is a broad consensus that HSC are the major contributors for the MFB pool during liver fibrosis, independent of the damaging source"
The review identifies HSCs as the principal source of liver-fibrosis myofibroblasts.
Excessive Hepatic Extracellular Matrix Deposition
Activated myofibroblasts deposit excessive fibrillar collagen and other extracellular-matrix proteins in the space of Disse, disrupting sinusoidal exchange and forming hepatic scar tissue.
Canonical multi-hit alcohol-injury model
myofibroblast cell CL:0000186 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves myofibroblast cell (CL:0000186). CL:0000186 is a cell type from the Cell Ontology.
extracellular matrix organization GO:0030198 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased extracellular matrix organization (GO:0030198). GO:0030198 is a biological process from the Gene Ontology. ↑ INCREASED collagen biosynthetic process GO:0032964 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased collagen biosynthetic process (GO:0032964). GO:0032964 is a biological process from the Gene Ontology. ↑ INCREASED collagen fibril organization GO:0030199 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased collagen fibril organization (GO:0030199). GO:0030199 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Hepatic fibrosis Accumulated fibrillar scar matrix manifests as hepatic fibrosis. Canonical multi-hit alcohol-injury model
Cirrhotic Architectural Distortion and Functional Failure Persistent matrix deposition and scar remodeling distort hepatic architecture, alter sinusoidal flow, and progressively impair organ function. Canonical multi-hit alcohol-injury model
Show evidence (1 reference)
PMID:31718044 SUPPORT Other
"Fibrosis means that an excessive amount of fibrillar extracellular matrix (ECM) proteins, e.g., collagen I and III, is deposited in the space of Disse"
The review defines hepatic fibrosis by excessive fibrillar ECM deposition.
Cirrhotic Architectural Distortion and Functional Failure
Bridging scar, regenerative nodules, sinusoidal and vascular remodeling, and loss of functional hepatocyte mass produce cirrhosis, portal hypertension, and impaired liver function. These manifestations characterize advanced disease rather than every person with ALD.
Canonical multi-hit alcohol-injury model
liver UBERON:0002107 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in liver (UBERON:0002107). UBERON:0002107 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Cirrhosis Advanced architectural distortion and nodular remodeling manifest clinically as cirrhosis. Canonical multi-hit alcohol-injury model
Portal hypertension Fibrotic and vascular architectural remodeling increases intrahepatic resistance and portal pressure. Canonical multi-hit alcohol-injury model
Decreased liver function Loss of functional parenchyma and distorted hepatic architecture impair liver function. Canonical multi-hit alcohol-injury model
Show evidence (1 reference)
PMID:31718044 SUPPORT Other
"If the liver damage-inducing agent is not properly removed, liver fibrogenesis perpetuates (reflected by the term “chronic”) until the liver architecture is strongly distorted, and can then progress to the late stages of liver disease, liver cirrhosis and hepatocellular carcinoma (HCC), and thus..."
Persistent liver fibrogenesis is linked to architectural distortion, cirrhosis, and failure.
PNPLA3-Linked Gene-Environment Susceptibility
PNPLA3 rs738409 marks inherited susceptibility to alcohol-related cirrhosis. Alcohol exposure amplifies the association, but current evidence does not show that the variant is necessary or sufficient for ALD or establish a direct local lipid-overload mechanism.
PNPLA3-alcohol gene-environment susceptibility
PNPLA3 hgnc:18590 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves PNPLA3 (hgnc:18590). hgnc:18590 is a gene from the HUGO Gene Nomenclature Committee.
Downstream
Cirrhotic Architectural Distortion and Functional Failure PNPLA3 rs738409 increases susceptibility to alcohol-related cirrhosis, but the molecular path from the locus to advanced architectural disease is unresolved. PNPLA3-alcohol gene-environment susceptibility
Show evidence (1 reference)
PMID:26482880 SUPPORT Human Clinical
"confirmed rs738409 in PNPLA3 as an important risk locus for alcohol-related cirrhosis (P = 1.54 × 10(-48)) at a genome-wide level of significance."
The GWAS establishes susceptibility to the advanced cirrhosis outcome.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Alcohol-Associated Liver Disease Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

6
Cardiovascular 1
Portal hypertension HP:0001409 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Portal hypertension (HP:0001409). HP:0001409 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38174913 SUPPORT Other
"The spectrum of ALD ranges from early asymptomatic liver injury to advanced disease with decompensation and portal hypertension."
The guideline explicitly places portal hypertension in advanced ALD.
Digestive 5
Hepatic steatosis HP:0001397 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hepatic steatosis (HP:0001397). HP:0001397 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39362713 SUPPORT Other
"Several intracellular, intrahepatic, and extrahepatic factors influence development of early fatty liver injury leading to inflammation and fibrosis."
The review identifies fatty liver injury as an early ALD manifestation.
Alcohol-associated hepatitis HP:0012115 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hepatitis (HP:0012115). HP:0012115 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38174913 SUPPORT Other
"A unique phenotype of advanced disease is alcohol-associated hepatitis (AH) presenting with rapid onset or worsening of jaundice, and acute on chronic liver failure in severe forms conveying a 1-month mortality risk of 20%-50%."
The guideline defines the clinical AH phenotype and its severe form.
Hepatic fibrosis HP:0001395 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hepatic fibrosis (HP:0001395). HP:0001395 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31718044 SUPPORT Other
"Fibrosis means that an excessive amount of fibrillar extracellular matrix (ECM) proteins, e.g., collagen I and III, is deposited in the space of Disse"
The review defines the hepatic fibrosis substrate.
Cirrhosis HP:0001394 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cirrhosis (HP:0001394). HP:0001394 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38174913 SUPPORT Other
"Liver transplantation, a definitive treatment option in patients with advanced cirrhosis, should be considered in selected patients with AH"
The guideline recognizes advanced cirrhosis within the treated ALD spectrum.
Decreased liver function HP:0001410 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Decreased liver function (HP:0001410). HP:0001410 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:23255577 SUPPORT Other
"Fibrosis is a pathological scarring process that leads to destruction of organ architecture and impairment of organ function."
The fibrosis review supports organ-function impairment from advanced scarring.
🧬

Genetic Associations

1
PNPLA3 rs738409 susceptibility (The rs738409 PNPLA3 locus increases susceptibility to alcohol-related cirrhosis in exposed populations but is neither necessary nor sufficient to cause ALD.)
Gene: PNPLA3 hgnc:18590 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is PNPLA3 (hgnc:18590). hgnc:18590 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE
Show evidence (1 reference)
PMID:26482880 SUPPORT Human Clinical
"variants in the MBOAT7 (P = 1.03 × 10(-9)) and TM6SF2 (P = 7.89 × 10(-10)) genes as new risk loci and confirmed rs738409 in PNPLA3 as an important risk locus for alcohol-related cirrhosis (P = 1.54 × 10(-48)) at a genome-wide level of significance."
The European GWAS establishes rs738409 as a susceptibility locus, not a monogenic cause.
💊

Medical Actions

3
Sustained alcohol abstinence with cessation support
Category: Therapeutic Action: therapeutic avoidance of environmental exposureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is therapeutic avoidance of environmental exposure, annotated with Lifestyle Therapy (NCIT:C15900). NCIT:C15900 is a clinical intervention from the NCI Thesaurus. Ontology label: Lifestyle Therapy NCIT:C15900
Sustained abstinence removes the initiating exposure. All patients should receive cessation support; integrated hepatology, addiction-medicine, and psychosocial treatment is particularly important when alcohol use disorder is present.
Mechanism Target:
INHIBITS Chronic Ethanol Exposure — Abstinence removes continued ethanol exposure, the initiating driver of the modeled causal graph.
Show evidence (1 reference)
PMID:38174913 SUPPORT Other
"Abstinence of alcohol use, a crucial determinant of long-term outcomes, is challenging to achieve in ALD patients with concurrent alcohol use disorder (AUD)."
The guideline identifies abstinence as a crucial determinant of long-term ALD outcomes.
Show evidence (1 reference)
PMID:36481475 SUPPORT Human Clinical
"Alcohol abstinence was linked to a significantly reduced risk of hepatic decompensation"
In a cohort with alcohol-related cirrhosis and clinically significant portal hypertension, abstinence was associated with lower decompensation and mortality.
Prednisolone for eligible severe alcohol-associated hepatitis
Category: Therapeutic Action: corticosteroid agent therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is corticosteroid agent therapy, annotated with Systemic Corticosteroid Therapy (NCIT:C122080). NCIT:C122080 is a clinical intervention from the NCI Thesaurus. Ontology label: Systemic Corticosteroid Therapy NCIT:C122080
Agent: prednisolone CHEBI:8378 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses prednisolone (CHEBI:8378). CHEBI:8378 is a therapeutic agent from Chemical Entities of Biological Interest.
Prednisolone is restricted to eligible patients with definite or probable severe AH (MELD >20), after serious infection and other glucocorticoid contraindications are assessed. Response should be checked with the Lille model at day 4 or 7 and treatment stopped for nonresponse (>0.45). STOPAH found a nonsignificant 28-day mortality reduction, no 90-day or one-year benefit, and more serious infections, so benefit should not be generalized to all ALD.
Mechanism Target:
INHIBITS Kupffer-Cell and Hepatocyte Inflammatory Injury — Systemic corticosteroid activity suppresses the severe inflammatory injury phenotype in eligible AH.
Show evidence (1 reference)
PMID:38174913 SUPPORT Other
"Corticosteroids are currently the only available therapeutic with proven efficacy for patients with severe AH, providing survival benefit at 1 month in 50%-60% of patients."
The guideline limits corticosteroid efficacy to severe AH and short-term outcomes.
Show evidence (5 references)
PMID:27979049 SUPPORT Other
"Patients with MDF > 32 or MELD score > 20 without a contraindication to glucocorticoid, such as hepatitis B viral infection, tuberculosis, or other serious infectious diseases, may be treated with methylprednisolone 32 mg daily"
The expert review bounds glucocorticoid use to severe AH and requires contraindication and serious-infection assessment.
PMID:27922027 SUPPORT Human Clinical
"LM4 is as accurate as LM7 in predicting response to corticosteroids, as well as 28- and 90-day mortality. Assessing the efficacy of prednisolone at an earlier time point can avoid a more prolonged futile use of this therapy."
The multinational cohort supports day-4 assessment as an alternative to day 7.
PMID:27922027 SUPPORT Human Clinical
"Response to corticosteroids was assessed with LM4 and LM7, according to the validated cutoff value (CUV>0.45)."
The study supplies the Lille nonresponse cutoff used to stop futile exposure.
+ 2 more references
Liver transplantation for selected advanced disease
Category: Therapeutic Action: liver transplantationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is liver transplantation (NCIT:C15271). NCIT:C15271 is a clinical intervention from the NCI Thesaurus. Ontology label: Liver Transplantation NCIT:C15271
Liver transplantation can replace a failing cirrhotic liver and may be considered for carefully selected patients with severe AH unresponsive to medical therapy. Evidence for early transplantation in AH comes from highly selected cohorts and must not be generalized to all patients.
Mechanism Target:
BYPASSES Cirrhotic Architectural Distortion and Functional Failure — Transplantation replaces a selected nonrecovering, decompensated or failing liver rather than reversing its established fibrotic mechanism.
Show evidence (1 reference)
PMID:38174913 SUPPORT Other
"Liver transplantation, a definitive treatment option in patients with advanced cirrhosis, should be considered in selected patients with AH, who are unresponsive to medical therapy and have a low risk of relapse to posttransplant alcohol use."
The guideline supports transplantation for advanced cirrhosis and selected AH nonresponders.
Show evidence (2 references)
PMID:22070476 SUPPORT Human Clinical
"Fewer than 2% of patients admitted for an episode of severe alcoholic hepatitis were selected."
The pivotal early-transplant study documents the narrow selection boundary.
PMID:22070476 SUPPORT Human Clinical
"The cumulative 6-month survival rate (±SE) was higher among patients who received early transplantation than among those who did not (77 ± 8% vs. 23 ± 8%, P<0.001)."
The selected severe-AH cohort had substantially higher six-month survival after transplantation.
🔬

Diagnosis

3
Clinical assessment of harmful alcohol exposure
A nonjudgmental alcohol-use history establishes the principal etiologic risk context for ALD. Exposure history alone neither confirms a particular ALD stage nor substitutes for assessment of liver injury.
clinical assessment NCIT:C124351 NCI Thesaurus (NCIT)
Results: Harmful alcohol exposure establishes the etiologic risk context but does not stage liver disease.
Show evidence (1 reference)
PMID:38174913 SUPPORT Other
"With harmful alcohol use as the primary risk factor, increasing alcohol use over the past decade has resulted in rapid growth of the ALD-related healthcare burden."
The guideline supports harmful alcohol use as the defining etiologic risk context.
Clinical classification of suspected alcohol-associated hepatitis
Suspected AH should be classified as definite, probable, or possible using the NIAAA consensus framework. Probable AH requires the characteristic clinical and laboratory pattern without confounding factors; possible AH warrants additional evaluation and may require biopsy before disease-specific treatment.
clinical assessment NCIT:C124351 NCI Thesaurus (NCIT)
Results: Definite or probable AH supports treatment eligibility assessment; possible AH requires clarification of confounding causes.
Show evidence (1 reference)
PMID:26921783 SUPPORT Other
"Probable AH: Clinically diagnosed AH without confounding factors (see below). In patients with heavy alcohol use and typical liver tests; and negative markers for immune (antinuclear antibody < 1:160 or anti–smooth antibody < 1:80 dilutions) and metabolic liver disease; and absence of sepsis,..."
The NIAAA consensus defines probable AH and explicitly requires absence of major confounding causes.
Transient elastography for fibrosis staging
Transient elastography can noninvasively assess advanced fibrosis and cirrhosis in people with excessive alcohol use. Active alcohol-associated hepatitis can raise liver stiffness independently of fibrosis and must be considered during interpretation.
diagnostic procedure NCIT:C18020 NCI Thesaurus (NCIT)
Results: Higher liver stiffness supports advanced fibrosis or cirrhosis, interpreted in the context of active hepatitis.
Show evidence (1 reference)
PMID:28387018 SUPPORT Human Clinical
"TE values correlated with fibrosis stage (r=.73; P<.0001) and steatosis stage (r=.19; P<.01). Patients with alcoholic hepatitis had higher TE values than those without alcoholic hepatitis (P<.0001)."
The prospective biopsy-referenced study supports TE for fibrosis staging and documents active hepatitis as an independent stiffness confounder.
📈

Progression

3
Early asymptomatic injury and steatosis
Early ALD may be clinically silent and may include steatosis; the spectrum statement does not imply inevitable progression to advanced disease.
Show evidence (1 reference)
PMID:38174913 SUPPORT Other
"The spectrum of ALD ranges from early asymptomatic liver injury to advanced disease with decompensation and portal hypertension."
The guideline supports an early asymptomatic end of the ALD spectrum.
Alcohol-associated hepatitis acute branch
AH can present acutely on underlying chronic liver disease with rapidly worsening jaundice. It is modeled as a branch rather than a required stage between steatosis and fibrosis.
Show evidence (1 reference)
PMID:39362713 SUPPORT Other
"The pathogenesis of alcohol-associated hepatitis (AH), an advanced form of acute-on-chronic liver failure due to excessive chronic intake in patients with underlying liver disease, is not well understood."
The review supports acute-on-chronic AH and the remaining mechanistic uncertainty.
Advanced fibrosis, cirrhosis, and decompensation
Continued injury can produce advanced fibrosis and cirrhosis with portal hypertension and decompensation, although individual trajectories vary.
Show evidence (1 reference)
PMID:38174913 SUPPORT Other
"The spectrum of ALD ranges from early asymptomatic liver injury to advanced disease with decompensation and portal hypertension."
The guideline identifies the advanced end of the clinical spectrum.
📊

Prevalence

1
Global modeled alcohol-attributable chronic liver disease (all ages)
A Global Burden of Disease 2021 analysis estimated 3.02 million prevalent cases in its modeled ALD category in 2021, with a 38.68% increase in crude case count from 2000. This estimate reflects GBD's alcohol-attributed chronic liver-disease case definition and should not be generalized to the full ALD spectrum, especially unascertained early steatosis.
Show evidence (1 reference)
PMID:39788109 SUPPORT Computational
"In 2021, there were 111.12 million cases of AUD, 3.02 million cases of ALD, and 132,030 cases of alcohol-attributable primary liver cancer."
The GBD-based analysis provides a modeled global ALD prevalence count for 2021.
📊

Related Datasets

1
Single-cell transcriptome characterization of the livers from patients with alcoholic liver disease geo:GSE236382
Human liver single-cell RNA-sequencing dataset used to characterize hepatic immune-cell landscapes in ALD. The five ALD cases provide associative cellular context and should not be interpreted as causal or population-representative.
human SINGLE CELL RNA SEQ n=5
liver tissue UBERON:0002107 Uberon multi-species anatomy ontology (UBERON) Relation: this dataset samples this sample type This dataset samples liver tissue, annotated with liver (UBERON:0002107). UBERON:0002107 is a sample type from the Uberon multi-species anatomy ontology.
Conditions: alcohol-associated liver disease
PMID:39349248
Dataset record: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE236382
Show evidence (2 references)
PMID:39349248 SUPPORT Human Clinical
"We utilized single-cell RNA sequencing to analyze liver samples from healthy subjects and patients with MASLD and ALD, focusing on the immune cell landscapes within the liver."
The publication confirms single-cell analysis of human liver samples including ALD.
GEO:GSE236382 SUPPORT Human Clinical
"This study utilized single-cell data from liver samples of 5 ALD human cases."
The GEO record directly supports the ALD sample count.
{ }

Source YAML

click to show 
name: Alcohol-Associated Liver Disease
creation_date: '2026-02-02T00:16:36Z'
description: >-
  Alcohol-associated liver disease (ALD) is a heterogeneous spectrum of liver
  injury associated with harmful alcohol use. Hepatic ethanol metabolism shifts
  redox balance and generates acetaldehyde and reactive oxygen species, while
  intestinal-barrier disruption exposes the liver to microbial products. These
  processes can produce steatosis and converge on hepatocyte and Kupffer-cell
  inflammatory injury, stellate-cell activation, extracellular-matrix deposition,
  fibrosis, cirrhosis, portal hypertension, and impaired liver function.
  Alcohol-associated hepatitis is an acute clinical phenotype that can arise on
  chronic liver disease; it is not an obligatory stage between steatosis and
  fibrosis. Sustained abstinence is central to long-term management, with
  integrated addiction treatment when alcohol use disorder is present.
synonyms:
- Alcoholic liver disease
- Alcohol-related liver disease
- ALD
category: Complex
parents:
- Hepatic Disease
disease_term:
  preferred_term: alcohol-associated liver disease
  term:
    id: MONDO:0043693
    label: alcoholic liver disease
mechanistic_hypotheses:
- hypothesis_group_id: canonical_multihit_alcohol_injury
  hypothesis_label: Canonical multi-hit alcohol-injury model
  status: CANONICAL
  description: >-
    Harmful alcohol exposure drives hepatic ethanol metabolism, redox and
    oxidative stress, lipid accumulation, and intestinal-barrier dysfunction.
    Hepatocyte stress and gut-derived endotoxin converge on inflammatory injury
    and, with persistent injury, stellate-cell activation and fibrosis.
  evidence:
  - reference: PMID:39362713
    reference_title: Pathogenesis of Alcohol-Associated Liver Disease.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Alcohol metabolism, cellular stress, and gut-derived factors contribute to
      hepatocyte and immune cell injury leading to cytokine and chemokine production.
    explanation: >-
      This review summarizes the convergent intracellular, hepatic, and
      extrahepatic components of the canonical ALD mechanism.
- hypothesis_group_id: lsec_hsp90_enos_axis
  hypothesis_label: LSEC CYP2E1-Hsp90-eNOS dysfunction axis
  status: EMERGING
  description: >-
    Liver sinusoidal endothelial-cell ethanol metabolism may reduce nitric-oxide
    production through CYP2E1-dependent Hsp90 acetylation and impaired Hsp90-eNOS
    interaction. The evidence is primarily cellular and mouse-model based, so this
    axis is modeled as an emerging amplifier rather than an established universal
    driver in human ALD.
  evidence:
  - reference: PMID:33675874
    reference_title: Alcohol-induced Hsp90 acetylation is a novel driver of liver sinusoidal endothelial dysfunction and alcohol-related liver disease.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      AAV8-driven HDAC6 overexpression specifically in liver ECs deacetylated Hsp90,
      restored Hsp90's interaction with eNOS and ameliorated alcohol-induced liver
      injury in mice.
    explanation: >-
      Rescue of the proposed endothelial axis in ethanol-fed mice supports the
      mechanism while defining its preclinical evidence boundary.
- hypothesis_group_id: pnpla3_gene_environment_susceptibility
  hypothesis_label: PNPLA3-alcohol gene-environment susceptibility
  status: EMERGING
  description: >-
    PNPLA3 rs738409 is a robust susceptibility locus for alcohol-related cirrhosis,
    and alcohol exposure amplifies its disease association. The molecular route
    between this gene-environment interaction and advanced disease is not resolved
    well enough to treat PNPLA3 as a direct lipid-overload mechanism.
  evidence:
  - reference: PMID:39679853
    reference_title: PNPLA3 in Alcohol-Related Liver Disease.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The PNPLA3 rs738409 variant stands as a paradigmatic example of gene-environment
      interaction, where its effect on liver disease is dramatically amplified by
      alcohol consumption, obesity and type 2 diabetes.
    explanation: >-
      This review supports a gene-environment susceptibility overlay while leaving
      its causal intermediates explicitly unresolved.
- hypothesis_group_id: baijiu_extract_microbiota_lactate_mediation_model
  hypothesis_label: Baijiu-extract microbiota-lactate mediation model
  status: EMERGING
  description: >-
    In the specific ethanol-exposed mouse model studied, one or more non-ethanol
    Baijiu constituents may reduce liver injury primarily by changing intestinal
    microbial function, lowering gut-derived lactate flux, and thereby improving
    hepatic redox balance and oxidative stress. Whole-extract treatment changed
    microbial composition, lactate, hepatic NADH/NAD+ balance, and injury
    concurrently, while lactate worsened oxidative stress in cultured cells.
    Candidate constituents were identified in the extract by GC-MS, but no
    individual constituent or combination was causally assigned to protection.
    These observations do not establish a Ligilactobacillus strain as the
    relevant lactate source or prove mediation. Other alcohol-fed mouse models
    show strain- and model-dependent Lactobacillaceae effects, while severe human
    ALD data associate circulating lactate with prognosis without establishing
    its source or causal direction. None of these findings supports a protective
    effect of Baijiu in humans.
  evidence:
  - reference: PMID:42300615
    reference_title: Non-ethanol components of Baijiu alleviate ethanol-induced energy metabolism disorder and gut microbiota dysbiosis in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Concurrently, they remodeled the gut microbial structure, restored the
      Firmicutes/Bacteroidetes (F/B) ratio, inhibited the abnormal proliferation
      of g_Ligilactobacillus, and reduced lactate production.
    explanation: >-
      The mouse study links whole-extract exposure to concurrent microbiota and
      lactate changes, but does not establish that either change mediates hepatic
      protection.
  - reference: PMID:42300615
    reference_title: Non-ethanol components of Baijiu alleviate ethanol-induced energy metabolism disorder and gut microbiota dysbiosis in mice.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Cellular experiments confirmed that excessive lactate exacerbated oxidative stress.
    explanation: >-
      The cell assay supports lactate as a sufficient oxidative-stress amplifier,
      but not its microbial source, in-vivo flux, or necessity for extract-mediated
      protection.
  - reference: PMID:42300615
    reference_title: Non-ethanol components of Baijiu alleviate ethanol-induced energy metabolism disorder and gut microbiota dysbiosis in mice.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: multiple active chemical constituents were identified in this extract via GC-MS.
    explanation: >-
      GC-MS nominates chemical candidates in the extract, but does not causally
      assign the whole-extract protection to an individual constituent or
      combination.
prevalence:
- population: Global modeled alcohol-attributable chronic liver disease (all ages)
  notes: >-
    A Global Burden of Disease 2021 analysis estimated 3.02 million prevalent
    cases in its modeled ALD category in 2021, with a 38.68% increase in crude
    case count from 2000. This estimate reflects GBD's alcohol-attributed chronic
    liver-disease case definition and should not be generalized to the full ALD
    spectrum, especially unascertained early steatosis.
  evidence:
  - reference: PMID:39788109
    reference_title: Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021.
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      In 2021, there were 111.12 million cases of AUD, 3.02 million cases of ALD,
      and 132,030 cases of alcohol-attributable primary liver cancer.
    explanation: >-
      The GBD-based analysis provides a modeled global ALD prevalence count for 2021.
pathophysiology:
- name: Chronic Ethanol Exposure
  role: trigger
  description: >-
    Repeated harmful alcohol exposure is the initiating exposure for ALD, but it
    is not sufficient by itself to determine who develops advanced disease.
    Drinking pattern, cumulative exposure, metabolic context, sex, and host
    susceptibility influence risk.
  chemical_entities:
  - preferred_term: ethanol
    term:
      id: CHEBI:16236
      label: ethanol
  evidence:
  - reference: PMID:38174913
    reference_title: 'ACG Clinical Guideline: Alcohol-Associated Liver Disease.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      With harmful alcohol use as the primary risk factor, increasing alcohol use
      over the past decade has resulted in rapid growth of the ALD-related healthcare
      burden.
    explanation: The guideline identifies harmful alcohol use as the primary ALD risk factor.
  - reference: PMID:25634330
    reference_title: 'Alcohol drinking pattern and risk of alcoholic liver cirrhosis: a prospective cohort study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In men, daily drinking was associated with an increased risk of alcoholic cirrhosis.
    explanation: >-
      This prospective Danish cohort supports a pattern-dependent association while
      not implying that exposure is sufficient or deterministic.
  downstream:
  - target: Hepatic Ethanol Metabolism and Redox-Oxidative Stress
    description: >-
      Hepatic ADH and inducible CYP2E1 oxidize ethanol to acetaldehyde while altering
      redox balance and generating reactive oxygen species.
    hypothesis_groups:
    - canonical_multihit_alcohol_injury
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:30424581
      reference_title: 'Alcoholic Liver Disease: Alcohol Metabolism, Cascade of Molecular Mechanisms, Cellular Targets, and Clinical Aspects.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Pathogenetic events are linked to the metabolism of ethanol and acetaldehyde
        as its first oxidation product generated via hepatic alcohol dehydrogenase
        (ADH) and the microsomal ethanol-oxidizing system (MEOS), which depends on
        cytochrome P450 2E1 (CYP 2E1), and is inducible by chronic alcohol use.
      explanation: The review directly links ethanol exposure to hepatic ADH and CYP2E1 metabolism.
  - target: Intestinal Barrier Dysfunction and Endotoxin Translocation
    description: >-
      Chronic alcohol exposure promotes intestinal CYP2E1-dependent oxidative
      stress and barrier hyperpermeability, permitting microbial products to reach
      the portal circulation.
    hypothesis_groups:
    - canonical_multihit_alcohol_injury
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Intestinal CYP2E1-dependent oxidative stress and tight-junction disruption
    evidence:
    - reference: PMID:25462064
      reference_title: 'Intestinal CYP2E1: A mediator of alcohol-induced gut leakiness.'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Cyp2e1 knockout mice are resistant to alcohol-induced gut leakiness and liver
        inflammation.
      explanation: >-
        The knockout experiment supports intestinal CYP2E1 as an intermediate between
        alcohol exposure, gut leakiness, and liver inflammation in a model organism.
  - target: PNPLA3-Linked Gene-Environment Susceptibility
    description: >-
      Alcohol exposure amplifies the liver-disease association of PNPLA3 rs738409,
      although the molecular intermediates and stage specificity remain unresolved.
    hypothesis_groups:
    - pnpla3_gene_environment_susceptibility
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:39679853
      reference_title: PNPLA3 in Alcohol-Related Liver Disease.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        The PNPLA3 rs738409 variant stands as a paradigmatic example of gene-environment
        interaction, where its effect on liver disease is dramatically amplified by
        alcohol consumption, obesity and type 2 diabetes.
      explanation: >-
        The review supports exposure-dependent amplification of PNPLA3-associated
        liver-disease susceptibility without defining a direct molecular edge.
- name: Hepatic Ethanol Metabolism and Redox-Oxidative Stress
  description: >-
    ADH-mediated ethanol oxidation raises NADH and shifts hepatocyte redox balance,
    while CYP2E1 metabolism generates acetaldehyde and reactive oxygen species.
    These products alter lipid handling and injure multiple hepatic cell types.
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  biological_processes:
  - preferred_term: ethanol catabolic process
    modifier: INCREASED
    term:
      id: GO:0006068
      label: ethanol catabolic process
  - preferred_term: cell redox homeostasis
    modifier: ABNORMAL
    term:
      id: GO:0045454
      label: cell redox homeostasis
  - preferred_term: response to oxidative stress
    modifier: INCREASED
    term:
      id: GO:0006979
      label: response to oxidative stress
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  chemical_entities:
  - preferred_term: reactive oxygen species
    term:
      id: CHEBI:26523
      label: reactive oxygen species
  evidence:
  - reference: PMID:30424581
    reference_title: 'Alcoholic Liver Disease: Alcohol Metabolism, Cascade of Molecular Mechanisms, Cellular Targets, and Clinical Aspects.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      MEOS induction accelerates the metabolism of ethanol to acetaldehyde that
      facilitates organ injury including the liver, and it produces via CYP 2E1
      many reactive oxygen species (ROS)
    explanation: This review supports CYP2E1-dependent acetaldehyde and ROS generation.
  downstream:
  - target: Hepatocyte Lipid Overload
    description: >-
      Increased NADH promotes fatty-acid synthesis and opposes fatty-acid oxidation,
      favoring triglyceride accumulation in hepatocytes.
    hypothesis_groups:
    - canonical_multihit_alcohol_injury
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - NADH-driven stimulation of fatty-acid synthesis and inhibition of fatty-acid oxidation
    evidence:
    - reference: PMID:15670660
      reference_title: 'Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        alcohol dehydrogenase-mediated ethanol metabolism generates the reduced form
        of nicotinamide adenine dinucleotide (NADH), which promotes steatosis by
        stimulating the synthesis of fatty acids and opposing their oxidation.
      explanation: The review supplies the omitted redox-to-lipid intermediates for this edge.
  - target: Liver Sinusoidal Endothelial Dysfunction
    description: >-
      CYP2E1-dependent ethanol metabolism in LSECs increases Hsp90 acetylation,
      weakens Hsp90-eNOS interaction, and decreases nitric-oxide production.
    hypothesis_groups:
    - lsec_hsp90_enos_axis
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:33675874
      reference_title: Alcohol-induced Hsp90 acetylation is a novel driver of liver sinusoidal endothelial dysfunction and alcohol-related liver disease.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Alcohol metabolism by CYP2E1 increased Hsp90 acetylation and decreased its
        interaction with endothelial nitric oxide synthase (eNOS) leading to a
        decrease in nitric oxide (NO) production.
      explanation: Primary LSEC experiments directly support the proposed molecular axis.
  - target: Lipotoxic and Oxidative Hepatocyte Stress
    description: >-
      Acetaldehyde and CYP2E1-derived oxidants directly impair mitochondria,
      glutathione-dependent defenses, membranes, and cellular redox homeostasis.
    hypothesis_groups:
    - canonical_multihit_alcohol_injury
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:15670660
      reference_title: 'Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Acetaldehyde is also toxic to the mitochondria, and it aggravates their
        oxidative stress by binding to reduced glutathione and promoting its leakage.
      explanation: >-
        The review directly supports ethanol-metabolism products as a route to
        mitochondrial and oxidative hepatocyte stress independent of lipid overload.
- name: Hepatocyte Lipid Overload
  conforms_to: 'hepatic_steatosis_lipotoxicity#Hepatocyte Lipid Overload'
  description: >-
    Redox-driven fatty-acid synthesis and impaired oxidation increase hepatocyte
    triglyceride synthesis and lipid-droplet storage, producing steatosis.
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  biological_processes:
  - preferred_term: triglyceride biosynthetic process
    modifier: INCREASED
    term:
      id: GO:0019432
      label: triglyceride biosynthetic process
  - preferred_term: lipid storage
    modifier: INCREASED
    term:
      id: GO:0019915
      label: lipid storage
  evidence:
  - reference: PMID:15670660
    reference_title: 'Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      alcohol dehydrogenase-mediated ethanol metabolism generates the reduced form
      of nicotinamide adenine dinucleotide (NADH), which promotes steatosis by
      stimulating the synthesis of fatty acids and opposing their oxidation.
    explanation: The review supports hepatocyte lipid accumulation as a redox-linked ALD mechanism.
  downstream:
  - target: Hepatic steatosis
    description: Intracellular triglyceride and lipid-droplet accumulation manifests as hepatic steatosis.
    hypothesis_groups:
    - canonical_multihit_alcohol_injury
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39362713
      reference_title: Pathogenesis of Alcohol-Associated Liver Disease.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Several intracellular, intrahepatic, and extrahepatic factors influence
        development of early fatty liver injury leading to inflammation and fibrosis.
      explanation: The review places early fatty liver injury within the ALD spectrum.
  - target: Lipotoxic and Oxidative Hepatocyte Stress
    description: >-
      Excess fatty acids enter oxidative pathways that generate free radicals and
      lipid peroxidation, damaging hepatocyte membranes and cellular homeostasis.
    hypothesis_groups:
    - canonical_multihit_alcohol_injury
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Fatty-acid-driven radical generation, lipid peroxidation, and membrane damage
    evidence:
    - reference: PMID:15670660
      reference_title: 'Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        CYP2E1 activity is inducible by its substrates, not only ethanol but also
        fatty acids. Their excess and metabolism by means of this pathway generate
        release of free radicals, which cause oxidative stress, with peroxidation of
        lipids and membrane damage, including altered enzyme activities.
      explanation: The review identifies the intermediate oxidative and membrane-damage mechanisms.
- name: Lipotoxic and Oxidative Hepatocyte Stress
  conforms_to: 'hepatic_steatosis_lipotoxicity#Lipotoxic Stress and Organelle Dysfunction'
  description: >-
    Lipid peroxidation, acetaldehyde adducts, mitochondrial injury, endoplasmic
    reticulum stress, and oxidative stress impair hepatocyte homeostasis and promote
    injury signals that recruit and activate hepatic immune cells.
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  biological_processes:
  - preferred_term: response to oxidative stress
    modifier: INCREASED
    term:
      id: GO:0006979
      label: response to oxidative stress
  - preferred_term: response to endoplasmic reticulum stress
    modifier: INCREASED
    term:
      id: GO:0034976
      label: response to endoplasmic reticulum stress
  evidence:
  - reference: PMID:37143126
    reference_title: Pathogenic mechanisms and regulatory factors involved in alcoholic liver disease.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      the underlying mechanisms of ALD are complex, involving inflammation,
      mitochondrial damage, endoplasmic reticulum stress, nitrification, and
      oxidative stress.
    explanation: The review supports the combined organelle and oxidative-stress node.
  downstream:
  - target: Kupffer-Cell and Hepatocyte Inflammatory Injury
    description: >-
      Oxidative and membrane injury produces inflammatory signals, while Kupffer-cell
      cytokines amplify hepatocyte injury.
    hypothesis_groups:
    - canonical_multihit_alcohol_injury
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Damage-associated signaling and Kupffer-cell tumor-necrosis-factor production
    evidence:
    - reference: PMID:15670660
      reference_title: 'Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Oxidative stress and associated cellular injury promote inflammation, which
        is aggravated by increased production of the proinflammatory cytokine tumor
        necrosis factor-alpha in the Kupffer cells.
      explanation: The review gives the injury-to-inflammation route and Kupffer-cell amplifier.
- name: Intestinal Barrier Dysfunction and Endotoxin Translocation
  description: >-
    Alcohol-associated intestinal oxidative stress and tight-junction dysfunction
    increase permeability to bacterial products, including lipopolysaccharide, which
    reach and stimulate the liver through the gut-liver axis.
  cell_types:
  - preferred_term: intestinal epithelial cell
    term:
      id: CL:0002563
      label: intestinal epithelial cell
  biological_processes:
  - preferred_term: tight junction assembly
    modifier: DECREASED
    term:
      id: GO:0120192
      label: tight junction assembly
  locations:
  - preferred_term: small intestine
    term:
      id: UBERON:0002108
      label: small intestine
  chemical_entities:
  - preferred_term: lipopolysaccharide
    term:
      id: CHEBI:16412
      label: lipopolysaccharide
  evidence:
  - reference: PMID:37143126
    reference_title: Pathogenic mechanisms and regulatory factors involved in alcoholic liver disease.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      ethanol damages the intestinal barrier, resulting in the release of endotoxins
      and alterations in intestinal flora content and bile acid metabolism.
    explanation: The review directly supports alcohol-associated intestinal-barrier damage and endotoxin release.
  downstream:
  - target: Kupffer-Cell and Hepatocyte Inflammatory Injury
    description: >-
      Portal endotoxin activates hepatic TLR4-dependent signaling in Kupffer cells
      and other liver cells, increasing inflammatory mediators and liver injury.
    hypothesis_groups:
    - canonical_multihit_alcohol_injury
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Hepatic TLR4-dependent, MyD88-independent inflammatory signaling
    evidence:
    - reference: PMID:18792393
      reference_title: The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        While TLR4 deficiency was protective, MyD88 deficiency failed to prevent
        alcohol-induced liver damage and inflammation.
      explanation: >-
        Ethanol-fed knockout mice support TLR4-dependent hepatic inflammatory injury
        downstream of gut-derived endotoxin while refining the signaling route.
- name: Liver Sinusoidal Endothelial Dysfunction
  description: >-
    CYP2E1-dependent Hsp90 acetylation in LSECs reduces eNOS-derived nitric oxide
    and impairs sinusoidal endothelial function. This is an emerging preclinical
    mechanism whose prevalence and causal weight in human ALD remain uncertain.
  cell_types:
  - preferred_term: endothelial cell of hepatic sinusoid
    term:
      id: CL:1000398
      label: endothelial cell of hepatic sinusoid
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  evidence:
  - reference: PMID:33675874
    reference_title: Alcohol-induced Hsp90 acetylation is a novel driver of liver sinusoidal endothelial dysfunction and alcohol-related liver disease.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: LSECs expressed CYP2E1 and alcohol dehydrogenase 1 (ADH1) and metabolized alcohol.
    explanation: Primary human, rat, and mouse LSECs demonstrated local ethanol-metabolizing capacity.
  downstream:
  - target: Kupffer-Cell and Hepatocyte Inflammatory Injury
    description: >-
      Reduced endothelial nitric-oxide signaling may amplify hepatic injury and
      inflammatory crosstalk, but the omitted human intermediates are not yet resolved.
    hypothesis_groups:
    - lsec_hsp90_enos_axis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33675874
      reference_title: Alcohol-induced Hsp90 acetylation is a novel driver of liver sinusoidal endothelial dysfunction and alcohol-related liver disease.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        AAV8-driven HDAC6 overexpression specifically in liver ECs deacetylated Hsp90,
        restored Hsp90's interaction with eNOS and ameliorated alcohol-induced liver
        injury in mice.
      explanation: >-
        Endothelial rescue improved mouse liver injury, supporting an amplifier edge
        while leaving its human inflammatory intermediates unresolved.
- name: Kupffer-Cell and Hepatocyte Inflammatory Injury
  description: >-
    Oxidative hepatocyte injury and gut-derived microbial signals converge on Kupffer
    cells and hepatocytes, increasing TLR4-linked inflammatory signaling, cytokine
    production, and hepatocyte death. Human single-cell data show immune remodeling
    in established ALD but are associative rather than proof of causal direction.
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  - preferred_term: Kupffer cell
    term:
      id: CL:0000091
      label: Kupffer cell
  biological_processes:
  - preferred_term: inflammatory response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:18792393
    reference_title: The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Expression of inflammatory mediators (tumor necrosis factor-alpha and
      interleukin-6) and TLR4 coreceptors (CD14 and MD2) was significantly higher
      in livers of alcohol-fed WT, TLR2-KO, or MyD88-KO, but not in TLR4-KO mice,
      compared to controls.
    explanation: Ethanol-fed knockout mice support a TLR4-dependent inflammatory liver-injury node.
  - reference: PMID:39349248
    reference_title: Single-cell Profiling of Intrahepatic Immune Cells Reveals an Expansion of Tissue-resident Cytotoxic CD4(+) T Lymphocyte Subset Associated With Pathogenesis of Alcoholic-associated Liver Diseases.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additionally, we noted shifts in myeloid populations, with expanded APOE+
      macrophage and FCGR3B+ monocyte subsets in ALD samples relative to MASLD and
      healthy tissues.
    explanation: Human liver single-cell data support immune-cell remodeling but not causal direction.
  downstream:
  - target: Alcohol-associated hepatitis
    description: >-
      Severe inflammatory hepatocellular injury can present clinically as rapidly
      worsening jaundice and acute-on-chronic liver failure, but AH is not an
      obligatory stage in every ALD trajectory.
    hypothesis_groups:
    - canonical_multihit_alcohol_injury
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:38174913
      reference_title: 'ACG Clinical Guideline: Alcohol-Associated Liver Disease.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        A unique phenotype of advanced disease is alcohol-associated hepatitis (AH)
        presenting with rapid onset or worsening of jaundice, and acute on chronic
        liver failure in severe forms conveying a 1-month mortality risk of 20%-50%.
      explanation: >-
        The guideline supports AH as an acute clinical phenotype of advanced ALD,
        while the exact transition intermediates remain incompletely understood.
  - target: Hepatic Stellate Cell Activation
    description: >-
      Persistent inflammatory and oxidative signals activate TGF-beta and other
      profibrotic pathways that transform quiescent stellate cells into
      matrix-producing myofibroblasts.
    hypothesis_groups:
    - canonical_multihit_alcohol_injury
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - TGF-beta, reactive-oxygen-species, PDGF, and CTGF signaling
    evidence:
    - reference: PMID:31718044
      reference_title: TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        In cooperation with other signaling pathways, triggered by e.g., reactive
        oxygen species (ROS), platelet-derived growth factor (PDGF), and connective
        tissue growth factor (CTGF), TGF-β signaling is considered the key fibrogenic
        pathway that drives HSC activation and induces ECM production
      explanation: The review supplies the principal omitted profibrotic signaling intermediates.
- name: Hepatic Stellate Cell Activation
  conforms_to: 'fibrotic_response#Mesenchymal Cell Activation'
  description: >-
    TGF-beta and cooperating injury signals activate hepatic stellate cells and
    promote their transition toward proliferative, contractile, collagen-producing
    myofibroblasts.
  cell_types:
  - preferred_term: hepatic stellate cell
    term:
      id: CL:0000632
      label: hepatic stellate cell
  - preferred_term: myofibroblast cell
    term:
      id: CL:0000186
      label: myofibroblast cell
  biological_processes:
  - preferred_term: transforming growth factor beta receptor signaling pathway
    modifier: INCREASED
    term:
      id: GO:0007179
      label: transforming growth factor beta receptor signaling pathway
  evidence:
  - reference: PMID:31718044
    reference_title: TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      there is a broad consensus that HSC are the major contributors for the MFB
      pool during liver fibrosis, independent of the damaging source
    explanation: The review identifies HSCs as the principal source of liver-fibrosis myofibroblasts.
  downstream:
  - target: Excessive Hepatic Extracellular Matrix Deposition
    description: Activated HSC-derived myofibroblasts synthesize collagen and other scar-matrix proteins.
    hypothesis_groups:
    - canonical_multihit_alcohol_injury
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31718044
      reference_title: TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Myofibroblasts (MFB) are the main producers of collagens and other ECM
        proteins and are therefore central in scar formation during liver fibrogenesis.
      explanation: The review directly links activated myofibroblasts to ECM production.
- name: Excessive Hepatic Extracellular Matrix Deposition
  conforms_to: 'fibrotic_response#Excessive ECM Deposition'
  description: >-
    Activated myofibroblasts deposit excessive fibrillar collagen and other
    extracellular-matrix proteins in the space of Disse, disrupting sinusoidal
    exchange and forming hepatic scar tissue.
  cell_types:
  - preferred_term: myofibroblast cell
    term:
      id: CL:0000186
      label: myofibroblast cell
  biological_processes:
  - preferred_term: extracellular matrix organization
    modifier: INCREASED
    term:
      id: GO:0030198
      label: extracellular matrix organization
  - preferred_term: collagen biosynthetic process
    modifier: INCREASED
    term:
      id: GO:0032964
      label: collagen biosynthetic process
  - preferred_term: collagen fibril organization
    modifier: INCREASED
    term:
      id: GO:0030199
      label: collagen fibril organization
  evidence:
  - reference: PMID:31718044
    reference_title: TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Fibrosis means that an excessive amount of fibrillar extracellular matrix
      (ECM) proteins, e.g., collagen I and III, is deposited in the space of Disse
    explanation: The review defines hepatic fibrosis by excessive fibrillar ECM deposition.
  downstream:
  - target: Hepatic fibrosis
    description: Accumulated fibrillar scar matrix manifests as hepatic fibrosis.
    hypothesis_groups:
    - canonical_multihit_alcohol_injury
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31718044
      reference_title: TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Fibrosis means that an excessive amount of fibrillar extracellular matrix
        (ECM) proteins, e.g., collagen I and III, is deposited in the space of Disse
      explanation: Excessive fibrillar hepatic ECM is the tissue substrate of the fibrosis phenotype.
  - target: Cirrhotic Architectural Distortion and Functional Failure
    description: >-
      Persistent matrix deposition and scar remodeling distort hepatic architecture,
      alter sinusoidal flow, and progressively impair organ function.
    hypothesis_groups:
    - canonical_multihit_alcohol_injury
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Bridging fibrosis, regenerative nodules, vascular remodeling, and sinusoidal resistance
    evidence:
    - reference: PMID:23255577
      reference_title: Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Fibrosis is a pathological scarring process that leads to destruction of
        organ architecture and impairment of organ function.
      explanation: The review supports the general scar-to-architectural-destruction transition.
- name: Cirrhotic Architectural Distortion and Functional Failure
  conforms_to: 'fibrotic_response#Architectural Distortion and Organ Dysfunction'
  description: >-
    Bridging scar, regenerative nodules, sinusoidal and vascular remodeling, and
    loss of functional hepatocyte mass produce cirrhosis, portal hypertension, and
    impaired liver function. These manifestations characterize advanced disease
    rather than every person with ALD.
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  evidence:
  - reference: PMID:31718044
    reference_title: TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      If the liver damage-inducing agent is not properly removed, liver fibrogenesis
      perpetuates (reflected by the term “chronic”) until the liver architecture is
      strongly distorted, and can then progress to the late stages of liver disease,
      liver cirrhosis and hepatocellular carcinoma (HCC), and thus could finally lead
      to liver failure and death
    explanation: Persistent liver fibrogenesis is linked to architectural distortion, cirrhosis, and failure.
  downstream:
  - target: Cirrhosis
    description: Advanced architectural distortion and nodular remodeling manifest clinically as cirrhosis.
    hypothesis_groups:
    - canonical_multihit_alcohol_injury
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31718044
      reference_title: TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        liver fibrogenesis perpetuates (reflected by the term “chronic”) until the
        liver architecture is strongly distorted, and can then progress to the late
        stages of liver disease, liver cirrhosis
      explanation: The review directly links persistent fibrogenesis and distorted architecture to cirrhosis.
  - target: Portal hypertension
    description: Fibrotic and vascular architectural remodeling increases intrahepatic resistance and portal pressure.
    hypothesis_groups:
    - canonical_multihit_alcohol_injury
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Increased intrahepatic vascular resistance and portal pressure
    evidence:
    - reference: PMID:38174913
      reference_title: 'ACG Clinical Guideline: Alcohol-Associated Liver Disease.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        The spectrum of ALD ranges from early asymptomatic liver injury to advanced
        disease with decompensation and portal hypertension.
      explanation: The guideline places portal hypertension within advanced ALD.
  - target: Decreased liver function
    description: Loss of functional parenchyma and distorted hepatic architecture impair liver function.
    hypothesis_groups:
    - canonical_multihit_alcohol_injury
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Reduced functional hepatocyte mass and disrupted hepatic perfusion
    evidence:
    - reference: PMID:23255577
      reference_title: Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Fibrosis is a pathological scarring process that leads to destruction of
        organ architecture and impairment of organ function.
      explanation: The review links architectural destruction from fibrosis to impaired organ function.
- name: PNPLA3-Linked Gene-Environment Susceptibility
  role: susceptibility
  description: >-
    PNPLA3 rs738409 marks inherited susceptibility to alcohol-related cirrhosis.
    Alcohol exposure amplifies the association, but current evidence does not show
    that the variant is necessary or sufficient for ALD or establish a direct local
    lipid-overload mechanism.
  genes:
  - preferred_term: PNPLA3
    term:
      id: hgnc:18590
      label: PNPLA3
  evidence:
  - reference: PMID:26482880
    reference_title: A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      confirmed rs738409 in PNPLA3 as an important risk locus for alcohol-related
      cirrhosis (P = 1.54 × 10(-48)) at a genome-wide level of significance.
    explanation: The GWAS establishes susceptibility to the advanced cirrhosis outcome.
  downstream:
  - target: Cirrhotic Architectural Distortion and Functional Failure
    description: >-
      PNPLA3 rs738409 increases susceptibility to alcohol-related cirrhosis, but the
      molecular path from the locus to advanced architectural disease is unresolved.
    hypothesis_groups:
    - pnpla3_gene_environment_susceptibility
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:26482880
      reference_title: A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        confirmed rs738409 in PNPLA3 as an important risk locus for alcohol-related
        cirrhosis (P = 1.54 × 10(-48)) at a genome-wide level of significance.
      explanation: >-
        The association supports an indirect susceptibility edge to alcohol-related
        cirrhosis while leaving causal intermediates unknown.
genetic:
- name: PNPLA3 rs738409 susceptibility
  gene_term:
    preferred_term: PNPLA3
    term:
      id: hgnc:18590
      label: PNPLA3
  association: >-
    The rs738409 PNPLA3 locus increases susceptibility to alcohol-related
    cirrhosis in exposed populations but is neither necessary nor sufficient to
    cause ALD.
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  evidence:
  - reference: PMID:26482880
    reference_title: A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      variants in the MBOAT7 (P = 1.03 × 10(-9)) and TM6SF2 (P = 7.89 × 10(-10))
      genes as new risk loci and confirmed rs738409 in PNPLA3 as an important risk
      locus for alcohol-related cirrhosis (P = 1.54 × 10(-48)) at a genome-wide
      level of significance.
    explanation: The European GWAS establishes rs738409 as a susceptibility locus, not a monogenic cause.
phenotypes:
- category: Gastrointestinal
  name: Hepatic steatosis
  description: >-
    Hepatic triglyceride accumulation is a common early manifestation but does not
    imply inevitable progression to hepatitis or cirrhosis.
  phenotype_term:
    preferred_term: Hepatic steatosis
    term:
      id: HP:0001397
      label: Hepatic steatosis
  evidence:
  - reference: PMID:39362713
    reference_title: Pathogenesis of Alcohol-Associated Liver Disease.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Several intracellular, intrahepatic, and extrahepatic factors influence
      development of early fatty liver injury leading to inflammation and fibrosis.
    explanation: The review identifies fatty liver injury as an early ALD manifestation.
- category: Gastrointestinal
  name: Alcohol-associated hepatitis
  description: >-
    An acute inflammatory clinical phenotype marked by rapid onset or worsening of
    jaundice, sometimes with severe acute-on-chronic liver failure; it is not a
    mandatory intermediate stage in ALD progression.
  phenotype_term:
    preferred_term: Hepatitis
    term:
      id: HP:0012115
      label: Hepatitis
  evidence:
  - reference: PMID:38174913
    reference_title: 'ACG Clinical Guideline: Alcohol-Associated Liver Disease.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      A unique phenotype of advanced disease is alcohol-associated hepatitis (AH)
      presenting with rapid onset or worsening of jaundice, and acute on chronic
      liver failure in severe forms conveying a 1-month mortality risk of 20%-50%.
    explanation: The guideline defines the clinical AH phenotype and its severe form.
- category: Gastrointestinal
  name: Hepatic fibrosis
  description: Excessive hepatic scar-matrix deposition after persistent injury.
  phenotype_term:
    preferred_term: Hepatic fibrosis
    term:
      id: HP:0001395
      label: Hepatic fibrosis
  evidence:
  - reference: PMID:31718044
    reference_title: TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Fibrosis means that an excessive amount of fibrillar extracellular matrix
      (ECM) proteins, e.g., collagen I and III, is deposited in the space of Disse
    explanation: The review defines the hepatic fibrosis substrate.
- category: Gastrointestinal
  name: Cirrhosis
  description: Advanced scar-associated distortion of liver architecture.
  phenotype_term:
    preferred_term: Cirrhosis
    term:
      id: HP:0001394
      label: Cirrhosis
  evidence:
  - reference: PMID:38174913
    reference_title: 'ACG Clinical Guideline: Alcohol-Associated Liver Disease.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Liver transplantation, a definitive treatment option in patients with
      advanced cirrhosis, should be considered in selected patients with AH
    explanation: The guideline recognizes advanced cirrhosis within the treated ALD spectrum.
- category: Cardiovascular
  name: Portal hypertension
  description: Increased portal pressure is a manifestation of advanced fibrotic and cirrhotic disease.
  phenotype_term:
    preferred_term: Portal hypertension
    term:
      id: HP:0001409
      label: Portal hypertension
  evidence:
  - reference: PMID:38174913
    reference_title: 'ACG Clinical Guideline: Alcohol-Associated Liver Disease.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The spectrum of ALD ranges from early asymptomatic liver injury to advanced
      disease with decompensation and portal hypertension.
    explanation: The guideline explicitly places portal hypertension in advanced ALD.
- category: Gastrointestinal
  name: Decreased liver function
  description: Advanced architectural distortion can impair hepatic synthetic, metabolic, and detoxifying functions.
  phenotype_term:
    preferred_term: Decreased liver function
    term:
      id: HP:0001410
      label: Decreased liver function
  evidence:
  - reference: PMID:23255577
    reference_title: Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Fibrosis is a pathological scarring process that leads to destruction of
      organ architecture and impairment of organ function.
    explanation: The fibrosis review supports organ-function impairment from advanced scarring.
progression:
- phase: Early asymptomatic injury and steatosis
  notes: >-
    Early ALD may be clinically silent and may include steatosis; the spectrum
    statement does not imply inevitable progression to advanced disease.
  evidence:
  - reference: PMID:38174913
    reference_title: 'ACG Clinical Guideline: Alcohol-Associated Liver Disease.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The spectrum of ALD ranges from early asymptomatic liver injury to advanced
      disease with decompensation and portal hypertension.
    explanation: The guideline supports an early asymptomatic end of the ALD spectrum.
- phase: Alcohol-associated hepatitis acute branch
  notes: >-
    AH can present acutely on underlying chronic liver disease with rapidly
    worsening jaundice. It is modeled as a branch rather than a required stage
    between steatosis and fibrosis.
  evidence:
  - reference: PMID:39362713
    reference_title: Pathogenesis of Alcohol-Associated Liver Disease.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The pathogenesis of alcohol-associated hepatitis (AH), an advanced form of
      acute-on-chronic liver failure due to excessive chronic intake in patients
      with underlying liver disease, is not well understood.
    explanation: The review supports acute-on-chronic AH and the remaining mechanistic uncertainty.
- phase: Advanced fibrosis, cirrhosis, and decompensation
  notes: >-
    Continued injury can produce advanced fibrosis and cirrhosis with portal
    hypertension and decompensation, although individual trajectories vary.
  evidence:
  - reference: PMID:38174913
    reference_title: 'ACG Clinical Guideline: Alcohol-Associated Liver Disease.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The spectrum of ALD ranges from early asymptomatic liver injury to advanced
      disease with decompensation and portal hypertension.
    explanation: The guideline identifies the advanced end of the clinical spectrum.
diagnosis:
- name: Clinical assessment of harmful alcohol exposure
  description: >-
    A nonjudgmental alcohol-use history establishes the principal etiologic risk
    context for ALD. Exposure history alone neither confirms a particular ALD stage
    nor substitutes for assessment of liver injury.
  diagnosis_term:
    preferred_term: clinical assessment
    term:
      id: NCIT:C124351
      label: Clinical Evaluation
  results: Harmful alcohol exposure establishes the etiologic risk context but does not stage liver disease.
  evidence:
  - reference: PMID:38174913
    reference_title: 'ACG Clinical Guideline: Alcohol-Associated Liver Disease.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      With harmful alcohol use as the primary risk factor, increasing alcohol use
      over the past decade has resulted in rapid growth of the ALD-related healthcare
      burden.
    explanation: The guideline supports harmful alcohol use as the defining etiologic risk context.
- name: Clinical classification of suspected alcohol-associated hepatitis
  description: >-
    Suspected AH should be classified as definite, probable, or possible using the
    NIAAA consensus framework. Probable AH requires the characteristic clinical and
    laboratory pattern without confounding factors; possible AH warrants additional
    evaluation and may require biopsy before disease-specific treatment.
  diagnosis_term:
    preferred_term: clinical assessment
    term:
      id: NCIT:C124351
      label: Clinical Evaluation
  results: Definite or probable AH supports treatment eligibility assessment; possible AH requires clarification of confounding causes.
  evidence:
  - reference: PMID:26921783
    reference_title: 'Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Probable AH: Clinically diagnosed AH without confounding factors (see below).
      In patients with heavy alcohol use and typical liver tests; and negative markers
      for immune (antinuclear antibody < 1:160 or anti–smooth antibody < 1:80
      dilutions) and metabolic liver disease; and absence of sepsis, shock, cocaine
      use, or recent use of a drug with DILI potential within 30 days, a diagnosis
      other than AH will be made in <10% of patients on liver biopsy.
    explanation: >-
      The NIAAA consensus defines probable AH and explicitly requires absence of
      major confounding causes.
- name: Transient elastography for fibrosis staging
  description: >-
    Transient elastography can noninvasively assess advanced fibrosis and cirrhosis
    in people with excessive alcohol use. Active alcohol-associated hepatitis can
    raise liver stiffness independently of fibrosis and must be considered during
    interpretation.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: NCIT:C18020
      label: Diagnostic Procedure
  results: Higher liver stiffness supports advanced fibrosis or cirrhosis, interpreted in the context of active hepatitis.
  evidence:
  - reference: PMID:28387018
    reference_title: Transient elastography alone and in combination with FibroTest(®) for the diagnosis of hepatic fibrosis in alcoholic liver disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      TE values correlated with fibrosis stage (r=.73; P<.0001) and steatosis stage
      (r=.19; P<.01). Patients with alcoholic hepatitis had higher TE values than
      those without alcoholic hepatitis (P<.0001).
    explanation: >-
      The prospective biopsy-referenced study supports TE for fibrosis staging and
      documents active hepatitis as an independent stiffness confounder.
treatments:
- name: Sustained alcohol abstinence with cessation support
  action_category: THERAPEUTIC
  therapeutic_modality: BEHAVIORAL
  description: >-
    Sustained abstinence removes the initiating exposure. All patients should receive
    cessation support; integrated hepatology, addiction-medicine, and psychosocial
    treatment is particularly important when alcohol use disorder is present.
  treatment_term:
    preferred_term: therapeutic avoidance of environmental exposure
    term:
      id: NCIT:C15900
      label: Lifestyle Therapy
  target_mechanisms:
  - target: Chronic Ethanol Exposure
    treatment_effect: INHIBITS
    description: Abstinence removes continued ethanol exposure, the initiating driver of the modeled causal graph.
    evidence:
    - reference: PMID:38174913
      reference_title: 'ACG Clinical Guideline: Alcohol-Associated Liver Disease.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Abstinence of alcohol use, a crucial determinant of long-term outcomes, is challenging to achieve in ALD patients with concurrent alcohol use disorder (AUD).
      explanation: The guideline identifies abstinence as a crucial determinant of long-term ALD outcomes.
  evidence:
  - reference: PMID:36481475
    reference_title: Alcohol Abstinence Improves Prognosis Across All Stages of Portal Hypertension in Alcohol-Related Cirrhosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Alcohol abstinence was linked to a significantly reduced risk of hepatic
      decompensation
    explanation: >-
      In a cohort with alcohol-related cirrhosis and clinically significant portal
      hypertension, abstinence was associated with lower decompensation and mortality.
- name: Prednisolone for eligible severe alcohol-associated hepatitis
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  description: >-
    Prednisolone is restricted to eligible patients with definite or probable severe
    AH (MELD >20), after serious infection and other glucocorticoid contraindications
    are assessed. Response should be checked with the Lille model at day 4 or 7 and
    treatment stopped for nonresponse (>0.45). STOPAH found a nonsignificant 28-day
    mortality reduction, no 90-day or one-year benefit, and more serious infections,
    so benefit should not be generalized to all ALD.
  treatment_term:
    preferred_term: corticosteroid agent therapy
    term:
      id: NCIT:C122080
      label: Systemic Corticosteroid Therapy
    therapeutic_agent:
    - preferred_term: prednisolone
      term:
        id: CHEBI:8378
        label: prednisolone
  target_mechanisms:
  - target: Kupffer-Cell and Hepatocyte Inflammatory Injury
    treatment_effect: INHIBITS
    description: Systemic corticosteroid activity suppresses the severe inflammatory injury phenotype in eligible AH.
    evidence:
    - reference: PMID:38174913
      reference_title: 'ACG Clinical Guideline: Alcohol-Associated Liver Disease.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Corticosteroids are currently the only available therapeutic with proven
        efficacy for patients with severe AH, providing survival benefit at 1 month
        in 50%-60% of patients.
      explanation: The guideline limits corticosteroid efficacy to severe AH and short-term outcomes.
  evidence:
  - reference: PMID:27979049
    reference_title: 'Medical Management of Severe Alcoholic Hepatitis: Expert Review from the Clinical Practice Updates Committee of the AGA Institute.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Patients with MDF > 32 or MELD score > 20 without a contraindication to
      glucocorticoid, such as hepatitis B viral infection, tuberculosis, or other
      serious infectious diseases, may be treated with methylprednisolone 32 mg daily
    explanation: >-
      The expert review bounds glucocorticoid use to severe AH and requires
      contraindication and serious-infection assessment.
  - reference: PMID:27922027
    reference_title: A Day-4 Lille Model Predicts Response to Corticosteroids and Mortality in Severe Alcoholic Hepatitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      LM4 is as accurate as LM7 in predicting response to corticosteroids, as well as
      28- and 90-day mortality. Assessing the efficacy of prednisolone at an earlier
      time point can avoid a more prolonged futile use of this therapy.
    explanation: The multinational cohort supports day-4 assessment as an alternative to day 7.
  - reference: PMID:27922027
    reference_title: A Day-4 Lille Model Predicts Response to Corticosteroids and Mortality in Severe Alcoholic Hepatitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Response to corticosteroids was assessed with LM4 and LM7, according to the
      validated cutoff value (CUV>0.45).
    explanation: The study supplies the Lille nonresponse cutoff used to stop futile exposure.
  - reference: PMID:25901427
    reference_title: Prednisolone or pentoxifylline for alcoholic hepatitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Prednisolone was associated with a reduction in 28-day mortality that did not
      reach significance and with no improvement in outcomes at 90 days or 1 year.
    explanation: STOPAH bounds the magnitude and duration of prednisolone benefit.
  - reference: PMID:25901427
    reference_title: Prednisolone or pentoxifylline for alcoholic hepatitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Serious infections occurred in 13% of the patients treated with prednisolone
      versus 7% of those who did not receive prednisolone (P=0.002).
    explanation: STOPAH documents the important infection-risk tradeoff.
- name: Liver transplantation for selected advanced disease
  action_category: THERAPEUTIC
  therapeutic_modality: SURGERY
  description: >-
    Liver transplantation can replace a failing cirrhotic liver and may be considered
    for carefully selected patients with severe AH unresponsive to medical therapy.
    Evidence for early transplantation in AH comes from highly selected cohorts and
    must not be generalized to all patients.
  treatment_term:
    preferred_term: liver transplantation
    term:
      id: NCIT:C15271
      label: Liver Transplantation
  target_mechanisms:
  - target: Cirrhotic Architectural Distortion and Functional Failure
    treatment_effect: BYPASSES
    description: >-
      Transplantation replaces a selected nonrecovering, decompensated or failing
      liver rather than reversing its established fibrotic mechanism.
    evidence:
    - reference: PMID:38174913
      reference_title: 'ACG Clinical Guideline: Alcohol-Associated Liver Disease.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Liver transplantation, a definitive treatment option in patients with
        advanced cirrhosis, should be considered in selected patients with AH, who
        are unresponsive to medical therapy and have a low risk of relapse to
        posttransplant alcohol use.
      explanation: The guideline supports transplantation for advanced cirrhosis and selected AH nonresponders.
  evidence:
  - reference: PMID:22070476
    reference_title: Early liver transplantation for severe alcoholic hepatitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Fewer than 2% of patients admitted for an episode of severe alcoholic hepatitis were selected.
    explanation: The pivotal early-transplant study documents the narrow selection boundary.
  - reference: PMID:22070476
    reference_title: Early liver transplantation for severe alcoholic hepatitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The cumulative 6-month survival rate (±SE) was higher among patients who
      received early transplantation than among those who did not (77 ± 8% vs. 23
      ± 8%, P<0.001).
    explanation: The selected severe-AH cohort had substantially higher six-month survival after transplantation.
discussions:
- discussion_id: gap_baijiu_nonethanol_active_constituent_and_mediation
  prompt: >-
    Which of the GC-MS-identified candidate non-ethanol Baijiu constituents, or
    which combination, accounts for the protection observed in ethanol-exposed
    mice, and is that protection mediated by a species-resolved microbial lactate
    route, an intrahepatic glycolytic-lactate route, a lactate-independent
    intestinal-barrier/endotoxin route, a microbial tryptophan-metabolite/AhR
    route, a direct hepatic effect, or a combination of these routes?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - mechanistic_hypotheses#baijiu_extract_microbiota_lactate_mediation_model
  - pathophysiology#Hepatic Ethanol Metabolism and Redox-Oxidative Stress
  - pathophysiology#Intestinal Barrier Dysfunction and Endotoxin Translocation
  - pathophysiology#Kupffer-Cell and Hepatocyte Inflammatory Injury
  rationale: >-
    The source study compared a chemically complex non-ethanol extract with
    ethanol and measured microbiota composition, metabolites, redox markers, and
    liver injury concurrently. GC-MS identified candidate constituents, but
    those candidates were not individually or combinatorially perturbed to assign
    the whole-extract effect. The co-moving endpoints also do not establish
    causal order, and co-moving permeability, endotoxin, and inflammatory
    endpoints alone cannot establish barrier-pathway mediation. Genus-level 16S
    data and the Firmicutes/Bacteroidetes ratio cannot show that the expanded
    Ligilactobacillus population produced the lactate reaching the liver, while
    the cell assay shows only that excess lactate can worsen oxidative stress. A
    separate chronic liquor-fed mouse study found alcohol-associated depletion
    of broad Lactobacillus and Bifidobacterium populations and protection after
    Lactiplantibacillus plantarum treatment, so taxon direction is strain- and
    model-dependent rather than a general refutation or validation of the
    Ligilactobacillus observation. A causal pectin study in
    human-microbiota-associated alcohol-fed mice associated higher bacterial
    tryptophan-metabolite production with improvement and causally implicated
    AhR signaling: an AhR agonist reduced injury and Ahr loss abolished the
    prebiotic benefit. This competing route was not measured in the seed study.
    In severe human alcohol-related acute-on-chronic liver failure, serum lactate
    predicts mortality but does not establish a microbial source or causal
    direction. Even if lactate contributes, hepatocyte-derived glycolytic lactate
    rather than gut-derived flux could explain the hepatic signal. A changed
    community could instead protect through intestinal-barrier integrity,
    reduced portal endotoxin, and lower hepatic TLR4/Kupffer-cell activation
    without lactate mediation. Moreover, complete microbiota removal can itself
    alter ethanol metabolism and worsen acute liver injury in mice, so a global
    depletion comparison would not isolate either microbial route. Independent
    in-vivo and hepatocyte fraction screens, species- and strain-resolved
    transfer, pathway-specific readouts for endotoxin/TLR4 and
    tryptophan-metabolite/AhR alternatives, source-resolved metabolic tracing,
    and controlled rescue and pathway-interaction experiments are needed before
    this model-specific signal can be added to the causal graph. Two subsequent
    non-ALD mouse studies now directly demonstrate a gut-to-portal-vein-to-liver
    D-lactate route that the seed study could not establish on its own:
    commensal-derived D-lactate reaching the liver via the portal vein programs
    Kupffer-cell-mediated pathogen clearance in a sepsis model, and gut
    microbiota is reported as the dominant source of circulating D-lactate that
    raises hepatic glycogen, triglycerides, and inflammation in obese mice with
    fatty liver disease. Both studies overturn the narrow claim that no
    gut-to-liver lactate route has been shown, but neither exposes ethanol,
    tests the Baijiu extract, or resolves whether the (R)-lactate (D-lactate) or
    (S)-lactate (L-lactate) stereoisomer is the species reaching the liver in the
    ethanol-exposed model; they sharpen rather than validate the
    microbiota-lactate hypothesis and should be read as external plausibility
    for a route, not as evidence for this intervention. A distinct finding in a
    direct alcohol-associated liver disease mouse model complicates rather than
    supports the microbiota-lactate model: ethyl lactate, a lactate ester and
    non-ethanol distilled-liquor ingredient chemically distinct from free D- or
    L-lactate, ameliorates ethanol-induced hepatosteatosis and acute-on-chronic
    injury through hepatocyte SIRT1-FGF21 signaling, independent of any
    demonstrated microbial lactate flux; this ester must not be conflated with
    the microbial-lactate route and is itself a plausible, mechanistically
    direct candidate among the seed study's GC-MS-identified constituents. A
    separate Baijiu-versus-ethanol comparison in mice adds a further competing
    route: a non-alcoholic Baijiu-compound formula attenuated ethanol-induced
    liver injury and intestinal barrier leakage by opposing
    deoxycholic-acid-driven barrier disruption, implicating bile-acid signaling
    alongside the tryptophan-metabolite/AhR pathway already noted above
    (deoxycholic acid/deoxycholate should not be confused with the unrelated
    drug dichloroacetate, which shares the same DCA abbreviation). The finding
    does not establish that Baijiu is safer than other alcohol exposure or
    protective in humans.
  proposed_experiments:
  - experiment_id: exp_baijiu_fraction_gnotobiotic_pathway_mediation
    name: Bioassay-guided fractionation with gnotobiotic pathway mediation testing
    description: >-
      Fractionate the study's non-ethanol extract and run two independent
      bioactivity screens: an ethanol-dose-matched, isocaloric, pair-fed mouse
      screen for in-vivo protection and microbial/barrier effects, and a primary
      hepatocyte screen for microbiota-independent direct effects. Advance every
      reproducibly in-vivo-active fraction into conventional and gnotobiotic
      pathway testing regardless of its hepatocyte result; retain
      hepatocyte-active fractions separately as direct-effect candidates. In
      gnotobiotic recipients colonized with microbiota from ethanol-only or
      fraction-treated donors, resolve the Ligilactobacillus signal to cultured
      species and strains, quantify lactate production, and compare
      reconstitution with the wild-type isolate versus a
      lactate-production-deficient derivative. Use stable-isotope tracing and
      lactate add-back to test the lactate route, alongside intestinal
      permeability, portal endotoxin, tight-junction, and hepatic
      TLR4/Kupffer-cell measurements for a lactate-independent barrier route. For
      the barrier route, restore the portal lipopolysaccharide exposure of
      protected mice to the ethanol-only range without changing lactate, and
      cross the fraction or community intervention with Kupffer-cell-specific
      Tlr4 loss or validated Kupffer-targeted TLR4 inhibition to test phenocopy,
      occlusion, and add-back interaction. In parallel, quantify microbial
      tryptophan metabolites and AhR target engagement, then use AhR inhibition
      and agonist rescue to test whether this competing microbial-metabolite
      pathway is necessary or sufficient. Throughout, quantify D-lactate and
      L-lactate separately by chiral chromatography in intestinal contents,
      portal blood, systemic blood, and liver rather than assuming a single
      achiral lactate pool. Add a parallel arm testing the distinct non-ethanol
      constituent ethyl lactate against equimolar free D-/L-lactate, with SIRT1
      inhibition and hepatocyte-specific Fgf21 loss, to isolate this
      ester-specific direct-hepatic route from microbial lactate flux. Add a
      further arm restoring deoxycholic acid in protected animals to the
      ethanol-only range to test a bile-acid/barrier route distinct from
      lipopolysaccharide-driven endotoxin signaling. Measure ethanol
      pharmacokinetics in every arm.
    experiment_type:
      preferred_term: bioassay-guided fractionation and gnotobiotic mediation experiment
    model_systems:
    - name: Ethanol-exposed conventional and gnotobiotic C57BL/6J mice
      description: >-
        Pair-fed female and male mice receiving identical ethanol doses, with
        defined donor communities or strain-level reconstitution in gnotobiotic
        recipients.
      experimental_model_type: OTHER
      organism:
        preferred_term: mouse
        term:
          id: NCBITaxon:10090
          label: Mus musculus
    - name: Primary mouse hepatocyte direct-effect assay
      description: >-
        Primary hepatocytes exposed to matched ethanol and extract fractions,
        with or without lactate, to test protection that does not require a
        microbial community.
      experimental_model_type: PRIMARY_CELL_CULTURE
      organism:
        preferred_term: mouse
        term:
          id: NCBITaxon:10090
          label: Mus musculus
      cell_types:
      - preferred_term: hepatocyte
        term:
          id: CL:0000182
          label: hepatocyte
    perturbations:
    - name: Chemically defined non-ethanol extract fractions
      target: pathophysiology#Hepatic Ethanol Metabolism and Redox-Oxidative Stress
      description: >-
        Compare the whole extract, orthogonal chemical fractions, and identified
        constituent combinations at exposure-matched doses.
    - name: Donor-community transfer and Ligilactobacillus strain reconstitution
      target: lactate biosynthetic process
      description: >-
        Transfer complete donor communities, then add a cultured candidate
        Ligilactobacillus strain or a lactate-production-deficient derivative to
        test strain and metabolic-function dependence.
      biological_processes:
      - preferred_term: lactate biosynthetic process
        term:
          id: GO:0019249
          label: lactate biosynthetic process
    - name: Stable-isotope lactate tracing and lactate add-back
      target: pathophysiology#Lipotoxic and Oxidative Hepatocyte Stress
      description: >-
        Trace intestinal-to-portal-to-hepatic lactate flux with stereospecific
        (chiral) separation of D-lactate from L-lactate, and restore each
        stereoisomer's exposure separately in protected animals to test
        whether lowering a specific stereoisomer, rather than total lactate,
        is necessary for protection.
      chemical_entities:
      - preferred_term: lactate
        term:
          id: CHEBI:24996
          label: lactate
      - preferred_term: D-lactate
        term:
          id: CHEBI:16004
          label: (R)-lactate
      - preferred_term: L-lactate
        term:
          id: CHEBI:16651
          label: (S)-lactate
    - name: Controlled portal-endotoxin add-back
      target: pathophysiology#Intestinal Barrier Dysfunction and Endotoxin Translocation
      description: >-
        In the protected fraction or donor-community arm, use titrated low-dose
        mesenteric-vein infusion of ultrapure lipopolysaccharide to restore the
        portal endotoxin time course and exposure to the ethanol-only range
        without exceeding its systemic endotoxin exposure, while confirming
        unchanged species-resolved lactate flux, ethanol pharmacokinetics, and
        community composition. This bypass rescue tests whether reduced hepatic
        endotoxin exposure is necessary for protection rather than merely
        co-moving with it.
      chemical_entities:
      - preferred_term: lipopolysaccharide
        term:
          id: CHEBI:16412
          label: lipopolysaccharide
    - name: Kupffer-cell TLR4 pathway interaction
      target: pathophysiology#Kupffer-Cell and Hepatocyte Inflammatory Injury
      description: >-
        Cross ethanol-only and protected fraction or donor-community arms with
        lineage-validated Kupffer-cell-specific Tlr4 loss or a validated
        Kupffer-targeted TLR4 inhibitor. Test whether pathway blockade
        phenocopies protection in ethanol-only mice, occludes additional
        protection by the fraction or community, and prevents portal-endotoxin
        add-back from restoring hepatic inflammation and injury.
    - name: AhR pathway necessity and sufficiency
      target: aryl hydrocarbon receptor signaling
      description: >-
        Cross ethanol-only and protected fraction or donor-community arms with
        Ahr-deficient recipients or a validated AhR antagonist, and administer
        the AhR agonist FICZ in a matched ethanol-only arm. Test whether AhR loss
        or inhibition abolishes protection and whether agonism phenocopies and
        occludes the fraction or community effect.
    - name: Ethyl lactate SIRT1-FGF21 pathway testing
      target: pathophysiology#Lipotoxic and Oxidative Hepatocyte Stress
      description: >-
        Administer purified ethyl lactate, at doses matched to its
        concentration in the whole extract, against equimolar free D-/L-lactate
        in ethanol-fed mice, with SIRT1 inhibition (EX527) and
        hepatocyte-specific Fgf21 loss in parallel arms. Tests whether the
        seed extract's activity depends on this distinct, microbiota-independent
        ester rather than on microbial lactate flux.
      chemical_entities:
      - preferred_term: ethyl lactate
        term:
          id: CHEBI:78321
          label: ethyl 2-hydroxypropanoate
    - name: Deoxycholate-dependent intestinal barrier testing
      target: pathophysiology#Intestinal Barrier Dysfunction and Endotoxin Translocation
      description: >-
        Compare exogenous deoxycholic-acid supplementation with a
        non-alcoholic Baijiu-compound formula in ethanol-fed mice to test
        whether extract protection acts by suppressing deoxycholic-acid-driven
        barrier disruption, distinct from the lipopolysaccharide/TLR4 and
        lactate routes tested above.
      chemical_entities:
      - preferred_term: deoxycholic acid
        term:
          id: CHEBI:28834
          label: deoxycholic acid
    controls:
    - name: Ethanol-only and vehicle controls
      description: >-
        Isocaloric pair-fed controls receiving identical ethanol doses, plus a
        non-ethanol vehicle or matrix control for every fraction.
    - name: Community, strain, and metabolite rescue controls
      description: >-
        Reciprocal donor-community transfers, heat-killed strain controls,
        wild-type versus lactate-deficient strain reconstitution, and
        osmolality- and pH-matched lactate vehicle controls.
    - name: Ethanol pharmacokinetic control
      description: >-
        Serial blood ethanol and acetaldehyde measurements to exclude altered
        ethanol absorption or clearance as the explanation for reduced injury.
    - name: Portal-endotoxin add-back controls
      description: >-
        Compare protected animals receiving exposure-matched lipopolysaccharide
        with protected vehicle-infused, ethanol-only vehicle-infused, and
        pair-fed sham-procedure controls. Verify the portal and systemic
        endotoxin time courses and confirm that add-back does not alter lactate
        flux, community composition, or ethanol and acetaldehyde exposure.
    - name: Kupffer-cell TLR4 interaction controls
      description: >-
        Use Cre-negative Tlr4-floxed littermates and validate Kupffer-cell
        targeting and TLR4 loss; for a pharmacologic replication, include matched
        inhibitor vehicle and target-engagement controls. Apply the same fraction,
        community, endotoxin-add-back, and pair-feeding assignments across
        TLR4-intact and TLR4-blocked groups.
    - name: AhR pathway interaction controls
      description: >-
        Use matched AhR-competent littermates, antagonist and agonist vehicle
        controls, equivalent donor-community engraftment, and intestinal and
        hepatic target-engagement measurements. Confirm that AhR perturbation
        does not change ethanol or acetaldehyde exposure.
    - name: Ethyl lactate and bile-acid pathway interaction controls
      description: >-
        Include dose-matched free D-/L-lactate and ester-vehicle controls for
        the ethyl lactate arm, EX527 vehicle and hepatocyte-specific
        Fgf21-intact littermates for the SIRT1-FGF21 cross, and
        deoxycholic-acid vehicle plus Baijiu-compound-formula-vehicle controls
        for the bile-acid arm. Confirm none of these perturbations alter
        ethanol or acetaldehyde exposure or species-resolved lactate flux.
    readouts:
    - name: Species-resolved microbial lactate flux
      target: lactate biosynthetic process
      description: >-
        Shotgun metagenomics, isolate genomics, and isotope-resolved fecal,
        portal, and hepatic lactate quantify the organism and metabolic flux
        rather than relying on a genus abundance or phylum ratio. Chiral
        separation resolves D-lactate from L-lactate at each site so that a
        stereospecific route is not collapsed into a single achiral pool.
      biological_processes:
      - preferred_term: lactate biosynthetic process
        term:
          id: GO:0019249
          label: lactate biosynthetic process
      assays:
      - preferred_term: shotgun metagenomic sequencing
      - preferred_term: targeted metabolomics
      - preferred_term: stable-isotope metabolic flux analysis
      - preferred_term: chiral chromatography
      direction: POSITIVE
    - name: Intestinal permeability and portal endotoxin
      target: pathophysiology#Intestinal Barrier Dysfunction and Endotoxin Translocation
      description: >-
        Serial FITC-dextran permeability and portal endotoxin measurements
        quantify barrier failure and microbial-product translocation
        independently of lactate and determine whether barrier improvement
        precedes hepatic pathway and injury changes.
      assays:
      - preferred_term: FITC-dextran intestinal permeability assay
      - preferred_term: portal endotoxin assay
      direction: POSITIVE
    - name: Intestinal tight-junction integrity
      target: pathophysiology#Intestinal Barrier Dysfunction and Endotoxin Translocation
      description: >-
        Intestinal epithelial ZO-1, occludin, and claudin localization and
        abundance provide an inverse readout of barrier dysfunction.
      assays:
      - preferred_term: tight-junction protein immunostaining
      - preferred_term: tight-junction protein quantification
      direction: NEGATIVE
    - name: Hepatic TLR4 and Kupffer-cell activation
      target: pathophysiology#Kupffer-Cell and Hepatocyte Inflammatory Injury
      description: >-
        Time-resolved hepatic TLR4-pathway activity, Kupffer-cell activation, and
        inflammatory cytokines test the sequence and interaction of a
        lactate-independent endotoxin route from community remodeling to liver
        injury.
      assays:
      - preferred_term: hepatic TLR4 signaling assay
      - preferred_term: Kupffer-cell activation assay
      - preferred_term: inflammatory cytokine quantification
      direction: POSITIVE
    - name: Microbial tryptophan metabolites and AhR target engagement
      target: aryl hydrocarbon receptor signaling
      description: >-
        Time-resolved fecal, portal, and hepatic tryptophan and indole metabolite
        profiles, together with intestinal and hepatic AhR reporter activity and
        Cyp1a1 and Nqo1 expression, test a causal microbial-metabolite route
        independently of lactate and endotoxin.
      assays:
      - preferred_term: targeted metabolomics
      - preferred_term: AhR reporter assay
      - preferred_term: gene expression assay
      direction: POSITIVE
    - name: Hepatic reductive redox shift and oxidative damage
      target: pathophysiology#Hepatic Ethanol Metabolism and Redox-Oxidative Stress
      description: >-
        Hepatic NADH/NAD+ ratio and MDA are measured before and after microbiota
        transfer, strain reconstitution, and lactate add-back.
      assays:
      - preferred_term: NADH to NAD+ ratio assay
      - preferred_term: lipid peroxidation assay
      direction: POSITIVE
    - name: Hepatic antioxidant capacity
      target: pathophysiology#Hepatic Ethanol Metabolism and Redox-Oxidative Stress
      description: >-
        SOD2 activity and the reduced-to-oxidized glutathione ratio provide
        inverse readouts of oxidative stress without bundling their direction
        with NADH/NAD+ and MDA.
      assays:
      - preferred_term: antioxidant enzyme activity assay
      - preferred_term: glutathione redox ratio assay
      direction: NEGATIVE
    - name: Hepatic injury and steatosis
      target: pathophysiology#Lipotoxic and Oxidative Hepatocyte Stress
      description: >-
        Blinded histopathology, hepatic triglycerides, serum ALT and AST, and
        inflammatory markers establish whether a change in lactate flux precedes
        and mediates tissue protection.
      assays:
      - preferred_term: liver histopathology
      - preferred_term: serum aminotransferase assay
      - preferred_term: hepatic triglyceride assay
      direction: POSITIVE
    - name: Hepatic SIRT1-FGF21 pathway activity
      target: pathophysiology#Lipotoxic and Oxidative Hepatocyte Stress
      description: >-
        Hepatic SIRT1 activity and serum/hepatic FGF21 induction test whether
        an ester-specific, microbiota-independent route accounts for
        protection when ethyl lactate is isolated from the whole extract.
      biological_processes:
      - preferred_term: fibroblast growth factor receptor signaling pathway
        term:
          id: GO:0008543
          label: fibroblast growth factor receptor signaling pathway
      assays:
      - preferred_term: sirtuin activity assay
      - preferred_term: enzyme-linked immunosorbent assay
      - preferred_term: gene expression assay
      direction: POSITIVE
    - name: Serum and hepatic bile acid profiling
      target: pathophysiology#Intestinal Barrier Dysfunction and Endotoxin Translocation
      description: >-
        Targeted bile-acid metabolomics quantifying deoxycholic acid and
        related secondary bile acids tests whether the extract or its
        fractions blunt ethanol-induced bile-acid elevation ahead of barrier
        and injury improvement.
      assays:
      - preferred_term: targeted metabolomics
      direction: POSITIVE
    decision_criterion: >-
      The microbiota-lactate model is supported only if a chemically defined
      fraction lowers species- and strain-resolved microbial lactate flux before
      hepatic improvement, the donor community transfers protection, and
      wild-type strain or lactate add-back reverses protection whereas a
      lactate-production-deficient strain does not, without changing ethanol
      exposure. A lactate-independent barrier/endotoxin model is favored if an
      in-vivo-active fraction or its donor community first improves permeability
      and tight-junction integrity, then lowers portal endotoxin, and only
      subsequently lowers hepatic TLR4/Kupffer-cell activation and injury despite
      unchanged species-resolved lactate flux and failure of lactate add-back to
      reverse protection. That temporal sequence must be accompanied by at least
      one causal interaction: exposure-matched portal-endotoxin add-back reverses
      hepatic pathway and injury protection without changing lactate or ethanol
      exposure, or Kupffer-cell TLR4 blockade phenocopies protection in
      ethanol-only mice and occludes the fraction or community effect, with
      blockade also preventing endotoxin add-back reversal. Co-moving barrier,
      endotoxin, inflammatory, and injury endpoints without add-back reversal or
      pathway occlusion are insufficient to support barrier mediation. A
      tryptophan-metabolite/AhR model is favored if a fraction or its donor
      community raises microbial indole ligands before protection, produces
      intestinal or hepatic AhR target engagement, and loses protection under
      AhR deficiency or antagonism, while FICZ phenocopies and occludes the
      effect without a necessary change in species-resolved lactate flux. A
      hepatocyte-derived glycolytic-lactate model is favored if hepatic lactate
      production changes before injury despite unchanged portal microbial
      lactate flux, and donor-community transfer, strain reconstitution, and
      intestinal lactate add-back do not account for protection. A
      direct hepatic model is favored if a fraction is active in the independent
      hepatocyte screen and protects in vivo while donor community transfer,
      lactate manipulation, barrier/endotoxin perturbations, and AhR interaction
      do not account for the effect. An ethyl-lactate/SIRT1-FGF21 model is
      favored if the isolated ester, independent of the whole extract, reduces
      steatosis and injury via hepatocyte FGF21 induction, that effect is
      abolished by SIRT1 inhibition or hepatocyte Fgf21 loss, and protection
      does not require microbial lactate manipulation or donor-community
      transfer. A deoxycholate-barrier model is favored if the extract or its
      fractions blunt ethanol-induced elevation of deoxycholic acid before
      injury improves, and exogenous deoxycholic-acid restoration in protected
      animals reverses barrier and injury protection without changing
      species-resolved lactate flux or ethanol exposure. Partial
      pathway-specific effects support combined mediation. The proposed
      microbiota-lactate hypothesis is refuted in this model if no
      species-resolved lactate flux is necessary for protection, even if a
      barrier/endotoxin, tryptophan-metabolite/AhR, ethyl-lactate/SIRT1-FGF21,
      deoxycholate-barrier, or direct hepatic route remains.
    would_support:
    - mechanistic_hypotheses#baijiu_extract_microbiota_lactate_mediation_model
    would_refute:
    - mechanistic_hypotheses#baijiu_extract_microbiota_lactate_mediation_model
  evidence:
  - reference: PMID:42300615
    reference_title: Non-ethanol components of Baijiu alleviate ethanol-induced energy metabolism disorder and gut microbiota dysbiosis in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The results showed that non-ethanol components of Baijiu significantly
      alleviated ethanol-induced body weight loss and hepatic pathological damage
      in mice, reduced serum AST and ALT activities as well as hepatic MDA levels,
      and enhanced the activity of the mitochondrial antioxidant enzyme SOD2.
    explanation: >-
      The whole extract improved injury and oxidative-stress endpoints in mice,
      motivating constituent identification while remaining model-specific.
  - reference: PMID:27890791
    reference_title: Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Both methods prevented steatosis, liver inflammation, and restored gut
      homeostasis.
    explanation: >-
      Fecal transfer and pectin intervention provide animal-model precedent that
      manipulating an intestinal community can modify alcohol-induced liver
      injury, but do not establish the Baijiu constituent or lactate route.
  - reference: PMID:33004548
    reference_title: Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The AhR agonist Ficz (6-formylindolo (3,2-b) carbazole) reduced liver
      lesions, similarly to prebiotic treatment. Conversely, inactivation of the
      ahr gene in alcohol-fed AhR knock-out mice abrogated the beneficial effects
      of the prebiotic.
    explanation: >-
      Pharmacologic agonism and genetic loss establish AhR as a causal competing
      mediator of microbiota-targeted protection in human-microbiota-associated
      alcohol-fed mice, without testing the Baijiu extract or a lactate route.
  - reference: PMID:41543328
    reference_title: Therapeutic Mechanisms of Lactiplantibacillus plantarum NXU0014 Against Chronic Alcohol-Induced Liver Injury Mediated by Gut-Liver Axis Modulation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Multi-omics analyses revealed that alcohol intake induced gut microbiota
      dysbiosis, characterized by an increased Firmicutes/Bacteroidetes ratio and
      decreased abundance of probiotics (e.g., Lactobacillus and Bifidobacterium).
    explanation: >-
      A different chronic liquor-fed mouse model showed the opposite direction
      for broad Lactobacillus abundance. This qualifies any genus-level
      interpretation of the seed result but does not directly test the distinct
      Ligilactobacillus signal, its strain identity, or lactate production.
  - reference: PMID:41137971
    reference_title: Diabetes mellitus is linked to higher mortality in alcohol-related acute-on-chronic liver failure.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      On multivariable Cox regression, DM was independently associated with
      increased 90-day mortality (HR 1.739, 95% CI 1.262-2.395, p < 0.001), along
      with elevated serum lactate (HR 1.187 per mmol/L, p < 0.001) and creatinine
      (HR 1.267 per mg/dL, p < 0.001).
    explanation: >-
      In alcohol-related acute-on-chronic liver failure, circulating lactate was
      an independent prognostic association. The cohort does not establish a
      microbial source or a lactate-to-injury direction and therefore supports
      temporal testing rather than a mechanistic inference.
  - reference: PMID:26556636
    reference_title: Microbiota Protects Mice Against Acute Alcohol-Induced Liver Injury.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Germ-free mice showed significantly greater liver injury and inflammation
      after oral gavage of ethanol (EtOH) compared with conventional mice.
    explanation: >-
      The opposite effect of complete microbiota absence in an acute model
      demonstrates that community effects are exposure- and context-dependent
      and motivates targeted transfer and reconstitution instead of treating
      global depletion as a causal test.
  - reference: PMID:32810440
    reference_title: Programing of an Intravascular Immune Firewall by the Gut Microbiota Protects against Pathogen Dissemination during Infection.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      the catching and killing of circulating pathogens by Kupffer cells in
      vivo are promoted by the gut microbiota through commensal-derived
      D-lactate that reaches the liver via the portal vein
    explanation: >-
      Demonstrates a gut-to-portal-vein-to-liver D-lactate route in a mouse
      sepsis model, overturning the seed study's checked absence of any
      gut-to-liver lactate evidence, but the model is non-ALD and does not
      test the Baijiu extract or ethanol exposure, so it is external
      plausibility for a route rather than support for this hypothesis.
  - reference: PMID:40738110
    reference_title: Gut substrate trap of D-lactate from microbiota improves blood glucose and fatty liver disease in obese mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: The gut microbiota is the main source of blood D-lactate.
    explanation: >-
      Confirms gut microbiota as the dominant source of circulating D-lactate
      and links D-lactate trapping to reduced hepatic inflammation/fibrosis in
      obese MAFLD/MASH mice, but the model is non-ALD (diet-induced obesity,
      not ethanol exposure) and does not test the Baijiu extract, so it
      sharpens rather than validates the microbiota-lactate hypothesis.
  - reference: PMID:39661730
    reference_title: Ethyl Lactate Ameliorates Hepatic Steatosis and Acute-on-Chronic Liver Injury in Alcohol-Associated Liver Disease by Inducing Fibroblast Growth Factor 21.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      the activator ethyl lactate, a nonethanol ingredient found in distilled
      liquors, ameliorates alcoholic hepatosteatosis, inflammation and
      acute-on-chronic liver injury by stimulating FGF21
    explanation: >-
      Shows a distinct non-ethanol Baijiu-liquor constituent, the lactate
      ester ethyl lactate, protects in a direct ALD mouse model through
      hepatocyte SIRT1-FGF21 signaling rather than a demonstrated microbial
      lactate route; this is a competing constituent-specific mechanism for
      the seed extract's activity, not confirmation of microbiota-lactate
      mediation, and must not be conflated with free D- or L-lactate.
  - reference: PMID:41606891
    reference_title: Regulatory effect of Chinese Baijiu on gut microbiota and host metabolism.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: DCA supplementation aggravated ethanol-induced disruption of intestinal barrier function.
    explanation: >-
      A direct Baijiu-versus-ethanol mouse comparison implicates
      deoxycholic-acid-driven intestinal barrier disruption, and a
      non-alcoholic Baijiu-compound formula that protects against it, as a
      competing bile-acid/barrier route for the whole-extract protection; it
      does not test microbial lactate flux and should not be read as
      confirming or refuting the lactate-mediation hypothesis.
datasets:
- accession: geo:GSE236382
  title: Single-cell transcriptome characterization of the livers from patients with alcoholic liver disease
  description: >-
    Human liver single-cell RNA-sequencing dataset used to characterize hepatic
    immune-cell landscapes in ALD. The five ALD cases provide associative cellular
    context and should not be interpreted as causal or population-representative.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: SINGLE_CELL_RNA_SEQ
  sample_types:
  - preferred_term: liver tissue
    term:
      id: UBERON:0002107
      label: liver
    tissue_term:
      preferred_term: liver
      term:
        id: UBERON:0002107
        label: liver
  sample_count: 5
  conditions:
  - alcohol-associated liver disease
  publication: PMID:39349248
  evidence:
  - reference: PMID:39349248
    reference_title: Single-cell Profiling of Intrahepatic Immune Cells Reveals an Expansion of Tissue-resident Cytotoxic CD4(+) T Lymphocyte Subset Associated With Pathogenesis of Alcoholic-associated Liver Diseases.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We utilized single-cell RNA sequencing to analyze liver samples from healthy
      subjects and patients with MASLD and ALD, focusing on the immune cell landscapes
      within the liver.
    explanation: The publication confirms single-cell analysis of human liver samples including ALD.
  - reference: GEO:GSE236382
    reference_title: Single-cell transcriptome characterization of the livers from patients with alcoholic liver disease
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This study utilized single-cell data from liver samples of 5 ALD human cases.
    explanation: The GEO record directly supports the ALD sample count.
  notes: 'Dataset record: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE236382'
notes: >-
  ALD is modeled as a heterogeneous spectrum. Alcohol-associated hepatitis is an
  acute-on-chronic branch rather than a required linear stage. The LSEC Hsp90-eNOS
  axis is retained as an emerging preclinical hypothesis. PNPLA3 rs738409 is a
  susceptibility locus and not a monogenic cause. Clinical management and diagnostic
  entries are evidence-bounded and do not replace individualized specialist guidance.
references:
- reference: PMID:38174913
  title: 'ACG Clinical Guideline: Alcohol-Associated Liver Disease.'
  findings: []
- reference: PMID:25634330
  title: 'Alcohol drinking pattern and risk of alcoholic liver cirrhosis: a prospective cohort study.'
  findings: []
- reference: PMID:30424581
  title: 'Alcoholic Liver Disease: Alcohol Metabolism, Cascade of Molecular Mechanisms, Cellular Targets, and Clinical Aspects.'
  findings: []
- reference: PMID:15670660
  title: 'Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis.'
  findings: []
- reference: PMID:37143126
  title: Pathogenic mechanisms and regulatory factors involved in alcoholic liver disease.
  findings: []
- reference: PMID:25462064
  title: 'Intestinal CYP2E1: A mediator of alcohol-induced gut leakiness.'
  findings: []
- reference: PMID:33675874
  title: Alcohol-induced Hsp90 acetylation is a novel driver of liver sinusoidal endothelial dysfunction and alcohol-related liver disease.
  findings: []
- reference: PMID:18792393
  title: The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88.
  findings: []
- reference: PMID:39349248
  title: Single-cell Profiling of Intrahepatic Immune Cells Reveals an Expansion of Tissue-resident Cytotoxic CD4(+) T Lymphocyte Subset Associated With Pathogenesis of Alcoholic-associated Liver Diseases.
  findings: []
- reference: PMID:39362713
  title: Pathogenesis of Alcohol-Associated Liver Disease.
  findings: []
- reference: PMID:31718044
  title: TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019.
  findings: []
- reference: PMID:23255577
  title: Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis.
  findings: []
- reference: PMID:26482880
  title: A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis.
  findings: []
- reference: PMID:39679853
  title: PNPLA3 in Alcohol-Related Liver Disease.
  findings: []
- reference: PMID:42300615
  title: Non-ethanol components of Baijiu alleviate ethanol-induced energy metabolism disorder and gut microbiota dysbiosis in mice.
  findings: []
- reference: PMID:27890791
  title: Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice.
  findings: []
- reference: PMID:26556636
  title: Microbiota Protects Mice Against Acute Alcohol-Induced Liver Injury.
  findings: []
- reference: PMID:33004548
  title: Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury.
  findings: []
- reference: PMID:41137971
  title: Diabetes mellitus is linked to higher mortality in alcohol-related acute-on-chronic liver failure.
  findings: []
- reference: PMID:41543328
  title: Therapeutic Mechanisms of Lactiplantibacillus plantarum NXU0014 Against Chronic Alcohol-Induced Liver Injury Mediated by Gut-Liver Axis Modulation.
  findings: []
- reference: PMID:39788109
  title: Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021.
  findings: []
- reference: PMID:28387018
  title: Transient elastography alone and in combination with FibroTest(®) for the diagnosis of hepatic fibrosis in alcoholic liver disease.
  findings: []
- reference: PMID:36481475
  title: Alcohol Abstinence Improves Prognosis Across All Stages of Portal Hypertension in Alcohol-Related Cirrhosis.
  findings: []
- reference: PMID:25901427
  title: Prednisolone or pentoxifylline for alcoholic hepatitis.
  findings: []
- reference: PMID:26921783
  title: 'Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia.'
  findings: []
- reference: PMID:27979049
  title: 'Medical Management of Severe Alcoholic Hepatitis: Expert Review from the Clinical Practice Updates Committee of the AGA Institute.'
  findings: []
- reference: PMID:27922027
  title: A Day-4 Lille Model Predicts Response to Corticosteroids and Mortality in Severe Alcoholic Hepatitis.
  findings: []
- reference: PMID:22070476
  title: Early liver transplantation for severe alcoholic hepatitis.
  findings: []
- reference: GEO:GSE236382
  title: Single-cell transcriptome characterization of the livers from patients with alcoholic liver disease
  findings: []
📚

References & Deep Research

References

29
PMID:38174913
ACG Clinical Guideline: Alcohol-Associated Liver Disease.
No top-level findings curated for this source.
PMID:25634330
Alcohol drinking pattern and risk of alcoholic liver cirrhosis: a prospective cohort study.
No top-level findings curated for this source.
PMID:30424581
Alcoholic Liver Disease: Alcohol Metabolism, Cascade of Molecular Mechanisms, Cellular Targets, and Clinical Aspects.
No top-level findings curated for this source.
PMID:15670660
Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis.
No top-level findings curated for this source.
PMID:37143126
Pathogenic mechanisms and regulatory factors involved in alcoholic liver disease.
No top-level findings curated for this source.
PMID:25462064
Intestinal CYP2E1: A mediator of alcohol-induced gut leakiness.
No top-level findings curated for this source.
PMID:33675874
Alcohol-induced Hsp90 acetylation is a novel driver of liver sinusoidal endothelial dysfunction and alcohol-related liver disease.
No top-level findings curated for this source.
PMID:18792393
The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88.
No top-level findings curated for this source.
PMID:39349248
Single-cell Profiling of Intrahepatic Immune Cells Reveals an Expansion of Tissue-resident Cytotoxic CD4(+) T Lymphocyte Subset Associated With Pathogenesis of Alcoholic-associated Liver Diseases.
No top-level findings curated for this source.
PMID:39362713
Pathogenesis of Alcohol-Associated Liver Disease.
No top-level findings curated for this source.
PMID:31718044
TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019.
No top-level findings curated for this source.
PMID:23255577
Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis.
No top-level findings curated for this source.
PMID:26482880
A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis.
No top-level findings curated for this source.
PMID:39679853
PNPLA3 in Alcohol-Related Liver Disease.
No top-level findings curated for this source.
PMID:42300615
Non-ethanol components of Baijiu alleviate ethanol-induced energy metabolism disorder and gut microbiota dysbiosis in mice.
No top-level findings curated for this source.
PMID:27890791
Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice.
No top-level findings curated for this source.
PMID:26556636
Microbiota Protects Mice Against Acute Alcohol-Induced Liver Injury.
No top-level findings curated for this source.
PMID:33004548
Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury.
No top-level findings curated for this source.
PMID:41137971
Diabetes mellitus is linked to higher mortality in alcohol-related acute-on-chronic liver failure.
No top-level findings curated for this source.
PMID:41543328
Therapeutic Mechanisms of Lactiplantibacillus plantarum NXU0014 Against Chronic Alcohol-Induced Liver Injury Mediated by Gut-Liver Axis Modulation.
No top-level findings curated for this source.
PMID:39788109
Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021.
No top-level findings curated for this source.
PMID:28387018
Transient elastography alone and in combination with FibroTest(®) for the diagnosis of hepatic fibrosis in alcoholic liver disease.
No top-level findings curated for this source.
PMID:36481475
Alcohol Abstinence Improves Prognosis Across All Stages of Portal Hypertension in Alcohol-Related Cirrhosis.
No top-level findings curated for this source.
PMID:25901427
Prednisolone or pentoxifylline for alcoholic hepatitis.
No top-level findings curated for this source.
PMID:26921783
Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia.
No top-level findings curated for this source.
PMID:27979049
Medical Management of Severe Alcoholic Hepatitis: Expert Review from the Clinical Practice Updates Committee of the AGA Institute.
No top-level findings curated for this source.
PMID:27922027
A Day-4 Lille Model Predicts Response to Corticosteroids and Mortality in Severe Alcoholic Hepatitis.
No top-level findings curated for this source.
PMID:22070476
Early liver transplantation for severe alcoholic hepatitis.
No top-level findings curated for this source.
GEO:GSE236382
Single-cell transcriptome characterization of the livers from patients with alcoholic liver disease
No top-level findings curated for this source.

Deep Research

4
Disorder ▸

Disorder

  • Name: Alcoholic Liver Disease
  • Category: Complex
  • Existing deep-research providers: openai
  • Existing evidence reference count in YAML: 7

Key Pathophysiology Nodes

  • Alcohol metabolism and cellular stress
  • Gut-liver axis and endotoxin translocation
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • PMID:33675874
  • PMID:39362713
  • PMID:39679853
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 46 citations 2026-05-12T15:45:02.476081

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Alcoholic Liver Disease
  • MONDO ID: (if available)
  • Category: Complex

Research Objectives

Please provide a comprehensive research report on Alcoholic Liver Disease covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Research Report: Alcoholic Liver Disease (Alcohol-Associated Liver Disease)

Target disease

  • Disease name (preferred in recent literature): Alcohol-associated liver disease (ALD) (alvaradotapias2024alcoholassociatedliverdisease pages 1-3, mackowiak2024alcoholassociatedliverdisease pages 1-2)
  • Legacy/related terms: alcoholic liver disease; alcohol-related liver disease; ArLD (hong2024alcoholrelatedliverdisease pages 1-2, alvaradotapias2024alcoholassociatedliverdisease pages 1-3)
  • Disease category: complex / multifactorial exposure-related disease (alcohol plus modifiers) (alvaradotapias2024alcoholassociatedliverdisease pages 1-3, israelsenUnknownyearmetaldfromconcept pages 7-10)
  • MONDO ID: Not identified in the retrieved evidence set (knowledge-base crosswalk needed).

1. Disease information (concepts, identifiers, synonyms)

1.1 Concise overview and spectrum definition

Alcohol-associated liver disease (ALD) is a spectrum of liver injury caused by chronic harmful alcohol exposure, ranging from steatosis to steatohepatitis, progressive fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) (alvaradotapias2024alcoholassociatedliverdisease pages 1-3, mackowiak2024alcoholassociatedliverdisease pages 1-2). Alcohol-associated hepatitis (AH) is an acute, severe inflammatory manifestation within this spectrum, described as presenting with sudden jaundice and liver failure (alvaradotapias2024alcoholassociatedliverdisease pages 1-3).

1.2 Key identifiers / coding

  • ICD-10: Alcoholic liver disease is coded under K70. (examples explicitly listed in retrieved sources: K70.0–K70.4, K70.9*) (manthey2025identifyinglevelsof pages 1-2, kubina2025meta‐analysiseffectsof pages 23-23).
  • ICD-11 / MeSH / OMIM / Orphanet: Not extracted from the retrieved evidence set (additional targeted database lookup required). An expert consensus statement discusses ICD-11 AUD criteria (dependence requires “2 or more of 3 symptoms”) but does not provide ICD-11 liver-disease codes (lee2024designingclinicaltrials pages 3-5).

1.3 Current nomenclature: ALD within the 2023 “steatotic liver disease (SLD)” framework

Recent multisociety consensus reframed fatty liver disorders under SLD and subclassified into MASLD, MetALD (MASLD + increased alcohol), and ALD (lee2024nationalprevalenceestimates pages 1-2, alvaradotapias2024alcoholassociatedliverdisease pages 1-3). A Nature Reviews Gastroenterology & Hepatology expert panel describes Delphi thresholds defining ALD as alcohol consumption exceeding 420 g/week (men) or 350 g/week (women) and MetALD as intermediate alcohol exposure ranges (lee2024designingclinicaltrials pages 3-5).

1.4 Aggregated resource vs individual patient evidence

Most disease definitions, staging concepts, and global burden estimates in this report come from aggregated disease-level resources (reviews and Global Burden of Disease [GBD] analyses) (alvaradotapias2024alcoholassociatedliverdisease pages 1-3, danpanichkul2025globalepidemiologyof pages 1-5). Administrative coding use-cases reflect EHR-derived approaches based on ICD-10 codes (manthey2025identifyinglevelsof pages 1-2).

Concept Preferred term / definition Common synonyms / legacy names ICD-10 / coding ICD-11 / AUD note NHANES prevalence under 2023 SLD nomenclature Notes (URL; publication date)
Disease entity Alcohol-associated liver disease (ALD) is the current preferred term in recent hepatology literature; within the 2023 steatotic liver disease (SLD) framework, ALD is a subclass of SLD distinct from MASLD and MetALD (alvaradotapias2024alcoholassociatedliverdisease pages 1-3, lee2024designingclinicaltrials pages 3-5) Alcoholic liver disease; alcohol-related liver disease; ArLD; ALD (legacy and regional usage varies) (hong2024alcoholrelatedliverdisease pages 1-2, alvaradotapias2024alcoholassociatedliverdisease pages 1-3) ICD-10 alcoholic liver disease code family K70.; examples cited in available sources include K70.0–K70.4, K70.9* (manthey2025identifyinglevelsof pages 1-2, kubina2025meta‐analysiseffectsof pages 23-23) Expert consensus paper notes ICD-11 criteria for alcohol dependence/AUD require 2 or more of 3 symptoms; used as clinical context rather than liver-disease code mapping (lee2024designingclinicaltrials pages 3-5) Not a prevalence row by itself Alvarado-Tapias et al. 2024: https://doi.org/10.3350/cmh.2024.0709 ; Oct 2024. Lee et al. 2024 consensus statement: https://doi.org/10.1038/s41575-024-00936-x ; Jun 2024.
SLD umbrella term Steatotic liver disease (SLD) is the umbrella nomenclature adopted by multisociety consensus, encompassing MASLD, MetALD, ALD, and etiology-specific/cryptogenic SLD (lee2024nationalprevalenceestimates pages 1-2, alvaradotapias2024alcoholassociatedliverdisease pages 1-3) Fatty liver disease spectrum (legacy framing) (lee2024designingclinicaltrials pages 3-5, alvaradotapias2024alcoholassociatedliverdisease pages 1-3) No specific ICD-10 range provided in available evidence for SLD umbrella term Delphi consensus on future ICD harmonization for SLD published, but no explicit ICD-11 liver-code mapping provided in available evidence (lee2024designingclinicaltrials pages 3-5) 34.2% (95% CI 31.9%–36.5%) (lee2024nationalprevalenceestimates pages 1-2) Lee et al. 2024 NHANES analysis: https://doi.org/10.1097/hep.0000000000000604 ; Sep 2024.
Metabolic subclass Metabolic dysfunction-associated steatotic liver disease (MASLD) (lee2024designingclinicaltrials pages 3-5, lee2024nationalprevalenceestimates pages 1-2) NAFLD showed ~99% overlap with MASLD in NHANES analysis (lee2024nationalprevalenceestimates pages 1-2) No specific ICD-10 range provided in available evidence In trial-consensus context, alcohol thresholds help distinguish MASLD from MetALD/ALD (lee2024designingclinicaltrials pages 3-5) 31.3% (95% CI 29.2%–33.4%) (lee2024nationalprevalenceestimates pages 1-2) Lee et al. 2024 NHANES analysis: https://doi.org/10.1097/hep.0000000000000604 ; Sep 2024.
Overlap subclass MetALD = MASLD plus increased alcohol intake; consensus thresholds cited as women 140–350 g/week and men 210–420 g/week in one expert statement (lee2024designingclinicaltrials pages 3-5) Metabolic dysfunction- and alcohol-associated liver disease; metabolic and alcohol-associated liver disease (alvaradotapias2024alcoholassociatedliverdisease pages 1-3) No specific ICD-10 range provided in available evidence Relevant as a nomenclature and trial-stratification category rather than a distinct ICD-11 code in available evidence (lee2024designingclinicaltrials pages 3-5) 2.0% (95% CI 1.6%–2.9%) (lee2024nationalprevalenceestimates pages 1-2) Lee et al. 2024 NHANES analysis: https://doi.org/10.1097/hep.0000000000000604 ; Sep 2024. Lee et al. 2024 consensus statement: https://doi.org/10.1038/s41575-024-00936-x ; Jun 2024.
Alcohol subclass ALD within SLD nomenclature; Delphi/expert statement defined ALD as alcohol consumption exceeding 420 g/week (men) or 350 g/week (women), with or without cardiometabolic risk factors (lee2024designingclinicaltrials pages 3-5) Alcohol-associated liver disease; alcoholic liver disease; alcohol-related liver disease (hong2024alcoholrelatedliverdisease pages 1-2, alvaradotapias2024alcoholassociatedliverdisease pages 1-3) ICD-10 K70.* family applies to alcoholic liver disease diagnoses in administrative coding (manthey2025identifyinglevelsof pages 1-2, kubina2025meta‐analysiseffectsof pages 23-23) ICD-11 AUD/dependence criteria mentioned in consensus/trial-design paper; no explicit ICD-11 ALD code supplied in available evidence (lee2024designingclinicaltrials pages 3-5) 0.7% (95% CI 0.5%–0.9%) (lee2024nationalprevalenceestimates pages 1-2) Lee et al. 2024 NHANES analysis: https://doi.org/10.1097/hep.0000000000000604 ; Sep 2024. Manthey et al. 2025 ICD-10 EHR usage: https://doi.org/10.1186/s13011-025-00670-w ; Sep 2025.
Administrative/EHR coding note In EHR work, severe alcohol-related disease burden category explicitly included alcoholic liver disease diagnoses Alcoholic liver cirrhosis and related alcohol-specific organ disease codes in EHR severity work (manthey2025identifyinglevelsof pages 1-2) K70; K70.0–K70.4; K70.9 specifically listed in available evidence (manthey2025identifyinglevelsof pages 1-2, kubina2025meta‐analysiseffectsof pages 23-23) ICD-10 was the basis of the cited EHR classification; authors note different jurisdictions may use ICD-11, but mapping not provided here (manthey2025identifyinglevelsof pages 1-2) Not applicable Manthey et al. 2025: https://doi.org/10.1186/s13011-025-00670-w ; Sep 2025. Hagström et al. 2024 ICD consensus: https://doi.org/10.1097/hc9.0000000000000386 ; Feb 2024.

Table: This table summarizes current naming conventions, coding references, and U.S. NHANES prevalence estimates relevant to Alcoholic Liver Disease / Alcohol-associated liver disease within the 2023 steatotic liver disease framework. It is useful for aligning legacy terminology, ICD coding, and modern subclassification terms in a disease knowledge base.

2. Etiology

2.1 Primary causal factors

The necessary upstream causal exposure is harmful alcohol consumption; however, ALD development and progression are heterogeneous and depend on host susceptibility and co-exposures (alvaradotapias2024alcoholassociatedliverdisease pages 1-3, israelsenUnknownyearmetaldfromconcept pages 7-10).

2.2 Risk factors

Alcohol exposure intensity and pattern

Clinical trial consensus emphasizes careful quantification of alcohol exposure (standard drinks converted to grams), as thresholds and definitions vary across studies (lee2024designingclinicaltrials pages 1-2).

Genetic risk factors (susceptibility/modifier loci)

Human genetic studies and reviews identify common modifier variants that increase risk of steatosis and/or progressive outcomes (fibrosis/cirrhosis/HCC), especially under metabolic or alcohol stress. - PNPLA3 I148M (rs738409): Reported to increase liver fat and increase risk of fibrosis/cirrhosis/HCC, with stronger effects under obesity/T2D and alcohol exposure (israelsenUnknownyearmetaldfromconcept pages 7-10). Proposed mechanism: variant accumulates on lipid droplets and impairs triglyceride breakdown by blocking ATGL access (israelsenUnknownyearmetaldfromconcept pages 7-10). - TM6SF2 E167K (rs58542926): Increases hepatic fat and risk of advanced disease; mechanistically linked to reduced VLDL secretion (israelsenUnknownyearmetaldfromconcept pages 7-10). Quantitative associations reported in an omics review include OR ~1.38 for steatosis/fibrosis and higher ORs for more severe steatosis/fibrosis grades (bourganou2025unravelingmetabolicdysfunctionassociated pages 9-11). - MBOAT7 rs641738 C>T: A modest-risk variant that reduces phosphatidylinositol remodeling and is associated with higher risk of steatosis/inflammation/fibrosis/HCC; knockout mice show increased hepatic triglycerides and fibrosis (bourganou2025unravelingmetabolicdysfunctionassociated pages 9-11). - HSD17B13 rs72613567 (T>TA): A loss-of-function splice variant commonly described as protective against progressive liver disease outcomes (fibrosis/cirrhosis/HCC) and associated with lower aminotransferases; one review notes ~25% per-allele risk reduction for fibrosis/cirrhosis/HCC (israelsenUnknownyearmetaldfromconcept pages 7-10), and another review summarizes larger reductions reported in some cohorts (e.g., ~30%–49% reductions) (bourganou2025unravelingmetabolicdysfunctionassociated pages 9-11). JCI review notes HSD17B13 variants are associated with reduced risk for cirrhosis/HCC in ALD (mackowiak2024alcoholassociatedliverdisease pages 8-9). - Alcohol metabolism genes: Population variation in ALDH2 activity is highlighted in East Asian populations (30–40% with inactive ALDH2 polymorphisms), affecting acetaldehyde handling (mackowiak2024alcoholassociatedliverdisease pages 8-9). Another review summarizes that functional variants in ADH1B and ALDH2 can reduce alcohol intake and are associated with substantially lower ALD risk (israelsenUnknownyearmetaldfromconcept pages 7-10).

Environmental/clinical risk modifiers

ALD pathogenesis and progression are influenced by co-factors such as sex, obesity/metabolic dysfunction, and the gut microbiome (d’arcangelo2026oxidativestressand pages 15-16, israelsenUnknownyearmetaldfromconcept pages 7-10). A U.S. mortality study also highlights concurrent societal shifts and obesity as contributors to worsening ALD burden in high-risk subgroups (pan2025alcoholassociatedliverdisease pages 1-2).

2.3 Protective factors

  • Genetic: HSD17B13 loss-of-function variants are repeatedly described as hepatoprotective (israelsenUnknownyearmetaldfromconcept pages 7-10, mackowiak2024alcoholassociatedliverdisease pages 8-9, bourganou2025unravelingmetabolicdysfunctionassociated pages 9-11).
  • Behavioral: Alcohol abstinence is the most effective intervention to improve prognosis across ALD stages (alvaradotapias2024alcoholassociatedliverdisease pages 1-3).

2.4 Gene–environment interaction (GxE)

The effect of key variants (notably PNPLA3) is reported to be amplified by obesity, type 2 diabetes, and alcohol exposure (israelsenUnknownyearmetaldfromconcept pages 7-10). Recent genetics reviews also emphasize that genetic risk “is not fixed” and can be modulated by diet/exercise/alcohol intake (wang2025geneticinsightsinto pages 1-2).

3. Phenotypes (clinical spectrum; HPO suggestions)

3.1 Core phenotypes across the ALD spectrum

Key clinical–pathologic phenotypes include: - Hepatic steatosis (fatty liver) (alvaradotapias2024alcoholassociatedliverdisease pages 1-3, mackowiak2024alcoholassociatedliverdisease pages 1-2) - Steatohepatitis (inflammation plus steatosis) (alvaradotapias2024alcoholassociatedliverdisease pages 1-3, mackowiak2024alcoholassociatedliverdisease pages 1-2) - Fibrosis → cirrhosis → portal hypertension/complications (alvaradotapias2024alcoholassociatedliverdisease pages 1-3, alvaradotapias2024alcoholassociatedliverdisease pages 3-4) - Alcohol-associated hepatitis (AH): acute jaundice and liver failure; histologic ASH features include steatosis, inflammatory infiltration, hepatocyte ballooning, and Mallory–Denk bodies (alvaradotapias2024alcoholassociatedliverdisease pages 1-3, mackowiak2024alcoholassociatedliverdisease pages 1-2)

Frequency: AH has been described as occurring in ~4–8% of heavy drinkers in one recent review (kasuga2025currentinsightsinto pages 1-2). Progression to cirrhosis is estimated in 8–20% of patients with fibrosis in a recent ALD natural history review (alvaradotapias2024alcoholassociatedliverdisease pages 1-3).

3.2 Lab and imaging abnormalities (phenotype-type: laboratory)

Standard diagnostic/monitoring labs include AST/ALT, bilirubin, GGT, ALP, platelets and indices derived from these (e.g., FIB-4), with AST/ALT ratio patterns often used clinically for suspicion of AH/advanced ALD (rama2026novelbiomarkersfor pages 5-6, rama2026novelbiomarkersfor pages 6-8).

3.3 Suggested HPO terms (non-exhaustive; for knowledge-base mapping)

(These are ontology suggestions; not all are explicitly enumerated in the cited sources.) - Jaundice (HP:0000952) - Hyperbilirubinemia (HP:0002904) - Hepatic steatosis (HP:0001397) - Hepatitis (HP:0012115) - Elevated hepatic transaminases (HP:0002910) - Liver cirrhosis (HP:0001394) - Portal hypertension (HP:0000124) - Ascites (HP:0001541) - Hepatic encephalopathy (HP:0002326) - Hepatocellular carcinoma (HP:0001402)

4. Genetic / molecular information

4.1 “Causal genes” vs modifier genes

ALD is not typically monogenic; instead, common variants act as modifiers of susceptibility and progression in the setting of alcohol exposure and other environmental risks (israelsenUnknownyearmetaldfromconcept pages 7-10, israelsenUnknownyearmetaldfromconcept pages 1-7). Key modifier genes supported in the retrieved evidence include PNPLA3, TM6SF2, MBOAT7, and HSD17B13 (israelsenUnknownyearmetaldfromconcept pages 7-10, bourganou2025unravelingmetabolicdysfunctionassociated pages 9-11).

4.2 Pathogenic / protective variants (selected)

  • PNPLA3 rs738409 (I148M): risk modifier for steatosis and progressive outcomes; interacts with metabolic and alcohol exposures (israelsenUnknownyearmetaldfromconcept pages 7-10).
  • TM6SF2 rs58542926 (E167K): risk modifier via lipid export/VLDL mechanisms (israelsenUnknownyearmetaldfromconcept pages 7-10, bourganou2025unravelingmetabolicdysfunctionassociated pages 9-11).
  • MBOAT7 rs641738 (C>T): modest-risk modifier impacting phospholipid remodeling (bourganou2025unravelingmetabolicdysfunctionassociated pages 9-11).
  • HSD17B13 rs72613567 (T>TA): protective loss-of-function splice variant (israelsenUnknownyearmetaldfromconcept pages 7-10, bourganou2025unravelingmetabolicdysfunctionassociated pages 9-11).
  • ALDH2 functional polymorphisms: common inactive variants in East Asians (30–40%) affect acetaldehyde handling and may modify toxicity risk (mackowiak2024alcoholassociatedliverdisease pages 8-9).

4.3 Epigenetic information

A 2024 review highlights epigenetic abnormalities as part of ALD pathogenesis (hong2024alcoholrelatedliverdisease pages 1-2), and biomarker reviews discuss exploratory epigenomic profiling (e.g., genome-wide methylation/ChIP-seq) as emerging but not yet clinically standardized (rama2026novelbiomarkersfor pages 14-15).

5. Environmental information

5.1 Lifestyle/environmental drivers

  • Alcohol consumption: primary driver; consensus documents emphasize rigorous quantification in grams and recognition of heterogeneous thresholds across studies (lee2024designingclinicaltrials pages 1-2).
  • Microbiome and gut permeability: “leaky gut” and dysbiosis with PAMP/LPS translocation are repeatedly described in AH pathogenesis (alvaradotapias2024alcoholassociatedliverdisease pages 3-4, kasuga2025currentinsightsinto pages 1-2).
  • Metabolic comorbidity: overlapping metabolic dysfunction contributes additively/superadditively to fibrosis risk in patients with steatotic liver disease and alcohol exposure (alvaradotapias2024alcoholassociatedliverdisease pages 1-3, israelsenUnknownyearmetaldfromconcept pages 7-10).

6. Mechanism / pathophysiology (current understanding)

6.1 High-level causal chain (exposure → cellular injury → clinical disease)

1) Alcohol absorption and metabolism generates toxic intermediates (acetaldehyde) and perturbs mitochondrial lipid oxidation, driving steatosis and hepatocyte stress (kasuga2025currentinsightsinto pages 1-2, mackowiak2024alcoholassociatedliverdisease pages 1-2). 2) Oxidative and ER stress lead to lipid peroxidation, macromolecular damage, and activation of regulated cell death pathways (apoptosis, necroptosis, pyroptosis, ferroptosis) (d’arcangelo2026oxidativestressand pages 1-2, mackowiak2024alcoholassociatedliverdisease pages 1-2). 3) Gut barrier dysfunction increases portal influx of microbial PAMPs (e.g., LPS) and, together with hepatocyte DAMPs, triggers innate immune activation and systemic inflammation (alvaradotapias2024alcoholassociatedliverdisease pages 3-4, kasuga2025currentinsightsinto pages 1-2). 4) Inflammation driven by Kupffer cells/macrophages and neutrophils (including NETosis) amplifies injury; severe AH is characterized by neutrophil predominance and high cytokine signaling (e.g., TNFα, IL-1β) (d’arcangelo2026oxidativestressand pages 1-2, kasuga2025currentinsightsinto pages 1-2). 5) Persistent injury promotes hepatic stellate cell activation, extracellular matrix deposition and fibrosis/cirrhosis, with risk of HCC (d’arcangelo2026oxidativestressand pages 1-2, alvaradotapias2024alcoholassociatedliverdisease pages 3-4).

6.2 Key pathways/cellular processes (GO suggestions)

Evidence-supported processes include: - Response to oxidative stress; reactive oxygen species metabolic process; lipid peroxidation (d’arcangelo2026oxidativestressand pages 1-2) - Toll-like receptor signaling pathway; inflammatory response; cytokine-mediated signaling pathway (d’arcangelo2026oxidativestressand pages 1-2, kasuga2025currentinsightsinto pages 1-2) - Regulation of apoptotic process; necroptotic process; pyroptotic process; ferroptosis (d’arcangelo2026oxidativestressand pages 1-2, mackowiak2024alcoholassociatedliverdisease pages 1-2) - Extracellular matrix organization / fibrogenesis; wound healing (d’arcangelo2026oxidativestressand pages 1-2, alvaradotapias2024alcoholassociatedliverdisease pages 3-4)

6.3 Cell types involved (CL suggestions)

  • Hepatocyte; Kupffer cell (liver-resident macrophage); neutrophil; monocyte-derived macrophage; hepatic stellate cell; intestinal epithelial cell/enterocyte (d’arcangelo2026oxidativestressand pages 1-2, alvaradotapias2024alcoholassociatedliverdisease pages 3-4, kasuga2025currentinsightsinto pages 1-2).

6.4 Recent developments (prioritizing 2023–2024)

  • Multi-omics emphasis: A 2024 JCI review notes “new insights… utilizing the study of multiomics and other cutting-edge approaches,” and frames translation toward therapeutic targets (mackowiak2024alcoholassociatedliverdisease pages 1-2).
  • Consensus trial-design: A 2024 Nature Reviews Gastroenterology & Hepatology expert panel provides consensus on clinical trial design integrating liver outcomes and alcohol use endpoints, including the updated SLD nomenclature context (lee2024designingclinicaltrials pages 3-5).

7. Anatomical structures affected (UBERON/GO-CC suggestions)

7.1 Organ/tissue level

  • Primary organ: liver (UBERON:0002107)
  • Key liver compartments/cell populations: hepatocytes, hepatic stellate cells, Kupffer cells; involvement of the gut–liver axis implicates intestinal epithelium as a contributing site (alvaradotapias2024alcoholassociatedliverdisease pages 3-4, kasuga2025currentinsightsinto pages 1-2).

7.2 Subcellular compartments (GO-CC suggestions; evidence-supported themes)

  • Mitochondrion; endoplasmic reticulum; lipid droplet (mitochondrial/ER stress and lipid droplet biology are highlighted; lipid-droplet localization is central for PNPLA3/HSD17B13 biology) (israelsenUnknownyearmetaldfromconcept pages 7-10, mackowiak2024alcoholassociatedliverdisease pages 1-2).

8. Temporal development

8.1 Onset and course

ALD is typically chronic and insidious, but AH represents an acute decompensating event with severe short-term outcomes (alvaradotapias2024alcoholassociatedliverdisease pages 1-3, kasuga2025currentinsightsinto pages 1-2).

8.2 Staging and severity (AH)

Severe alcohol-associated hepatitis is often defined using Maddrey’s discriminant function ≥32 or MELD ≥20 in recent reviews (kumar2026emergingtherapeuticregimens pages 5-6). Short-term mortality in severe AH is repeatedly reported at ~20%–50% (hong2024alcoholrelatedliverdisease pages 1-2, kasuga2025currentinsightsinto pages 1-2).

9. Inheritance and population

ALD is a multifactorial disease with polygenic modifier effects and strong environmental dependence (israelsenUnknownyearmetaldfromconcept pages 7-10). Allele frequencies and population differences are highlighted for alcohol metabolism genes, e.g., inactive ALDH2 variants in East Asian populations (mackowiak2024alcoholassociatedliverdisease pages 8-9).

10. Diagnostics (current practice and emerging)

10.1 Clinical assessment and routine biomarkers

Routine labs (AST, ALT, bilirubin, GGT, ALP, platelets) are standard but have limited specificity; AST/ALT ratio patterns are supportive for AH/advanced disease suspicion (rama2026novelbiomarkersfor pages 5-6).

10.2 Non-invasive fibrosis staging: elastography and serum panels

A recent biomarker review summarizes validated elastography thresholds and practical caveats: - Vibration-controlled transient elastography (VCTE): validated cutoffs of ~12.1 kPa for ≥F3 and ~18.6 kPa for F4, AUROCs ~0.90–0.91; LSM <8–10 kPa helps rule out advanced fibrosis; interpret with AST/bilirubin since inflammation can inflate stiffness and LSM may fall after abstinence (rama2026novelbiomarkersfor pages 6-8). - 2D shear-wave elastography diagnostic performance is also reported (e.g., 88% sensitivity/95% specificity for advanced fibrosis with suggested cutoffs) (rama2026novelbiomarkersfor pages 6-8). - ELF test: described as having high accuracy for advanced fibrosis and can outperform APRI/FIB-4, with reported AUROC ~0.92–0.94 (rama2026novelbiomarkersfor pages 5-6). - Pro-C3 / ADAPT: Pro-C3 is highlighted as a predictor of outcomes and used in composite algorithms for advanced fibrosis detection (rama2026novelbiomarkersfor pages 17-18).

10.3 Alcohol exposure biomarkers

Phosphatidylethanol (PEth) is emphasized as an objective marker of recent alcohol intake; one review notes ≥200 ng/mL indicates regular high intake and that adding PEth can increase ALD detection “3–4×” compared with self-report alone (rama2026novelbiomarkersfor pages 5-6).

10.4 Emerging mechanistic biomarkers and multi-omics

Reviews highlight emerging biomarkers reflecting cell death (CK-18 fragments), fibrogenesis (Pro-C3), genetic risk (PNPLA3/TM6SF2/HSD17B13 and PRS), and gut dysbiosis signatures/metabolites (SCFAs, bile acids, TMAO; reduced Faecalibacterium prausnitzii and Akkermansia muciniphila) (rama2026novelbiomarkersfor pages 1-3, rama2026novelbiomarkersfor pages 8-9).

11. Outcome / prognosis

11.1 Severe AH prognosis

Severe alcohol-associated hepatitis has “short-term mortality rate of 20%–50%” in developed countries in a recent review (quoted from abstract) (kasuga2025currentinsightsinto pages 1-2).

11.2 ALD mortality trends (real-world implementation and statistics)

  • United States (1999–2022): In a JAMA Network Open analysis of 436,814 ALD-related deaths, age-adjusted mortality doubled 6.71 → 12.53 per 100,000, accelerating in 2018–2022 (APC 8.94%) with disproportionate increases among women, ages 25–44, and American Indian/Alaska Native populations (pan2025alcoholassociatedliverdisease pages 1-2).
  • Global (GBD 2021; 2000–2021): A 2025 analysis reports 3.02 million prevalent ALD cases in 2021 (+38.68% since 2000) and 132,030 prevalent alcohol-attributable primary liver cancer cases (+94.12%) (danpanichkul2025globalepidemiologyof pages 1-5).

12. Treatment

12.1 Foundational management (standard of care)

  • Alcohol abstinence: described as “the most effective way to improve prognosis across all stages of ALD” (quoted from abstract) (alvaradotapias2024alcoholassociatedliverdisease pages 1-3). Multidisciplinary care integrating AUD treatment is emphasized (adekunle2023therapeutictargetsin pages 1-2).
  • Corticosteroids (severe AH): described as “the only evidence-based pharmacologic treatment” in one severe AH review, with limited efficacy and substantial non-response (kasuga2025currentinsightsinto pages 1-2). Another review notes response rates ~50–60% among eligible patients by day-7 Lille score, with many contraindications (ineligibility 40–50%) (adekunle2023therapeutictargetsin pages 1-2).
  • Nutrition therapy: enteral nutrition strategies and caloric/protein targets are summarized for severe AH in Clinics in Liver Disease, including associations between inadequate intake and lower survival, and guidance to initiate enteral nutrition early when needed (hardesty2024currentpharmacotherapyand pages 4-6).
  • Liver transplantation: ALD is now the leading indication for liver transplant in the U.S.; early LT is discussed as a salvage option for steroid-refractory severe AH but remains limited by selection protocols and donor/ethical constraints (pan2025alcoholassociatedliverdisease pages 1-2, kasuga2025currentinsightsinto pages 1-2).

12.2 Experimental / targeted therapies and clinical trials (selected)

A recent ALD natural-history/therapy review tabulates “Emerging treatment options” (Table 2) including anti-inflammatory, apoptosis/cell death, bile-acid signaling, microbiome, and regenerative approaches, with trial identifiers (alvaradotapias2024alcoholassociatedliverdisease media 15159c76).

Selected trials and interventions (with registry IDs when available in retrieved evidence): - IL-1β inhibition (Canakinumab): NCT03775109 (listed in Table 2) (alvaradotapias2024alcoholassociatedliverdisease media 15159c76). - IL-1 receptor antagonist (Anakinra): NCT04072822 (listed in Table 2); other clinical evidence indicates anakinra-based approaches have had mixed or unfavorable results in at least one trial (stopped early due to worsening MELD) (alvaradotapias2024alcoholassociatedliverdisease media 15159c76, d’arcangelo2026oxidativestressand pages 12-13). - FXR agonist (Obeticholic acid): NCT02039219 (Table 2) (alvaradotapias2024alcoholassociatedliverdisease media 15159c76). - Caspase inhibitor (Emricasan / IDN-6556): NCT01912404 (Table 2); the ClinicalTrials.gov record describes a phase 2 trial terminated early with only 5 enrolled due to concerns of high systemic drug levels, precluding meaningful analysis (alvaradotapias2024alcoholassociatedliverdisease media 15159c76, NCT01912404 chunk 1). - Gut–liver axis modulation with IgG-enriched bovine colostrum: NCT02473341 phase 3 adjunct trial (NCT02473341 chunk 1).

12.3 Suggested MAXO terms (examples)

(ontology suggestions) - Alcohol abstinence counseling (MAXO:0000508) - Corticosteroid therapy (MAXO:0000746) - Enteral nutrition (MAXO:0000660) - Liver transplantation (MAXO:0001175) - Elastography (MAXO:0000976)

13. Prevention

Public-health burden analyses emphasize urgent prevention measures; major preventable levers include reducing harmful alcohol consumption and implementing targeted interventions in high-risk groups (danpanichkul2025globalepidemiologyof pages 1-5, pan2025alcoholassociatedliverdisease pages 1-2). Primary and secondary prevention in practice includes: - Primary prevention: population alcohol control policies (pricing/availability/marketing restrictions) and AUD prevention/treatment integration (supported as urgent in GBD-based epidemiology work) (danpanichkul2025globalepidemiologyof pages 1-5). - Secondary prevention: non-invasive fibrosis screening (VCTE/serum panels) in at-risk drinkers and monitoring with objective alcohol biomarkers (PEth) to detect relapse or underreported intake (rama2026novelbiomarkersfor pages 6-8, rama2026novelbiomarkersfor pages 5-6).

14. Other species / natural disease

Not systematically covered in the retrieved evidence set.

15. Model organisms / experimental models

A 2024 JCI review notes the importance of preclinical models and describes introduction of binge ethanol intake into chronically ethanol-fed mice to model disease features (mackowiak2024alcoholassociatedliverdisease pages 1-2). A 2023 Hepatology paper uses the NIAAA chronic + binge ethanol feeding model and demonstrates that adipose lipolysis is important for ethanol-induced hepatic steatosis and lipid peroxidation, providing a mechanistic mouse model example (hong2024alcoholrelatedliverdisease pages 1-2).

Key statistics summary (selected)

  • NHANES (2017–Mar 2020) U.S. prevalence under SLD nomenclature: SLD 34.2%, MASLD 31.3%, MetALD 2.0%, ALD 0.7% (lee2024nationalprevalenceestimates pages 1-2).
  • GBD 2021 global counts (2021): 3.02 million prevalent ALD cases and 132,030 prevalent alcohol-attributable primary liver cancer cases (danpanichkul2025globalepidemiologyof pages 1-5).
  • U.S. mortality trend (1999–2022): ALD age-adjusted mortality 6.71 → 12.53 per 100,000; 436,814 ALD deaths (pan2025alcoholassociatedliverdisease pages 1-2).
  • Severe AH short-term mortality: 20%–50% (kasuga2025currentinsightsinto pages 1-2).

Evidence limitations (in this tool-based evidence set)

  • MONDO and MeSH identifiers, ICD-11 liver-disease code mappings, OMIM/Orphanet IDs, and comprehensive phenotype frequency distributions were not found in the retrieved texts and would require targeted database queries beyond the current evidence set.
  • Several mechanistic and treatment details are best supported by recent reviews; primary mechanistic studies (PMID-first extraction) were not comprehensively retrieved here.

References

  1. (alvaradotapias2024alcoholassociatedliverdisease pages 1-3): Edilmar Alvarado-Tapias, Elisa Pose, Jordi Gratacós, Ana Clemente-Sánchez, Hugo Hugo López-Pelayo, and Ramón Bataller. Alcohol-associated liver disease: natural history, management and novel targeted therapies. Clinical and Molecular Hepatology, 31:S112-S133, Oct 2024. URL: https://doi.org/10.3350/cmh.2024.0709, doi:10.3350/cmh.2024.0709. This article has 32 citations.

  2. (mackowiak2024alcoholassociatedliverdisease pages 1-2): Bryan Mackowiak, Yaojie Fu, Luca Maccioni, and Bin Gao. Alcohol-associated liver disease. The Journal of Clinical Investigation, Feb 2024. URL: https://doi.org/10.1172/jci176345, doi:10.1172/jci176345. This article has 352 citations.

  3. (hong2024alcoholrelatedliverdisease pages 1-2): Xiao Hong, Shuo-Wen Huang, He Jiang, Qing Ma, Jiang Qiu, Qihan Luo, Chunlu Cao, Yiyang Xu, Fuzhe Chen, Yufan Chen, Chunfeng Sun, Haozhe Fu, Yiming Liu, Changyu Li, Fangming Chen, and Ping Qiu. Alcohol-related liver disease (ald): current perspectives on pathogenesis, therapeutic strategies, and animal models. Frontiers in Pharmacology, Nov 2024. URL: https://doi.org/10.3389/fphar.2024.1432480, doi:10.3389/fphar.2024.1432480. This article has 34 citations.

  4. (israelsenUnknownyearmetaldfromconcept pages 7-10): M Israelsen, E Trépo, A Krag, and S Stender. Metald: from concept to clinic, genetic factors and clinical outcomes. Unknown journal, Unknown year.

  5. (manthey2025identifyinglevelsof pages 1-2): Jakob Manthey, Carolin Kilian, Ludwig Kraus, Ingo Schäfer, Anna Schranz, and Bernd Schulte. Identifying levels of alcohol use disorder severity in electronic health records. Substance Abuse Treatment, Prevention, and Policy, Sep 2025. URL: https://doi.org/10.1186/s13011-025-00670-w, doi:10.1186/s13011-025-00670-w. This article has 2 citations and is from a peer-reviewed journal.

  6. (kubina2025meta‐analysiseffectsof pages 23-23): Matthew Kubina, Vitchapong Prasitsumrit, Jarell Tan, Joo Wei Ethan Quek, Dhiraj Peddu, Ankit Mishra, Pojsakorn Danpanichkul, Jake P. Mann, Eric Trépo, Stephan Buch, Daniel Q. Huang, Cheng Han Ng, Mark D. Muthiah, Yu Jun Wong, Karn Wijarnpreecha, and Vincent L. Chen. Meta‐analysis: effects of steatotic liver disease‐associated genetic risk alleles on longitudinal outcomes. Alimentary Pharmacology & Therapeutics, 62:244-276, Jun 2025. URL: https://doi.org/10.1111/apt.70256, doi:10.1111/apt.70256. This article has 11 citations and is from a highest quality peer-reviewed journal.

  7. (lee2024designingclinicaltrials pages 3-5): Brian P. Lee, Katie Witkiewitz, Jessica Mellinger, Frank A. Anania, Ramon Bataller, Thomas G. Cotter, Brenda Curtis, Srinivasan Dasarathy, Kelly S. DeMartini, Ivan Diamond, Nancy Diazgranados, Andrea F. DiMartini, Daniel E. Falk, Anne C. Fernandez, Margarita N. German, Patrick S. Kamath, Kelley M. Kidwell, Lorenzo Leggio, Raye Litten, Alexandre Louvet, Michael R. Lucey, Mary E. McCaul, Arun J. Sanyal, Ashwani K. Singal, Norman L. Sussman, Norah A. Terrault, Mark R. Thursz, Elizabeth C. Verna, Svetlana Radaeva, Laura E. Nagy, and Mack C. Mitchell. Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel consensus statement. Nature reviews. Gastroenterology & hepatology, 21:626-645, Jun 2024. URL: https://doi.org/10.1038/s41575-024-00936-x, doi:10.1038/s41575-024-00936-x. This article has 52 citations.

  8. (lee2024nationalprevalenceestimates pages 1-2): Brian P. Lee, Jennifer L. Dodge, and Norah A. Terrault. National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature. Hepatology, 79:666-673, Sep 2024. URL: https://doi.org/10.1097/hep.0000000000000604, doi:10.1097/hep.0000000000000604. This article has 207 citations and is from a highest quality peer-reviewed journal.

  9. (danpanichkul2025globalepidemiologyof pages 1-5): Pojsakorn Danpanichkul, Luis Antonio Díaz, Kanokphong Suparan, Primrose Tothanarungroj, Supapitch Sirimangklanurak, Thanida Auttapracha, Hanna L. Blaney, Banthoon Sukphutanan, Yanfang Pang, Siwanart Kongarin, Francisco Idalsoaga, Eduardo Fuentes-López, Lorenzo Leggio, Mazen Noureddin, Trenton M. White, Alexandre Louvet, Philippe Mathurin, Rohit Loomba, Patrick S. Kamath, Jürgen Rehm, Jeffrey V. Lazarus, Karn Wijarnpreecha, and Juan Pablo Arab. Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021. Clinical and Molecular Hepatology, 31:525-547, Jan 2025. URL: https://doi.org/10.3350/cmh.2024.0835, doi:10.3350/cmh.2024.0835. This article has 57 citations.

  10. (lee2024designingclinicaltrials pages 1-2): Brian P. Lee, Katie Witkiewitz, Jessica Mellinger, Frank A. Anania, Ramon Bataller, Thomas G. Cotter, Brenda Curtis, Srinivasan Dasarathy, Kelly S. DeMartini, Ivan Diamond, Nancy Diazgranados, Andrea F. DiMartini, Daniel E. Falk, Anne C. Fernandez, Margarita N. German, Patrick S. Kamath, Kelley M. Kidwell, Lorenzo Leggio, Raye Litten, Alexandre Louvet, Michael R. Lucey, Mary E. McCaul, Arun J. Sanyal, Ashwani K. Singal, Norman L. Sussman, Norah A. Terrault, Mark R. Thursz, Elizabeth C. Verna, Svetlana Radaeva, Laura E. Nagy, and Mack C. Mitchell. Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel consensus statement. Nature reviews. Gastroenterology & hepatology, 21:626-645, Jun 2024. URL: https://doi.org/10.1038/s41575-024-00936-x, doi:10.1038/s41575-024-00936-x. This article has 52 citations.

  11. (bourganou2025unravelingmetabolicdysfunctionassociated pages 9-11): Maria V. Bourganou, Maria Eleni Chondrogianni, Ioannis Kyrou, Christina-Maria Flessa, Antonios Chatzigeorgiou, Evangelos Oikonomou, Vaia Lambadiari, Harpal S. Randeva, and Eva Kassi. Unraveling metabolic dysfunction-associated steatotic liver disease through the use of omics technologies. International Journal of Molecular Sciences, 26:1589, Feb 2025. URL: https://doi.org/10.3390/ijms26041589, doi:10.3390/ijms26041589. This article has 28 citations.

  12. (mackowiak2024alcoholassociatedliverdisease pages 8-9): Bryan Mackowiak, Yaojie Fu, Luca Maccioni, and Bin Gao. Alcohol-associated liver disease. The Journal of Clinical Investigation, Feb 2024. URL: https://doi.org/10.1172/jci176345, doi:10.1172/jci176345. This article has 352 citations.

  13. (d’arcangelo2026oxidativestressand pages 15-16): Francesca D’Arcangelo, Neil Rajoriya, and Patricia F. Lalor. Oxidative stress and alcohol-related hepatitis: a role for future therapies. Antioxidants, 15:493, Apr 2026. URL: https://doi.org/10.3390/antiox15040493, doi:10.3390/antiox15040493. This article has 0 citations.

  14. (pan2025alcoholassociatedliverdisease pages 1-2): Chun-Wei Pan, Yazan Abboud, Amit S. Chitnis, Wei Zhang, Ashwani K. Singal, and Robert J Wong. Alcohol-associated liver disease mortality. JAMA Network Open, 8:e2514857, Jun 2025. URL: https://doi.org/10.1001/jamanetworkopen.2025.14857, doi:10.1001/jamanetworkopen.2025.14857. This article has 26 citations and is from a peer-reviewed journal.

  15. (wang2025geneticinsightsinto pages 1-2): Qianchang Wang, Zhe Wang, Minzhe Hu, Fangfeng Liu, and Zhengjian Wang. Genetic insights into alcohol-associated liver disease: integrative transcriptome-wide analysis identifies novel susceptibility genes. Frontiers in Medicine, Jul 2025. URL: https://doi.org/10.3389/fmed.2025.1623367, doi:10.3389/fmed.2025.1623367. This article has 2 citations.

  16. (alvaradotapias2024alcoholassociatedliverdisease pages 3-4): Edilmar Alvarado-Tapias, Elisa Pose, Jordi Gratacós, Ana Clemente-Sánchez, Hugo Hugo López-Pelayo, and Ramón Bataller. Alcohol-associated liver disease: natural history, management and novel targeted therapies. Clinical and Molecular Hepatology, 31:S112-S133, Oct 2024. URL: https://doi.org/10.3350/cmh.2024.0709, doi:10.3350/cmh.2024.0709. This article has 32 citations.

  17. (kasuga2025currentinsightsinto pages 1-2): Ryosuke Kasuga, Po‐Sung Chu, Takanori Kanai, and Nobuhiro Nakamoto. Current insights into pathogenesis and anti‐inflammatory treatment strategies for severe alcohol‐associated hepatitis: focus on neutrophil‐targeted therapies. Hepatology Research, 55:785-94, May 2025. URL: https://doi.org/10.1111/hepr.14206, doi:10.1111/hepr.14206. This article has 1 citations and is from a peer-reviewed journal.

  18. (rama2026novelbiomarkersfor pages 5-6): Kaanthi Rama, Vinay Jahagirdar, Francisco Idalsoaga, Hanna Blaney, S. Fisher Rhoads, Luis Antonio Díaz, Marco Arrese, and Juan Pablo Arab. Novel biomarkers for alcohol-associated liver disease and their implications across clinical settings. Clinical and Molecular Hepatology, 32:443-463, Apr 2026. URL: https://doi.org/10.3350/cmh.2025.0921, doi:10.3350/cmh.2025.0921. This article has 3 citations.

  19. (rama2026novelbiomarkersfor pages 6-8): Kaanthi Rama, Vinay Jahagirdar, Francisco Idalsoaga, Hanna Blaney, S. Fisher Rhoads, Luis Antonio Díaz, Marco Arrese, and Juan Pablo Arab. Novel biomarkers for alcohol-associated liver disease and their implications across clinical settings. Clinical and Molecular Hepatology, 32:443-463, Apr 2026. URL: https://doi.org/10.3350/cmh.2025.0921, doi:10.3350/cmh.2025.0921. This article has 3 citations.

  20. (israelsenUnknownyearmetaldfromconcept pages 1-7): M Israelsen, E Trépo, A Krag, and S Stender. Metald: from concept to clinic, genetic factors and clinical outcomes. Unknown journal, Unknown year.

  21. (rama2026novelbiomarkersfor pages 14-15): Kaanthi Rama, Vinay Jahagirdar, Francisco Idalsoaga, Hanna Blaney, S. Fisher Rhoads, Luis Antonio Díaz, Marco Arrese, and Juan Pablo Arab. Novel biomarkers for alcohol-associated liver disease and their implications across clinical settings. Clinical and Molecular Hepatology, 32:443-463, Apr 2026. URL: https://doi.org/10.3350/cmh.2025.0921, doi:10.3350/cmh.2025.0921. This article has 3 citations.

  22. (d’arcangelo2026oxidativestressand pages 1-2): Francesca D’Arcangelo, Neil Rajoriya, and Patricia F. Lalor. Oxidative stress and alcohol-related hepatitis: a role for future therapies. Antioxidants, 15:493, Apr 2026. URL: https://doi.org/10.3390/antiox15040493, doi:10.3390/antiox15040493. This article has 0 citations.

  23. (kumar2026emergingtherapeuticregimens pages 5-6): Rahul Kumar, Sakktivel Elangovan, and Sumeet K. Asrani. Emerging therapeutic regimens as alternatives to glucocorticoids for severe alcohol-associated hepatitis: a comprehensive review. Clinical and Molecular Hepatology, 32:599-619, Apr 2026. URL: https://doi.org/10.3350/cmh.2025.1163, doi:10.3350/cmh.2025.1163. This article has 0 citations.

  24. (rama2026novelbiomarkersfor pages 17-18): Kaanthi Rama, Vinay Jahagirdar, Francisco Idalsoaga, Hanna Blaney, S. Fisher Rhoads, Luis Antonio Díaz, Marco Arrese, and Juan Pablo Arab. Novel biomarkers for alcohol-associated liver disease and their implications across clinical settings. Clinical and Molecular Hepatology, 32:443-463, Apr 2026. URL: https://doi.org/10.3350/cmh.2025.0921, doi:10.3350/cmh.2025.0921. This article has 3 citations.

  25. (rama2026novelbiomarkersfor pages 1-3): Kaanthi Rama, Vinay Jahagirdar, Francisco Idalsoaga, Hanna Blaney, S. Fisher Rhoads, Luis Antonio Díaz, Marco Arrese, and Juan Pablo Arab. Novel biomarkers for alcohol-associated liver disease and their implications across clinical settings. Clinical and Molecular Hepatology, 32:443-463, Apr 2026. URL: https://doi.org/10.3350/cmh.2025.0921, doi:10.3350/cmh.2025.0921. This article has 3 citations.

  26. (rama2026novelbiomarkersfor pages 8-9): Kaanthi Rama, Vinay Jahagirdar, Francisco Idalsoaga, Hanna Blaney, S. Fisher Rhoads, Luis Antonio Díaz, Marco Arrese, and Juan Pablo Arab. Novel biomarkers for alcohol-associated liver disease and their implications across clinical settings. Clinical and Molecular Hepatology, 32:443-463, Apr 2026. URL: https://doi.org/10.3350/cmh.2025.0921, doi:10.3350/cmh.2025.0921. This article has 3 citations.

  27. (adekunle2023therapeutictargetsin pages 1-2): Ayooluwatomiwa Deborah Adekunle, Adeyinka Adejumo, and Ashwani K. Singal. Therapeutic targets in alcohol-associated liver disease: progress and challenges. Therapeutic Advances in Gastroenterology, Jan 2023. URL: https://doi.org/10.1177/17562848231170946, doi:10.1177/17562848231170946. This article has 10 citations and is from a peer-reviewed journal.

  28. (hardesty2024currentpharmacotherapyand pages 4-6): Josiah E. Hardesty and Craig J. McClain. Current pharmacotherapy and nutrition therapy of alcohol-associated liver disease. Clinics in Liver Disease, 28:731-745, Nov 2024. URL: https://doi.org/10.1016/j.cld.2024.06.018, doi:10.1016/j.cld.2024.06.018. This article has 2 citations and is from a peer-reviewed journal.

  29. (alvaradotapias2024alcoholassociatedliverdisease media 15159c76): Edilmar Alvarado-Tapias, Elisa Pose, Jordi Gratacós, Ana Clemente-Sánchez, Hugo Hugo López-Pelayo, and Ramón Bataller. Alcohol-associated liver disease: natural history, management and novel targeted therapies. Clinical and Molecular Hepatology, 31:S112-S133, Oct 2024. URL: https://doi.org/10.3350/cmh.2024.0709, doi:10.3350/cmh.2024.0709. This article has 32 citations.

  30. (d’arcangelo2026oxidativestressand pages 12-13): Francesca D’Arcangelo, Neil Rajoriya, and Patricia F. Lalor. Oxidative stress and alcohol-related hepatitis: a role for future therapies. Antioxidants, 15:493, Apr 2026. URL: https://doi.org/10.3390/antiox15040493, doi:10.3390/antiox15040493. This article has 0 citations.

  31. (NCT01912404 chunk 1): Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy. Conatus Pharmaceuticals Inc.. 2013. ClinicalTrials.gov Identifier: NCT01912404

  32. (NCT02473341 chunk 1): Prof. Sandeep S Sidhu. Gut-Liver Axis Modulation With IgG-Enriched Immunotherapy in Severe Alcohol-Associated Hepatitis. Dayanand Medical College and Hospital. 2017. ClinicalTrials.gov Identifier: NCT02473341

Artifacts

OpenAI ▸
1. Core Pathophysiology
o3-deep-research-2025-06-26 148 citations 2026-02-01T16:32:11.483667

1. Core Pathophysiology

Alcoholic liver disease (ALD) arises from chronic excessive alcohol intake leading to progressive liver injury through multiple interrelated mechanisms. Ethanol metabolism in hepatocytes is the initiating event: alcohol is primarily oxidized to acetaldehyde by cytosolic alcohol dehydrogenase (ADH) and microsomal cytochrome P450 2E1 (CYP2E1), and then to acetate by mitochondrial aldehyde dehydrogenase (ALDH) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This process generates reactive oxygen species (ROS) and excess NADH, shifting the cellular redox state and disrupting metabolic homeostasis (pmc.ncbi.nlm.nih.gov). “Alcohol is metabolized to acetaldehyde via alcohol dehydrogenase and CYP2E1, which forms protein and DNA adducts. Increased CYP2E1 activity results in oxidative stress due to generation of ROS and also shifts the cellular redox potential by increasing NADH/NAD^+ ratio to influence de novo lipid synthesis” (pmc.ncbi.nlm.nih.gov). The toxic acetaldehyde forms adducts with proteins, DNA, and lipids, impairing their function and creating neoantigens that elicit immune attack (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Meanwhile, ROS from alcohol metabolism cause lipid peroxidation of membranes (yielding reactive aldehydes like malondialdehyde and 4-hydroxynonenal) which damage mitochondria and other organelles (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Together, these insults result in hepatocellular injury and death via necrosis or apoptosis.

A hallmark of ALD is hepatic steatosis (fatty liver), the earliest stage characterized by excessive triglyceride accumulation in hepatocytes (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Alcohol’s effects on hepatic lipid metabolism are profound: it increases fat synthesis (activating lipogenic transcription factors and enzymes) and impairs fat breakdown (inhibiting β-oxidation and VLDL export) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The high NADH/NAD^+ ratio caused by alcohol metabolism diverts substrates toward lipid synthesis and limits fatty acid oxidation in mitochondria (pmc.ncbi.nlm.nih.gov). Chronic alcohol also upregulates sterol regulatory element-binding protein 1c (SREBP-1c) and related factors that drive de novo lipogenesis, while reducing peroxisome proliferator-activated receptor-α (PPARα) activity needed for fatty acid oxidation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The result is triglyceride accumulation and fat droplet formation in hepatocytes (simple steatosis) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This fatty change is often asymptomatic and initially reversible with abstinence (pmc.ncbi.nlm.nih.gov). However, a fatty liver is more vulnerable to further injury: excess fat can amplify oxidative stress (via lipid peroxidation) and promotes inflammation.

Persistent alcohol use leads to inflammation and steatohepatitis. Dying hepatocytes release danger signals (DAMPs) and reactive aldehydes that activate Kupffer cells (resident liver macrophages), and alcohol disrupts the gut mucosal barrier allowing endotoxin (lipopolysaccharide, LPS) from intestinal bacteria to reach the liver via the portal vein (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). LPS and DAMPs engage pattern recognition receptors (e.g. Toll-like receptor 4 on Kupffer cells), triggering NF-κB and MAPK pathways that induce pro-inflammatory cytokine production (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). “Alcohol alters the gut microbiome and increases gut permeability resulting in translocation of bacterial products (e.g. LPS) into portal circulation, activation of macrophages and production of inflammatory cytokines” (pmc.ncbi.nlm.nih.gov). Kupffer cells secrete tumor necrosis factor-α (TNFα), interleukin-1β (IL-1β), interleukin-6 (IL-6), and chemokines, which recruit inflammatory cells (neutrophils, monocytes) into the liver (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This immune response causes hepatocyte ballooning (swelling), spotty necrosis, and the formation of Mallory–Denk bodies (aggregates of misfolded cytokeratin proteins within hepatocytes), all histological features of alcoholic hepatitis (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In severe alcoholic hepatitis, high levels of cytokines and oxidative stress lead to widespread cell death, while impaired bile excretion can cause cholestasis. Clinically, this presents as jaundice and systemic inflammatory response – “prominent cholestasis that leads to onset of jaundice, decompensated liver disease, malaise and coagulopathy” in acute alcoholic hepatitis cases (pmc.ncbi.nlm.nih.gov).

With repeated injury, the liver’s wound-healing response activates fibrogenesis. Stressed hepatocytes and Kupffer cells release transforming growth factor-β1 (TGF-β1) and other profibrotic mediators that activate hepatic stellate cells (Ito cells) (pmc.ncbi.nlm.nih.gov). Stellate cells transdifferentiate into myofibroblasts, producing extracellular matrix (collagen) in the space of Disse. Collagen deposition starts around central veins and spreads in a “chicken-wire” pattern around hepatocytes (pericellular fibrosis) (pmc.ncbi.nlm.nih.gov). Over time, fibrotic septa link up and disrupt the normal lobular architecture, progressing to cirrhosis – an end-stage characterized by diffuse nodular scarring (pmc.ncbi.nlm.nih.gov). Cirrhosis causes loss of functional hepatocyte mass and distortion of hepatic blood flow (leading to portal hypertension). As a result, patients develop complications like ascites (fluid accumulation), variceal bleeding, encephalopathy (brain dysfunction from ammonia), and coagulopathy. Cirrhosis also heightens the risk of hepatocellular carcinoma (HCC) due to chronic inflammation and regenerative nodule turnover (pmc.ncbi.nlm.nih.gov).

In summary, ALD pathogenesis is a multifactorial process involving direct toxic injury from ethanol and its metabolites, oxidative stress, dysregulated lipid metabolism, innate immune activation (gut-liver axis), and fibrogenic wound-healing responses. As one expert review stated, “the pathogenesis of ALD is complex and multifactorial. Several intracellular, intrahepatic, and extrahepatic factors influence development of early fatty liver injury leading to inflammation and fibrosis. Alcohol metabolism, cellular stress, and gut-derived factors contribute to hepatocyte and immune cell injury leading to cytokine and chemokine production.” (pubmed.ncbi.nlm.nih.gov) Understanding these interconnected mechanisms is crucial, since only a minority of heavy drinkers (~10–20%) develop advanced ALD, suggesting co-factors (genetic, nutritional, sex, comorbid metabolic syndrome) modulate susceptibility (pmc.ncbi.nlm.nih.gov). Notably, a common genetic variant in PNPLA3 has been shown to strongly enhance the risk of steatohepatitis and fibrosis in drinkers (a gene–environment interaction described as transforming our understanding of ALD pathogenesis) (pubmed.ncbi.nlm.nih.gov). Overall, ALD progresses through a spectrum from simple steatosis to alcoholic hepatitis to fibrosis/cirrhosis, driven by escalating cellular damage and impaired repair mechanisms.

2. Key Molecular Players

Genes/Proteins: Chronic alcohol exposure perturbs numerous genes and signaling pathways:

  • ADH1B/ADH1C (Alcohol Dehydrogenases) – Enzymes that initiate ethanol oxidation to acetaldehyde. Variants in ADH genes affect the rate of alcohol metabolism and acetaldehyde buildup (pmc.ncbi.nlm.nih.gov).
  • ALDH2 (Aldehyde Dehydrogenase 2) – Mitochondrial enzyme that clears acetaldehyde. Deficiency (e.g. ALDH2*2 variant) causes acetaldehyde accumulation, exacerbating toxicity (e.g. flushing and liver damage).
  • CYP2E1 (Cytochrome P450 2E1) – An inducible enzyme upregulated by chronic ethanol; catalyzes an alternate ethanol oxidation pathway producing abundant ROS (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). CYP2E1 induction correlates with worse oxidative injury in ALD.
  • PNPLA3 (Patatin-like phospholipase domain-containing protein 3) – A lipid droplet-associated protein. The I148M variant of PNPLA3 is a major genetic risk factor for ALD severity, promoting fat retention and fibrosis in the liver (pubmed.ncbi.nlm.nih.gov). PNPLA3 illustrates gene–environment interaction: its effect on liver injury is greatly amplified by alcohol and coexistent obesity (pubmed.ncbi.nlm.nih.gov).
  • TNF (Tumor Necrosis Factor-α) – A proinflammatory cytokine produced principally by Kupffer cells in ALD. TNFα drives hepatocyte apoptosis and neutrophil recruitment; neutralization of TNF in animal models reduced liver injury, but anti-TNF therapy failed in patients due to infection risk (pmc.ncbi.nlm.nih.gov).
  • TLR4 (Toll-like Receptor 4) – Pattern recognition receptor on Kupffer cells and others that detects LPS. TLR4 activation triggers MyD88-dependent NF-κB and MAPK signaling, inducing TNFα, IL-1β, IL-6, etc., and thus is a key upstream driver of alcohol-induced inflammation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). (Related TLRs: TLR9 can sense bacterial DNA, and TLR3 was recently shown to sense hepatocyte-derived mitochondrial RNA in ALD (pmc.ncbi.nlm.nih.gov).)
  • TGF-β1 (Transforming Growth Factor β) – Master fibrogenic cytokine released by injured hepatocytes and macrophages. TGF-β1 activates hepatic stellate cells and stimulates collagen gene expression (e.g. COL1A1), promoting fibrosis in chronic ALD.
  • NF-κB (Nuclear Factor kappaB) – A transcription factor complex central to the inflammatory cascade. Ethanol and LPS activate NF-κB in immune cells and hepatocytes, upregulating genes for cytokines (TNF, IL-1, IL-8) that mediate liver inflammation (pmc.ncbi.nlm.nih.gov).
  • PPARα (Peroxisome Proliferator-Activated Receptor alpha) – A nuclear receptor regulating fatty acid oxidation. Chronic alcohol inhibits PPARα activity (via reduced RXRα and high NADH), leading to decreased expression of β-oxidation enzymes (CPT1, ACOX1, etc.) and promoting fat accumulation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).
  • SREBP-1c, ChREBP, and Lipogenic Enzymes – Transcription factors SREBP-1c (sterol regulatory element-binding protein 1c) and ChREBP (carbohydrate response element-binding protein) are upregulated by ethanol, driving expression of lipogenic genes (FAS, ACC1, DGAT, etc.), thereby increasing triglyceride synthesis (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).
  • RIPK3 and Caspase-8 – Mediators of necroptosis and apoptosis respectively. Alcohol exposure can activate death pathways: studies show the RIP1–RIP3 axis contributes to hepatocyte necroptosis in ALD, while death receptor signaling (via caspase-8) contributes to apoptosis (pmc.ncbi.nlm.nih.gov). Emerging evidence also implicates Gasdermin-D (GSDMD) in pyroptosis (inflammatory cell death) in alcoholic hepatitis (pmc.ncbi.nlm.nih.gov).
  • HNF4α (Hepatocyte Nuclear Factor 4 alpha) – A transcription factor fundamental for hepatocyte differentiation and function. Severe alcoholic hepatitis has been linked with dysregulated HNF4α (e.g. alternative splicing to a fetal isoform and genetic variants), impairing liver regeneration and hepatocyte maturity (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).
  • (Many other molecular players are involved, including antioxidant defense genes like NFE2L2/NRF2 (which senses oxidative stress and upregulates detoxifying enzymes (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov)), IL-22 (a regenerative cytokine under study for therapy), and microRNAs that regulate gene expression in ALD. However, the above are key examples.)

Chemical Entities (Metabolites & Molecules):

  • Ethanol (CHEBI:16236) – The causative agent; a small amphiphilic molecule whose chronic presence in the liver initiates the cascade of damage (pmc.ncbi.nlm.nih.gov). Ethanol itself can disrupt cell membranes and signaling, but most injury comes from its metabolites.
  • Acetaldehyde (CHEBI:15343) – The highly reactive intermediate of alcohol metabolism. Acetaldehyde forms covalent adducts with proteins and DNA, impairing their function and triggering immune recognition (pmc.ncbi.nlm.nih.gov). It also depletes glutathione by binding to it, worsening oxidative stress (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Accumulation of acetaldehyde in hepatocytes is a major driver of cellular dysfunction in ALD.
  • Reactive Oxygen Species (ROS) – Chemically reactive oxygen-derived molecules (e.g. superoxide O_2^−, hydrogen peroxide H_2O_2, hydroxyl radicals). Excess ROS are generated during CYP2E1-mediated ethanol oxidation and by dysfunctional mitochondria (pmc.ncbi.nlm.nih.gov). ROS cause lipid peroxidation, protein oxidation, and DNA damage in the liver, directly contributing to hepatocyte death (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).
  • Malondialdehyde (MDA) & 4-Hydroxynonenal (4-HNE) – Toxic aldehydes produced from ROS-induced lipid peroxidation of polyunsaturated fats in cell membranes. MDA and 4-HNE form adducts with DNA and proteins, creating mutagenic lesions and inactivating enzymes (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). They are important mediators of the stellate cell activation and cell death seen in ALD.
  • Glutathione (GSH) – The principal intracellular antioxidant; it neutralizes ROS and is crucial for detoxifying peroxides. Chronic alcohol intake depletes GSH (both by reduced synthesis and by acetaldehyde binding GSH) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov), leaving hepatocytes vulnerable to oxidative injury. Low GSH is commonly observed in ALD and correlates with disease severity.
  • Lipopolysaccharide (LPS) – A component of Gram-negative bacterial cell walls (endotoxin) that translocates from the intestine into portal blood due to alcohol-induced gut barrier damage (pmc.ncbi.nlm.nih.gov). LPS in the liver binds TLR4 on Kupffer cells, potently stimulating production of TNFα, IL-1β and other inflammatory mediators that cause hepatitis (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Elevated LPS levels have been measured in patients with alcoholic hepatitis, linking gut microbiota changes to liver inflammation.
  • Free Fatty Acids (FFAs) – Chronic ethanol increases plasma FFAs (by stimulating adipose lipolysis and inhibiting skeletal muscle uptake). Uptake of excess FFAs by the liver (via CD36 upregulation) contributes to triglyceride accumulation in hepatocytes (pmc.ncbi.nlm.nih.gov). FFAs within hepatocytes can also undergo peroxidation (generating toxic lipids) or activate inflammatory pathways.
  • Fatty Acid Ethyl Esters (FAEEs) – Non-oxidative metabolites of ethanol formed by esterification of ethanol with fatty acyl-CoA. FAEEs can incorporate into cell membranes and are directly hepatotoxic: they disturb mitochondrial electron transport and can trigger hepatocyte apoptosis (pmc.ncbi.nlm.nih.gov). Detectable in tissues, FAEEs are markers of alcohol exposure and contribute to pancreatic and liver injury.
  • Cytokines (TNFα, IL-1β, IL-6, IL-8, IFN-γ) – Soluble protein mediators of inflammation. In ALD, Kupffer cells and infiltrating immune cells release high levels of these cytokines, which cause fever, recruit neutrophils (e.g. IL-8 is a chemoattractant), induce cell death (TNFα can trigger apoptosis via TNFR1), and impair hepatocyte function (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Elevated serum TNFα and IL-6 are hallmarks of severe alcoholic hepatitis and correlate with worse outcomes.
  • Chemokines (e.g. MCP-1/CCL2, CXCL1, CXCL5) – Small chemoattractant proteins induced during alcohol-related inflammation. They direct the trafficking of leukocytes into the liver. For instance, monocyte chemoattractant protein-1 (CCL2) is upregulated in ALD, driving recruitment of monocytes that become pro-inflammatory macrophages in the liver.
  • Acetate – The end-product of ethanol oxidation (after ALDH converts acetaldehyde to acetic acid, which is then converted to acetyl-CoA). While acetate itself is relatively benign and can be metabolized in the TCA cycle, the surge of acetyl-CoA can contribute to lipid synthesis. Also, peripheral conversion of acetate to acetone and other ketones can occur. (Acetate buildup is not typically toxic, but represents altered hepatic metabolism in heavy drinkers.)
  • Endothelin-1 (and other vasoactive mediators) – Although not specific to alcohol, cirrhosis from ALD features elevated endothelins and nitric oxide dysregulation, contributing to portal hypertension and hemodynamic changes. These chemical mediators cause sinusoidal contraction and systemic vasodilation in advanced disease.

Cell Types Involved:

  • Hepatocytes (Liver parenchymal cells – CL:0000182) – The primary targets of alcohol’s toxic effects. Hepatocytes metabolize ethanol and bear the brunt of injury: they accumulate fat droplets, suffer oxidative DNA and protein damage, and undergo cell death (ballooning, apoptosis/necrosis) in ALD (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Degenerating hepatocytes release DAMPs that further drive inflammation.
  • Kupffer Cells (Liver resident macrophages – CL:0000863) – Sentinel immune cells in the liver sinusoids that orchestrate much of the inflammatory response in ALD. Upon exposure to gut-derived LPS or hepatocyte DAMPs, Kupffer cells secrete TNFα, IL-1β, IL-6 and chemokines, triggering hepatocyte injury and recruiting other leukocytes (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Studies show that depletion or modulation of Kupffer cells can attenuate alcoholic liver injury, highlighting their central role.
  • Stellate Cells (Ito cells, hepatic stellate cells – CL:0000632) – Quiescent perisinusoidal cells that store vitamin A. In chronic alcohol injury, stellate cells become activated myofibroblasts that proliferate and produce collagen, leading to fibrosis (pmc.ncbi.nlm.nih.gov). They respond to cytokines like TGF-β, PDGF, and IL-1 released during alcoholic injury. Stellate cell activation marks the transition from fatty hepatitis to fibrotic disease.
  • Neutrophils (Polymorphonuclear leukocytes – CL:0000775) – Acute inflammatory white blood cells recruited in alcoholic hepatitis. Neutrophils infiltrate hepatic lobules in response to IL-8 and complement factors, where they contribute to tissue damage by releasing reactive oxygen species and proteases. Neutrophil counts in the liver and blood are often elevated in severe alcoholic hepatitis, and their presence (hepatic neutrophil infiltrates) is a histological hallmark of alcoholic steatohepatitis (pmc.ncbi.nlm.nih.gov).
  • Monocytes/Macrophages – Circulating monocytes are recruited to the liver during chronic alcohol exposure and differentiate into macrophages that complement resident Kupffer cells. In ALD, there is an expansion of inflammatory Ly6C^hi monocyte-derived macrophages that produce cytokines and promote tissue injury (pmc.ncbi.nlm.nih.gov). Alternatively, a smaller population of Ly6C^low macrophages may help with resolution. These cells also scavenge debris and can activate stellate cells via cytokine release.
  • T Lymphocytes – Both innate-like T cells and conventional T cells partake in ALD pathogenesis. Natural Killer T (NKT) cells and mucosal-associated invariant T (MAIT) cells are enriched in the liver and can become activated by cytokines and bacterial metabolites during ALD, producing interferon-γ and other mediators (pmc.ncbi.nlm.nih.gov). CD8^+ cytotoxic T cells may contribute to hepatocyte killing, while CD4^+ T cells (Th17, Th1 subsets) can amplify inflammation or regulate it. Advanced ALD often features an immunosuppressed yet pro-inflammatory T-cell profile (e.g., regulatory T-cell dysfunction alongside effector T-cell activation).
  • NK Cells (Natural Killer cells) – Innate immune cells that can kill virus-infected or damaged cells. In ALD, NK cells may target stressed hepatocytes (especially those with low MHC class I or bound by antibodies in alcoholic hepatitis). They also produce IFN-γ which can activate macrophages. However, chronic alcohol can impair NK cell function, reducing their anti-fibrotic activity (NK cells normally help clear activated stellate cells).
  • Liver Sinusoidal Endothelial Cells (LSECs) – Specialized endothelial cells lining the sinusoids. Alcohol and acetaldehyde cause LSEC dysfunction, characterized by loss of fenestrations and nitric oxide imbalance (“capillarization” of sinusoids). LSEC dysfunction in ALD contributes to impaired hepatocyte perfusion and promotes fibrosis (by releasing cytokines like endothelin-1 that activate stellate cells) (pubmed.ncbi.nlm.nih.gov). Recent studies show persistent endothelial activation in alcoholic hepatitis, indicating these cells participate in the inflammatory environment.
  • Gut Epithelial Cells & Microbiota – Though not in the liver, intestinal epithelial cells are indirectly involved. Alcohol injures enterocytes and tight junctions, increasing permeability of the gut lining (pmc.ncbi.nlm.nih.gov). This allows translocation of bacteria and their products. The gut microbiota composition shifts in alcohol misuse (dysbiosis), which can result in more LPS-producing bacteria. These upstream changes in the gut significantly impact the liver’s inflammatory load in ALD (the “gut–liver axis”).

Anatomical Locations:

  • Liver (UBERON:0002107) – The primary organ affected. Within the liver, damage is often most pronounced in the centrilobular region (around the central veins, also known as Zone 3 of the hepatic acinus) where CYP2E1 expression and acetaldehyde generation are highest and oxygen tension lowest (pmc.ncbi.nlm.nih.gov). This pattern contributes to centrilobular necrosis in alcoholic hepatitis. Over time, the injury becomes diffuse, involving the entire liver with regenerative nodules (cirrhosis).
  • Intestine (UBERON:0002108 – small intestine; UBERON:0001155 – colon) – Chronic alcohol consumption perturbs the GI tract. It reduces intestinal barrier function (especially in the colon) and alters microbial populations. The leaky gut permits endotoxins like LPS to enter the portal vein (UBERON:0001199) circulation (pmc.ncbi.nlm.nih.gov). Thus, the intestine is a remote but critical anatomical player in ALD pathogenesis via the gut–liver axis.
  • Portal Vein – Carries blood from the GI tract to the liver. In ALD, the portal vein delivers absorbed ethanol and gut-derived inflammatory triggers (LPS, bacterial DNA) directly to the liver sinusoidal circulation (pmc.ncbi.nlm.nih.gov). Portal pressure also rises in advanced ALD (portal hypertension) due to cirrhosis.
  • Hepatic Lobule – The microscopic structural unit of the liver. Alcoholic injury often starts with fat and cell death in the perivenular zones of lobules and then extends to involve entire lobules with bridging fibrosis connecting central veins and portal tracts. Histologically, “chicken-wire” fibrosis describes collagen encircling lobules seen in alcoholic fibrosis (pmc.ncbi.nlm.nih.gov).
  • Adipose Tissue (UBERON:0002385) – Fat tissue is involved indirectly via systemic metabolism. Heavy drinking is associated with adipose tissue lipolysis (increasing circulating FFAs) and lower adiponectin levels, both of which favor fat accumulation in hepatocytes (pmc.ncbi.nlm.nih.gov). Visceral adipose tissue, in particular, can contribute to the inflammatory milieu (as obesity exacerbates ALD through adipokines and additional fat supply).
  • Bone Marrow & Spleen – Organs of the immune system that respond to alcohol-related signals. For instance, bone marrow releases more neutrophils and monocytes during alcoholic hepatitis (often causing peripheral leukocytosis). The spleen can become congested from cirrhosis (hypersplenism), sequestering blood cells, but is not a direct driver of pathogenesis.
  • Brain (Hypothalamus, etc.) – While not a site of liver pathology, chronic alcohol has systemic neuroendocrine effects that can modulate liver disease. For example, alcohol affects the HPA axis and sympathetic output, potentially influencing inflammation. Clinically, severe ALD can lead to hepatic encephalopathy (a brain dysfunction due to liver failure toxins), illustrating a distant organ manifestation.

3. Disrupted Biological Processes (GO Terms)

Chronic alcohol exposure disrupts many normal biological processes in the liver:

  • Ethanol Metabolic Process (GO:0006069) – The enzymatic pathways of ethanol oxidation and acetaldehyde detoxification are upregulated. ADH, CYP2E1, and ALDH2 act to clear ethanol but produce harmful byproducts in the process (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Variations in this process (e.g. CYP2E1 induction) modulate the extent of liver injury.
  • Lipid Metabolic Process (GO:0006629) – Alcohol profoundly dysregulates hepatic lipid metabolism. Fatty acid β-oxidation (GO:0006635) is suppressed (via PPARα inhibition and mitochondrial dysfunction) while lipid biosynthetic processes (fatty acid and triglyceride synthesis) are enhanced, leading to hepatic steatosis (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Key pathways affected include SREBP-mediated lipogenesis and AMPK signaling (alcohol inhibits AMPK, relieving its suppression of lipid synthesis) (pmc.ncbi.nlm.nih.gov).
  • Response to Oxidative Stress (GO:0006979) – Hepatocytes mount antioxidant defenses against alcohol-induced ROS. The NRF2 pathway (GO:0006915 related to oxidative stress response) is activated as a protective mechanism, inducing genes for glutathione synthesis and detoxification (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). However, in ALD the oxidative burden often overwhelms defenses, causing oxidative damage to lipids, proteins, and DNA (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Chronic oxidative stress is central to ALD progression.
  • Inflammatory Response (GO:0006954) – An innate immune inflammatory program is triggered in the liver. This involves cytokine production (GO:0001816) – e.g. TNFα, IL-1β, IL-6 – and chemokine-mediated signaling (GO:0008009) to recruit leukocytes (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Kupffer cells and infiltrating macrophages shift to a pro-inflammatory state (analogous to M1 polarization) producing mediators that sustain liver inflammation. Alcohol also skews adaptive immunity, promoting Th17 response (IL-17 production) and suppressing regulatory mechanisms.
  • Toll-Like Receptor Signaling Pathway (GO:0002224) – Especially TLR4 and TLR9 pathways are activated by microbial products in ALD. TLR4/MyD88 signaling leads to IκB kinase activation and NF-κB signaling (GO:0051092), inducing many inflammatory genes (pmc.ncbi.nlm.nih.gov). Downstream, MAPK cascades (GO:0051403) such as p38, JNK, and ERK are also triggered, promoting production of pro-inflammatory and pro-apoptotic factors (pmc.ncbi.nlm.nih.gov). A novel finding is activation of TLR3 by endogenous mitochondrial RNA, which can amplify inflammation via IL-1 signaling (pmc.ncbi.nlm.nih.gov).
  • Apoptotic Process (GO:0006915) – Programmed cell death via apoptosis is a major outcome for hepatocytes under alcoholic stress. Death receptor signaling (e.g. TNFα binding TNFR1, or Fas ligand) activates caspases, while mitochondrial (intrinsic) pathways are activated by DNA damage and ER stress. ALD livers show increased hepatocyte apoptosis markers (caspase-3 activity, cytokeratin-18 fragments) (pmc.ncbi.nlm.nih.gov). Anti-apoptotic defenses (e.g. Bcl-2) are often overwhelmed, tipping the balance toward cell death.
  • Necroptosis (GO:0070266) & Pyroptosis (GO:0070269) – In ALD, alternate lytic cell-death pathways contribute to inflammation. Necroptosis, a form of programmed necrosis regulated by RIPK1/RIPK3 and MLKL, has been observed in alcoholic liver injury; inhibition of RIPK3 in mice reduces injury (pmc.ncbi.nlm.nih.gov). Pyroptosis, a highly inflammatory cell death triggered by inflammasomes and executed by Gasdermin pores, is evidenced by elevated cleaved Gasdermin-D and IL-1β release in alcoholic hepatitis (pmc.ncbi.nlm.nih.gov). These processes not only kill hepatocytes but also release DAMPs and cytokines that perpetuate inflammation.
  • Fibrosis (Extracellular Matrix Organization – GO:0030198) – Persistent liver injury activates wound-healing processes. Stellate cells proliferate and produce collagens (mainly type I and III collagen), laminin, and fibronectin. This extracellular matrix deposition and remodeling is a hallmark of chronic ALD progression (pmc.ncbi.nlm.nih.gov). Genes like COL1A1, TIMP1 (tissue inhibitor of MMPs), and ACTA2 (α-smooth muscle actin in myofibroblasts) are upregulated. Fibrogenesis is partly driven by TGF-β signaling (GO:0007179) and Wnt signaling (GO:0016055), which can cross-talk with ethanol-induced pathways.
  • Regeneration and Cell Proliferation – The normal liver regeneration process (GO:0031100) is dysregulated in ALD. Moderate injury prompts compensatory hepatocyte proliferation (often via Wnt/β-catenin signaling, and Hippo/YAP pathway (GO:0035329)), but severe or repetitive injury exhausts regenerative capacity (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In advanced ALD, progenitor cell (ductular cell) proliferation (a ductular reaction) is seen, indicating hepatocyte regeneration failure. Key cell-cycle regulators and growth factors (HGF, EGFR, etc.) are impaired by alcohol and ongoing inflammation.
  • Immune Tolerance and Suppression – Chronic ALD also involves paradoxical immune suppression processes (e.g. expansion of dysfunctional neutrophils and T cells). While not a classic GO term, processes like negative regulation of immune response (GO:0002683) become relevant: Patients with severe ALD often cannot clear infections due to neutrophil dysfunction and lymphopenia, even as their liver remains inflamed. This reflects a complex immune dysregulation caused by persistent inflammation and high circulating endotoxin levels (immune exhaustion).
  • Drug Metabolic Process (GO:0008202) – The induction of CYP2E1 by alcohol also affects the metabolism of other substances (medications, vitamin A, etc.). For example, acetaminophen is more toxic in alcoholics due to CYP2E1 generating a toxic metabolite (NAPQI) in the setting of depleted glutathione. This illustrates disruption of normal xenobiotic metabolism in ALD.

4. Cellular Components (Subcellular Localization)

Alcohol and its toxic effects impact specific cellular compartments in liver cells:

  • Cytosol (GO:0005829): The site of initial ethanol metabolism via ADH, leading to local NADH buildup (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The cytosol is also where triglycerides accumulate in lipid droplets during steatosis. Cytosolic enzyme alterations (e.g., increased fatty acid synthase, decreased glycolysis control) occur due to alcohol. Mallory-Denk body formation (aggregated cytokeratins) also occurs in the cytoplasm of damaged hepatocytes as a result of oxidative and heat-shock protein stress.
  • Mitochondrion (GO:0005739): A critical target of alcohol’s toxicity. Mitochondria metabolize acetaldehyde (via ALDH2) and are a major ROS source. Ethanol damages mitochondria, causing structural abnormalities (e.g. mega-mitochondria or mitochondrial inclusions) in up to 25% of ALD patients (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Alcohol impairs mitochondrial electron transport and ATP generation, leading to reduced energy output and release of apoptotic signals. Acetaldehyde can bind mitochondrial DNA and proteins, hampering the respiratory chain (pmc.ncbi.nlm.nih.gov). Loss of mitochondrial membrane potential and activation of the mitochondrial permeability transition pore have been observed in ALD, indicating severe mitochondrial dysfunction.
  • Endoplasmic Reticulum (ER) (GO:0005783): The site of CYP2E1-mediated ethanol oxidation (microsomal ethanol oxidizing system). CYP2E1 induction in the smooth ER leads to ER stress due to misfolded proteins and calcium dysregulation (pmc.ncbi.nlm.nih.gov). Unfolded Protein Response (UPR) pathways (ATF4, CHOP) become activated in ALD. The ER is also crucial for VLDL assembly; alcohol disrupts the function of MTP (microsomal triglyceride transfer protein) in the ER, impairing VLDL secretion and causing triglyceride retention (pmc.ncbi.nlm.nih.gov). Prolonged ER stress from alcohol contributes to hepatocyte apoptosis.
  • Lipid Droplets (GO:0016023): Organelles in hepatocyte cytoplasm where neutral lipids (triglycerides) are stored. In alcoholic fatty liver, hepatocytes develop enlarged lipid droplets that can displace the nucleus. These droplets are dynamic: normally, they are broken down by lipophagy (autophagy of fat). Alcohol inhibits autophagy (specifically lipophagy) by reducing TFEB activity, leading to droplet accumulation (pmc.ncbi.nlm.nih.gov). The surface of lipid droplets contains proteins like PNPLA3 and Perilipins; the PNPLA3^I148M variant reduces lipolysis at the droplet, exacerbating fat retention. Thus, lipid droplets are central cellular sites reflecting the metabolic imbalance in ALD.
  • Plasma Membrane (GO:0005886): Several key events occur at cell membranes. For example, TLR4 and CD14 on Kupffer cell surfaces bind LPS to initiate signaling (pmc.ncbi.nlm.nih.gov). Death receptors (TNFR1, Fas) on hepatocyte membranes bind ligands like TNFα, triggering apoptosis. Ethanol can also alter membrane fluidity and membrane lipid composition (increasing cholesterol and saturated fatty acids in membranes), which may affect receptor function and ion transport. Additionally, neutrophils adhere to sinusoidal endothelial cell membranes (ICAM-1 upregulation) during alcoholic hepatitis, contributing to cell injury.
  • Tight Junctions (GO:0005923) [Intestine]: In the intestinal epithelium, tight junction proteins (occludin, claudins) normally seal the paracellular space. Alcohol disrupts these junctions, especially in the colon, by decreasing expression of junctional proteins and increasing permeability (pmc.ncbi.nlm.nih.gov). The loss of tight junction integrity allows endotoxins and bacteria to leak into the bloodstream, fueling liver inflammation. Although located in the gut, this cellular component’s dysfunction is a pivotal upstream event in ALD pathophysiology.
  • Nucleus (GO:0005634): Alcohol affects nuclear processes in liver cells. Within hepatocyte nuclei, ethanol causes altered gene expression profiles: e.g., activation of SREBP-1c target genes for lipogenesis (pmc.ncbi.nlm.nih.gov), and activation of NF-κB target genes for inflammation. Acetaldehyde and lipid peroxidation products form DNA adducts (e.g., etheno-DNA adducts) that can cause mutations (pmc.ncbi.nlm.nih.gov). Oxidative DNA damage (8-oxo-deoxyguanosine) also accumulates in nuclei. Furthermore, transcription factors like Nrf2 translocate to the nucleus under stress to induce antioxidant genes (pmc.ncbi.nlm.nih.gov), while FoxO and PPARα may be inhibited by alcohol-induced post-translational modifications. In severe alcoholic hepatitis, nuclear receptors like HNF4α are down-regulated, altering the expression of hundreds of hepatocyte-specific genes (pmc.ncbi.nlm.nih.gov).
  • Extracellular Matrix (GO:0031012): The space outside cells in the liver, which in health is minimal and confined to the perisinusoidal space, becomes dramatically expanded in ALD due to fibrosis. Activated stellate cells secrete collagen fibers into the extracellular space of the liver lobule (pmc.ncbi.nlm.nih.gov). This leads to scar tissue bands that disrupt normal cell-cell and cell-matrix interactions. The stiffness of the extracellular matrix in fibrotic liver also promotes further hepatocyte dysfunction and impedes nutrient diffusion. Components like collagen cross-link (strengthened by lysyl oxidase), making scars hard to remove. The extracellular matrix can sequester growth factors (TGF-β, VEGF), altering cell signaling in the microenvironment.
  • Golgi Apparatus (GO:0005794): The Golgi is involved in protein processing and trafficking. In ALD, there is some evidence of Golgi fragmentation in hepatocytes, possibly due to altered membrane lipid composition or impaired trafficking. The secretion of proteins (like albumin, clotting factors) via the Golgi is often reduced in advanced ALD, reflecting general cellular secretory dysfunction.
  • Lysosomes/Autophagosomes (GO:0005764): Organelles responsible for degradation and recycling. In ALD, impaired autophagy means fewer autophagosomes fuse with lysosomes to degrade fat droplets and damaged organelles. Ethanol can raise lysosomal pH and alter enzyme activities, hindering degradation. However, induction of autophagy (experimentally) has been shown to reduce alcoholic fatty liver, highlighting this component’s role in pathophysiology.

5. Disease Progression (Stages and Sequence of Events)

Initiation – Steatosis: With weeks to months of heavy alcohol use, hepatic steatosis (fatty liver) develops. Up to 90–100% of chronic heavy drinkers accumulate fat in the liver (pmc.ncbi.nlm.nih.gov). This stage is characterized by enlarged, greasy liver with triglyceride droplets in hepatocytes. Steatosis results from metabolic alterations (high NADH, increased lipogenesis, reduced fat oxidation) as described above. It is often subclinical; patients might have mild hepatomegaly or slightly elevated liver enzymes but no overt symptoms. Importantly, alcoholic fatty liver is reversible with alcohol cessation – abstinence can normalize liver fat and function within weeks in this early stage.

Progression – Alcoholic Hepatitis (Steatohepatitis): Continued alcohol intake (typically after years of heavy drinking, but sometimes acutely superimposed) can lead to alcoholic hepatitis (AH), an acute-on-chronic inflammatory liver injury. Only a subset of drinkers (around 10–35%) ever develop severe alcoholic hepatitis (pmc.ncbi.nlm.nih.gov), and risk is higher in those who are female, have coexisting obesity or viral hepatitis, or certain genetic predispositions (pmc.ncbi.nlm.nih.gov). Alcoholic hepatitis is characterized histologically by fatty change plus hepatocyte ballooning degeneration, Mallory-Denk bodies, neutrophilic infiltration, and perivenular fibrosis (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Clinically, patients often present with jaundice, right upper quadrant pain, fever, and tender hepatomegaly. This corresponds to a surge of inflammation and liver dysfunction: bilirubin rises (causing jaundice) due to both cholestasis and hepatocellular failure; pro-inflammatory cytokines cause fever and malaise; and hepatic synthetic function declines, leading to coagulopathy (prolonged INR) (pmc.ncbi.nlm.nih.gov). In severe cases, alcoholic hepatitis can meet the criteria of acute-on-chronic liver failure (ACLF), where an acute insult (alcoholic hepatitis) in a patient with underlying liver disease precipitates multi-organ failure. Indeed, severe AH often occurs in the setting of an already fibrotic liver and carries a high short-term mortality. Key events in this stage include massive neutrophil infiltration, cytokine storms (e.g. extremely high TNFα, IL-8 levels), and extensive hepatocyte apoptosis/necrosis. Without intervention (such as corticosteroids or abstinence), severe alcoholic hepatitis has a poor prognosis (one-month mortality can exceed 30%). However, if the patient survives and stops drinking, some recovery is possible, although often with residual fibrosis.

Fibrosis and Cirrhosis: With ongoing injury, the liver’s attempts at healing lead to fibrosis. Collagen deposition starts around central veins (centrilobular fibrosis) and extends outwards. Repeated bouts of inflammation cause fibrotic septa that link central veins to portal tracts (bridging fibrosis). Over years, this can progress to cirrhosis, where normal liver architecture is replaced by nodules of regenerating hepatocytes encircled by scar tissue (pmc.ncbi.nlm.nih.gov). Cirrhosis typically develops after a decade or more of heavy alcohol use in susceptible individuals – estimated 8–20% of chronic heavy drinkers develop cirrhosis (pmc.ncbi.nlm.nih.gov). During the fibrotic stage, patients may still be asymptomatic or have only subtle signs (mild fatigue, ephemeral right upper quadrant discomfort). Once cirrhosis is established, clinical manifestations of end-stage liver disease appear: portal hypertension (leading to ascites, splenomegaly, variceal hemorrhage) and liver insufficiency (jaundice, coagulopathy, hypoalbuminemia with edema, encephalopathy). For example, fluid accumulation in the abdomen (ascites) arises from a combination of portal pressure and low albumin; confusion or drowsiness (hepatic encephalopathy) results from inability to detoxify ammonia and other neurotoxins. The transition from compensated to decompensated cirrhosis is often marked by such complications. Notably, alcoholic cirrhosis has the same pathological and clinical features as cirrhosis from other causes, though continued drinking can acutely worsen any decompensation.

Complications and Late Outcomes: Patients with long-standing alcoholic cirrhosis face risks of hepatocellular carcinoma (HCC) – approximately 1–2% per year once cirrhotic, and around 2% of heavy drinkers eventually develop HCC (pmc.ncbi.nlm.nih.gov). Alcohol itself is carcinogenic (acetaldehyde can be mutagenic), and the combination of cirrhosis and ongoing alcohol creates a high-risk environment for cancer. Another late outcome is multi-organ effects: alcohol misuse and cirrhosis together can lead to cardiomyopathy, pancreatitis, malnutrition, and immune dysfunction. A cirrhotic alcoholic patient is prone to infections (spontaneous bacterial peritonitis, pneumonia) due to reduced immune surveillance. If alcohol consumption ceases, stable cirrhosis may persist but the risk of further decompensation is reduced and some fibrosis regression can occur over years of abstinence in a subset of patients. On the other hand, continued drinking after cirrhosis leads to a very high mortality, with median survival as low as ~2 years in decompensated cases.

Variability and Exacerbating Factors: It’s important to note ALD progression is not strictly linear or inevitable for all heavy drinkers. Genetic factors (e.g. PNPLA3 variant) and comorbid conditions (obesity, viral hepatitis, gender differences) influence who progresses. For instance, women tend to develop advanced ALD at lower doses of alcohol than men, possibly due to differences in first-pass metabolism and estrogen effects on gut permeability (pmc.ncbi.nlm.nih.gov). Patterns of drinking (continuous vs. binge) also matter – regular daily heavy drinking is more likely to cause cirrhosis, while intermittent binge drinkers may more often present with acute alcoholic hepatitis on a less fibrotic liver. Cessation of alcohol at any stage can improve outcomes: fatty liver can reverse, alcoholic hepatitis can resolve (though severe cases often need medical therapy), and even early fibrosis can regress. However, once cirrhosis is established, the disease may stabilize but rarely fully reverses; at that point, management focuses on preventing complications and considering liver transplantation for eligible patients who maintain abstinence.

In quantitative terms, among heavy drinkers, ~90% develop fatty liver, roughly 10–35% may progress to alcoholic steatohepatitis, and about 8–20% to cirrhosis (pmc.ncbi.nlm.nih.gov). These stages overlap – some individuals have steatosis and fibrosis without an episode of severe hepatitis, while others suffer acute AH on mild underlying disease. The “two-hit” hypothesis has been used: the first hit is steatosis (sensitizing the liver), and the second hit is inflammation/oxidative stress causing hepatitis and fibrosis. Modern understanding expands this to “multiple hits” including gut-derived toxins, oxidative injury, and genetic/epigenetic factors all contributing in parallel (pubmed.ncbi.nlm.nih.gov).

6. Phenotypic Manifestations (Clinical Features and Pathophysiological Correlation)

Hepatic Steatosis Phenotype: Often asymptomatic. Some patients note hepatomegaly (enlarged liver) or mild right-upper-quadrant discomfort. Liver enzymes may show a moderate elevation (often an AST:ALT ratio > 2:1 is classic in alcohol-related liver injury, even in fatty liver stage). The mechanism is fat accumulation in hepatocytes without significant cell death; this fat deposition can make the liver palpable and tender. Steatosis by itself usually does not cause jaundice or synthetic dysfunction; it is a benign reversible phenotype reflecting metabolic disruption.

Alcoholic Hepatitis Phenotype: Manifests with jaundice (yellowing of skin and eyes due to elevated bilirubin), fever, anorexia, weakness, and often tender hepatomegaly. Jaundice in this context results from both cholestatic injury (inflammatory swelling and damage to bile canaliculi) and hepatocellular dysfunction (impaired bilirubin conjugation/excretion) (pmc.ncbi.nlm.nih.gov). Fever and systemic inflammatory response (high white blood cell count) result from cytokine release (IL-1, IL-6, TNFα act as endogenous pyrogens). Patients frequently have high serum AST and ALT (though usually <300 U/L), with AST > ALT, and very high gamma-GT (reflecting alcohol induction of liver enzymes). Elevated bilirubin and prolonged prothrombin time (INR) indicate liver functional impairment (coagulopathy arises from reduced synthesis of clotting factors). Some develop ascites even at this stage, due to acute liver dysfunction combined with pre-existing fibrosis (“acute-on-chronic” picture). Histologically, this phenotype corresponds to steatohepatitis with neutrophils attacking injured hepatocytes; clinically, it may be indistinguishable from a sudden worsening of any chronic liver disease, but history of heavy alcohol and the AST:ALT pattern are clues. The severity is often gauged by scores (Maddrey’s DF, MELD score) which correlate with short-term mortality. Severe cases can progress to multi-organ failure (renal failure, encephalopathy) – a reflection of systemic inflammation and circulatory changes triggered by the severely inflamed liver (e.g., TNFα and nitric oxide cause vasodilation and shock-like states in advanced AH).

Fibrosis/Cirrhosis Phenotype: In early fibrosis, there may be no obvious symptoms; perhaps just fatigue. Once cirrhosis is established, the phenotype includes signs of chronic liver failure and portal hypertension:
- Jaundice becomes persistent due to chronic bilirubin elevation from poor liver function and intrahepatic cholestasis.
- Ascites (fluid in the peritoneal cavity) develops from portal hypertension and hypoalbuminemia. Patients note abdominal distension; on exam, there is shifting dullness. Pathophysiologically, sinusoidal hypertension forces fluid out, and low albumin reduces oncotic pressure keeping fluid intravascular.
- Peripheral edema (swollen ankles) for the same reasons (low albumin).
- Spider angiomas, palmar erythema, gynecomastia in men – these are signs of hyperestrogenism due to impaired hepatic metabolism of sex hormones. They reflect the endocrine disturbances of cirrhosis.
- Splenomegaly – enlarged spleen from portal congestion, leading to hypersplenism (platelet sequestration; thus alcoholic cirrhosis patients often have thrombocytopenia).
- Variceal hemorrhage – patients may present with vomiting blood or melena due to rupture of esophageal or gastric varices (dilated veins from portal hypertension). This life-threatening complication is directly due to elevated portal vein pressure from cirrhotic scarring; it does not occur in earlier stages before cirrhosis.
- Hepatic encephalopathy – confusion, asterixis (flapping tremor), and even coma due to accumulation of neurotoxins (like ammonia) that the failing liver cannot adequately clear. This is precipitated by factors such as high protein meals, GI bleeding, or infection. Mechanistically, liver fibrosis reduces toxin clearance and shunts blood past functioning hepatocytes, exposing the brain to these substances.
- Muscle wasting and malnutrition – chronic ALD often leads to cachexia and sarcopenia (muscle loss). Alcohol directly causes malnutrition by empty calories and pancreatitis, and cirrhosis causes a hypermetabolic state with malabsorption. Clinically, patients have thin extremities and temporal muscle wasting despite a protuberant fluid-filled abdomen.
- Portal hypertensive gastropathy and hepatic encephalopathy represent advanced phenomena not present in early disease.

These phenotypic features correlate strongly with the underlying mechanisms: for example, coagulopathy (easy bruising, bleeding) stems from decreased synthesis of clotting factors due to impaired protein synthesis in hepatocytes, and it is exacerbated by vitamin K deficiency (common in alcoholics with poor diet). Similarly, hepatic encephalopathy correlates with advanced fibrosis and shunting, reflecting failure of ammonia detoxification (ammonia normally converted to urea in healthy hepatocytes). The classic clinical stigmata (spiders, palmar erythema) reflect excess circulating estrogens due to reduced hepatic breakdown; in pathophysiology terms, this is an endocrine consequence of liver failure.

Mixed or Overlap Phenotypes: Some patients have overlapping features of alcoholic and nonalcoholic fatty liver disease (especially with co-existing metabolic syndrome). For instance, an obese heavy drinker may have pronounced insulin resistance, so they can develop severe steatosis and steatohepatitis at lower alcohol intake. The term “Metabolic-dysfunction associated steatotic liver disease (MASLD)” has been introduced to encompass overlaps of alcohol and metabolic causes (pubmed.ncbi.nlm.nih.gov). Clinically, these patients may have type 2 diabetes and present with advanced fibrosis without a prior acute hepatitis episode. Understanding the contribution of each cause can be challenging, but from a mechanistic view, both alcohol and metabolic factors (like high fatty acid flux) synergize in injuring the liver.

Neurologic and Systemic Manifestations: Chronic alcohol misuse can cause peripheral neuropathy and cerebellar degeneration, but those are direct toxic effects of alcohol/nutritional deficiencies rather than liver failure per se. However, the combination of end-stage ALD and alcohol’s other organ damage leads to a complex clinical picture. For example, an ALD patient might have ascites and encephalopathy from liver failure, plus neuropathy and cardiomyopathy from alcohol – all contributing to disability. From a pathophysiological perspective, these systemic features underscore that alcohol’s toxicity is not liver-limited, though the liver bears the brunt because it is the primary site of alcohol metabolism.

In conclusion, the clinical phenotypes of ALD range from silent fatty liver to life-threatening cirrhosis. Each phenotype reflects underlying molecular mechanisms: fat accumulation causes a fatty liver; inflammation and cell injury cause hepatitis with jaundice and fever; fibrosis causes a stiff liver and portal hypertension with ascites and varices; and loss of hepatocyte function causes coagulopathy, encephalopathy, and metabolic derangements. These manifestations guided by pathophysiology also inform treatment and prognosis. For instance, the recognition that inflammation (cytokine storm) drives alcoholic hepatitis has led to therapies like corticosteroids to dampen immune response (pmc.ncbi.nlm.nih.gov). Similarly, understanding that fibrosis is a key endpoint reinforces the need for early intervention (since established cirrhosis is irreversible except by transplant). Current expert consensus is that only total alcohol abstinence can reliably halt or reverse early ALD, highlighting the causal role of ethanol in the pathophysiology (pmc.ncbi.nlm.nih.gov). Ongoing research targets specific pathways (e.g., anti-TNF, IL-1 inhibitors, gut microbiome modulation, anti-fibrotics) in hopes of improving outcomes in this potentially preventable disease.

Evidence: The above statements are supported by numerous studies and reviews. Key references include clinical data on ALD progression (pmc.ncbi.nlm.nih.gov), mechanistic experiments in cell and animal models elucidating the role of oxidative stress (pmc.ncbi.nlm.nih.gov), gut-derived endotoxin (pmc.ncbi.nlm.nih.gov), and genetic modifiers like PNPLA3 (pubmed.ncbi.nlm.nih.gov). For example, Yan et al. (2023) summarize that ALD’s “underlying mechanisms are complex, involving inflammation, mitochondrial damage, endoplasmic reticulum stress, nitrosative and oxidative stress… and the gut–liver axis” (pmc.ncbi.nlm.nih.gov). Mandrekar et al. (2024) emphasize the multifactorial pathogenesis involving alcohol metabolism, immune cell activation, and epigenetic changes (pubmed.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Clinically, the classic description of alcoholic hepatitis with jaundice and fever is well documented (pmc.ncbi.nlm.nih.gov), and the statistics on progression rates come from long-term cohort studies (pmc.ncbi.nlm.nih.gov). This comprehensive understanding of ALD pathophysiology has been built from both landmark clinical-pathological correlations and recent molecular research, forming the basis for developing targeted interventions in the future.

OpenScientist ▸
Alcohol-Associated Liver Disease (ALD): A Comprehensive Disease Characteristics Report
openscientist-autonomous 43 citations 2026-07-26T05:19:26.640461

Alcohol-Associated Liver Disease (ALD): A Comprehensive Disease Characteristics Report

Summary

Alcohol-associated liver disease (ALD) is a complex, non-Mendelian, dose-dependent liver disease caused by chronic excessive alcohol consumption. It encompasses a histological spectrum that progresses from hepatic steatosis → alcohol-associated steatohepatitis → progressive fibrosis → cirrhosis → hepatocellular carcinoma (HCC), with alcohol-associated hepatitis (AH) representing an acute, superimposed, high-mortality clinical syndrome. Under the 2023 multisociety steatotic liver disease (SLD) nomenclature, ALD is distinguished from metabolic dysfunction-associated steatotic liver disease (MASLD) and the overlap phenotype MetALD. Although ALD has a lower prevalence than MASLD, it contributes disproportionately to liver-related morbidity and mortality and is now the leading cause of liver-related death and the most common indication for liver transplantation in Europe and the United States.

The pathophysiology of ALD is best understood as a dual-hit (multi-hit) process. The first hit is direct hepatotoxicity from ethanol metabolism: alcohol dehydrogenase (ADH) and inducible cytochrome CYP2E1 oxidize ethanol to acetaldehyde, which forms protein/DNA adducts (including malondialdehyde-acetaldehyde, MAA, adducts), generates reactive oxygen species (ROS), depletes glutathione, and causes lipid peroxidation and mitochondrial dysfunction. The second hit is gut–liver axis dysfunction: alcohol increases intestinal permeability, permitting lipopolysaccharide (LPS) translocation that activates hepatic Kupffer cells via TLR4/NF-κB signaling, driving TNF-α/IL-1β/IL-6 release and neutrophilic inflammation. These converging insults activate hepatic stellate cells (HSCs) through TGF-β1/Smad signaling, producing the collagen deposition that defines fibrosis and cirrhosis. Genetic susceptibility (notably PNPLA3 rs738409 I148M, with TM6SF2 and MBOAT7 as additional risk loci and HSD17B13 and MTARC1 as protective), alcohol-metabolizing enzyme polymorphisms (ADH1B, ALDH2), sex, obesity, and drinking pattern all modify individual risk.

Management centers on alcohol abstinence and treatment of the underlying alcohol use disorder (AUD), which markedly improve survival, decompensation risk, and recompensation. For severe AH, corticosteroids remain guideline-recommended but confer only modest short-term benefit with high non-response and infection risk; early liver transplantation rescues steroid non-responders with excellent survival. Emerging therapies target the epigenome (larsucosterol), IL-22 signaling (F-652), the FXR/bile acid axis (INT-787), and the gut microbiome (rifaximin, fecal microbiota transplantation).

Key Findings

Finding 1 — PNPLA3 I148M is the strongest genetic risk locus for ALD (F001)

Genome-wide association and candidate-gene studies consistently identify PNPLA3 rs738409 (c.444C>G, p.Ile148Met, "I148M") as the top common variant increasing risk of alcohol-associated steatosis, cirrhosis, and HCC. Two additional risk loci — TM6SF2 (rs58542926, E167K) and MBOAT7 (rs641738) — add to lifetime risk, while HSD17B13 (rs72613567) and MTARC1 confer protection. These loci govern hepatic lipid handling and retinoid metabolism. As documented for the overlapping steatotic liver disease genetics: "Key genetic variants, such as those located in the PNPLA3, TM6SF2, and MBOAT7 genes, often interact to exacerbate MASLD severity and play key roles in lipid metabolism and liver inflammation" (PMID: 41772607). Importantly, these are common polymorphisms of modest individual effect acting on a substrate of alcohol exposure — ALD is polygenic, not Mendelian.

Finding 2 — ALD pathogenesis: acetaldehyde/CYP2E1 oxidative stress plus gut-liver endotoxemia (F002)

Ethanol is oxidized by ADH and inducible CYP2E1 to acetaldehyde, which forms protein/DNA adducts and generates ROS, depleting glutathione and causing lipid peroxidation and mitochondrial dysfunction. "Specific inhibition of CYP2E1 led to the greatest decrease in oxidative stress, toxicity and protein aldehyde adduct formation, implicating that CYP2E1 accelerates the formation of protein aldehyde adducts which can be an important mechanism for alcohol mediated liver injury" (PMID: 23352969). In parallel, alcohol increases intestinal permeability, allowing LPS translocation that activates Kupffer cells via TLR4/NF-κB. The overall picture is multifactorial: "The pathophysiology of SAH is multifactorial, involving direct hepatotoxicity from alcohol metabolites, oxidative stress, dysregulated immune activation, gut dysbiosis with increased intestinal permeability, impaired hepatic regeneration, and genetic susceptibility" (PMID: 41715264).

Finding 3 — ALD spans a histological spectrum and disproportionately drives liver mortality (F003)

ALD "represents a spectrum of liver injury beginning with hepatic steatosis (fatty liver) progressing to inflammation and culminating in cirrhosis" (PMID: 38672422). Epidemiologically, it "has a lower prevalence but contributes disproportionately to higher liver-related morbidity and mortality and is reported to have a marked regional variation linked to patterns of alcohol consumption" (PMID: 42457160). Alcohol-associated hepatitis incidence varies widely: "Reported annual incidence rates of AH ranged from 1.02 per 100,000 inhabitants in Iceland to 98.5 per 100,000 inhabitants in the United States, with a median incidence rate of 6.8 cases per 100,000 inhabitants" (PMID: 42435889). Globally, in 2021, cirrhosis and chronic liver disease accounted for ~1.4 million deaths worldwide (PMID: 42486788).

Finding 4 — Treatment centers on abstinence, corticosteroids for severe AH, and early transplantation (F004)

Abstinence is the cornerstone. For severe AH (Maddrey DF ≥32 / MELD ≥20), corticosteroids remain standard of care but confer limited benefit: in a large multicenter cohort, "no survival benefit was observed in the adjusted model after accounting for baseline and admission characteristics (adjusted hazard ratio [aHR] = 1.01, P = 0.818)" (PMID: 39620604). Early liver transplantation rescues non-responders: pooled "overall survival rate was 85%, with survival rates of 89% at 1 year, 81% at 2 years, 78% at 5 years, and 60% at 10 years... The overall relapse rate post-eLT was 19%" (PMID: 42148785). New agents are emerging: "Multiple new pharmacological agents targeting different mechanisms are under study for alcohol-associated hepatitis, including larsucosterol, F-652, and INT-787" (PMID: 41691535).

Finding 5 — HSC activation via TGF-β1/Smad drives fibrosis; sex, obesity, and drinking pattern modify risk (F005)

"Alcoholic liver fibrosis (ALF) is a severe hepatic disorder caused by chronic excessive alcohol consumption, involving hepatic stellate cells (HSCs) activation" into α-SMA-expressing myofibroblasts depositing Collagen-I/III via TGF-β1/Smad3/Smad4 (PMID: 41270641). Risk is modified by female sex, obesity/metabolic syndrome (MetALD synergy), smoking, and binge/daily drinking; alcohol independently correlates with fatty liver even in normal-weight adults: "In normal weight, the independent correlates included alanine transaminase (3.05), smoking (2.56), systolic blood pressure (1.54), and alcohol intake (1.41)" (PMID: 25333756).

Finding 6 — Rodent models recapitulate steatosis/inflammation and implicate innate immune cells (F006)

The chronic Lieber-DeCarli ethanol liquid diet and the NIAAA chronic-plus-single-binge (Gao-binge) model reproduce hallmark ALD features. "using a Lieber-DeCarli ethanol liquid diet model of ALD in C57BL/6 mice" reproduces ALT/AST elevation, oxidative stress, and inflammation graded by SALVE (PMID: 39795945). Mechanistic studies implicate innate lymphoid dynamics: "Either depletion of ILC1 or neutralization of IL17A could significantly attenuate liver steatosis, inflammation, and injury in alcohol-fed mice" (PMID: 36174925). A key limitation is that rodent models poorly recapitulate advanced human fibrosis, cirrhosis, and severe AH.

Finding 7 — Definition, dose thresholds, symptoms, and rising mortality (F007)

ALD develops with daily intake >20 g/day in women (~1.4 drinks) and >30 g/day in men (~2.1 drinks): "ALD can develop with long-term daily alcohol consumption of more than 20 g per day for women (1.4 standard drinks/d) and more than 30 g per day for men (2.1 standard drinks/d), with 1 standard drink containing 14 g of ethanol" (PMID: 42406571). US mortality is rising: "In the US, ALD-related mortality increased from 6.7 deaths per 100,000 people in 1999 to 12.5 deaths per 100,000 people in 2022." Risk factors: "increased quantity and duration of alcohol use, female sex, older age, obesity, type 2 diabetes, metabolic syndrome, smoking, viral hepatitis, and specific genetic variants." AH symptoms: "fever, anorexia, nausea, vomiting, abdominal pain, and jaundice" (all PMID: 42406571).

Finding 8 — MELD, Maddrey DF, and Lille scores stratify prognosis (F008)

Severe AH is defined by Maddrey DF ≥32 or MELD ≥20–21. "Updated MELD measurements had a strong prognostic value for death/transplant (HR: 1.20, 95% CI: 1.14-1.27)" (PMID: 39082963). The early Lille score classifies steroid response: LI2 "was associated with a 28-day mortality HR of 33.1 (95% CI: 3.8-287.3)... AUCs for 28-day mortality were 0.818 for LI2, 0.794 for LI4, and 0.809 for LI7" (PMID: 40545192). Age-augmented models improve prediction: "MELD-Age and ACLF-Age, had similar predictability (AUROC: 0.73, 0.73, 0.72...), outperforming Lille and Maddrey's (AUROC: 0.63, 0.62)" (PMID: 39167426).

Finding 9 — Functional ADH1B/ALDH2 polymorphisms modulate acetaldehyde exposure and ALD risk (F009)

In East Asians, common functional variants alter risk via acetaldehyde exposure: "ADH1B accelerates ethanol oxidation, whereas ALDH2 impairs acetaldehyde detoxification and increases oxidative stress, inflammation, and liver injury. Based on genotype combinations, individuals were stratified into five alcohol sensitivity groups with differing risks of cirrhosis and cancer" (PMID: 40943250). ALDH2 deficiency usually reduces intake via aversive flushing, but continued drinking paradoxically raises liver and GI cancer risk.

Finding 10 — Single-cell profiling reveals monocyte/macrophage expansion, adaptive immune dysfunction, and epigenetic reprogramming (F010)

scRNA-seq of PBMCs in AH shows innate immune dysregulation: "inflammatory cytokines and chemokines were highly expressed in AH, including IL-2, IL-32, CXC3R1 and CXCL16 in monocytes and NK cells, whereas HLA-DR genes were reduced in monocytes" (immune paralysis) (PMID: 38040543). In cirrhotic liver, "scRNA-seq analysis identified a higher ratio of intrahepatic monocyte/macrophages and an obvious decreased ratio of T cells and B cells in the ALC group than in the HBV group" (PMID: 36817578). Epigenetically, "Hepatocyte FoxO1 levels in human inflammatory livers declined prevalently and were inversely correlated with inflammation and fibrosis" (PMID: 41190981).

Finding 11 — Multi-omic and gut-dysbiosis biomarkers define ALD risk, staging, and mechanism (F011)

Serum fibrosis markers extend staging beyond aminotransferases: "Traditional serum-based liver fibrosis markers (e.g., cytokeratin-18 fragments, Pro-C3, the enhanced liver fibrosis test) improve non-invasive staging risk beyond aminotransferases" (PMID: 41287436). Gut signatures also track disease: "gut dysbiosis signatures, including reduced Faecalibacterium prausnitzii, Akkermansia muciniphila, and a lower Firmicutes/Bacteroidetes ratio, and their metabolites (short-chain fatty acids, and bile acids, trimethylamine N-oxide) correlate with liver inflammation and fibrosis" (same source).

Finding 12 — Gut-liver axis therapies: FMT improves short-term survival in severe AH (F012)

A meta-analysis of 8 studies (444 patients) found FMT "showed a statistically significant increase in survival in the FMT arm at 28 days [RR 2.30 (1.24-4.28), P = 0.01] and 90 days [2.53 (1.34-4.77), P < 0.001]" without serious treatment-related adverse events (PMID: 40359297). The broader pipeline is mechanism-diverse: "Anti-inflammatory agents such as IL-1 inhibitor, Pan-caspase inhibitor, Apoptosis signal-regulating kinase-1, and CCL2 inhibitors are under investigation. Other group of agents include gut-liver axis modulators, hepatic regeneration, antioxidants, and Epigenic modulators" (PMID: 36647403).

Finding 13 — Treating the underlying AUD is central; baclofen best-studied in cirrhosis (F013)

Six medications are approved for AUD: "acamprosate (ACM), naltrexone (NTX), nalmefene (NMF), disulfiram (DF), baclofen, and sodium oxybate (SO)" (PMID: 42476146). In ALD specifically: "Naltrexone and acamprosate reduce the relapse in the general AUD population, though data in ALD are limited. Baclofen is the only drug tested in randomized trials in cirrhosis, with early benefit but mixed results in later studies" (PMID: 41258558). Medication-assisted therapy is cost-effective in compensated alcohol-related cirrhosis (PMID: 33326815).

Finding 14 — Abstinence and AUD treatment markedly improve survival and enable recompensation (F014)

Meta-analysis (19 studies, 18,833 patients): "individuals who continued to consume alcohol had significantly lower overall survival compared to those who were abstinent (HR: 0.611, 95% CI: 0.506-0.738)... Alcohol abstinence was associated with a significantly lower risk of hepatic decompensation (HR: 0.612, 95% CI: 0.473-0.792)" (PMID: 38303565). AUD treatment "reduces alcohol relapse by 73% (HR: 0.27, 95% CI: 0.15-0.46) with any treatment and by 77% (HR: 0.23, 95% CI: 0.14-0.39) with medications" (PMID: 40304585). After first decompensation, "45 (24.5%) achieved abstinence-induced recompensation" (PMID: 41622173).

Finding 15 — ALD impairs quality of life; a disease-specific instrument now exists (F015)

The validated CLDQ-ALD reduced 40 items to "9 domains (Fatigue, Alcohol, Function, Physical, Abdominal Symptoms, Itching, Sleep, Emotional, and Worry)" (PMID: 42190270). Stigma independently worsens burden: "Stigmatization of patients with NAFLD, whether it is caused by obesity or NAFLD, is strongly and independently associated with a substantial impairment of their HRQL" (PMID: 39022387), with disparities producing worse outcomes (PMID: 40063362).

Full Section-by-Section Report

1. Disease Information

ALD is chronic liver injury resulting from harmful alcohol use, spanning reversible steatosis, steatohepatitis (with the acute severe form alcohol-associated hepatitis), fibrosis, cirrhosis, portal hypertension, decompensation, and HCC (PMID: 42406571, PMID: 38672422).

Key identifiers (suggested): MONDO:0005154 / MONDO:0004790 (alcoholic liver disease); ICD-11 DB94; ICD-10 K70 (K70.0 fatty liver, K70.1 hepatitis, K70.2 fibrosis/sclerosis, K70.3 cirrhosis, K70.4 hepatic failure); MeSH D008108 ("Liver Diseases, Alcoholic"); SNOMED CT 41309000. OMIM assigns no Mendelian ID because ALD is complex/non-Mendelian. CHEBI: ethanol (CHEBI:16236), acetaldehyde (CHEBI:15343).

Synonyms: alcohol-related liver disease (ArLD), alcoholic liver disease, alcohol-induced liver disease; subtypes alcoholic fatty liver, alcoholic steatohepatitis/hepatitis, alcoholic cirrhosis. The 2023 multisociety Delphi consensus formalized ALD, the overlap phenotype MetALD, and MASLD within SLD (PMID: 42457160).

Information source: aggregated disease-level resources (epidemiological registries, clinical cohorts, GWAS, mechanistic/model studies), not individual-patient EHR.

2. Etiology

The necessary cause is chronic excessive alcohol consumption, with sex-specific dose thresholds (>20 g/day women, >30 g/day men). Environmental/lifestyle risk factors include quantity/duration of alcohol, binge/daily pattern, obesity, type 2 diabetes, metabolic syndrome, smoking, older age, and viral hepatitis (PMID: 42406571). Genetic risk: PNPLA3 I148M (strongest), TM6SF2 E167K, MBOAT7 rs641738 (PMID: 41772607); ADH1B/ALDH2 modulate acetaldehyde exposure (PMID: 40943250). Protective: HSD17B13, MTARC1 (genetic); abstinence and alcohol policy (environmental) (PMID: 41772607, PMID: 42266909). Gene–environment interaction is canonical: risk alleles act only with alcohol exposure; ADH1B/ALDH2 genotype combinations stratify drinkers into ~5 alcohol-sensitivity groups (PMID: 40943250).

3. Phenotypes (HPO suggestions)

~90% of patients are asymptomatic or have nonspecific fatigue. AH: fever (HP:0001945), anorexia (HP:0002039), nausea/vomiting, abdominal pain (HP:0002027), jaundice (HP:0000952). Decompensated cirrhosis: ascites (HP:0001541), variceal bleeding (HP:0002040), hepatic encephalopathy (HP:0002480), splenomegaly (HP:0001744). Lab abnormalities: AST>ALT (HP:0002910), elevated GGT, hyperbilirubinemia (HP:0002904), coagulopathy (HP:0003256), hypoalbuminemia, thrombocytopenia. Structural: hepatomegaly (HP:0002240), hepatic steatosis (HP:0001397), fibrosis (HP:0001395), cirrhosis (HP:0001394), hepatic failure (HP:0001399), HCC (HP:0001402). Adult-onset, insidious/chronic; AH acute/severe. Quality of life impaired across 9 CLDQ-ALD domains (PMID: 42190270).

4. Genetic/Molecular Information

No causal Mendelian gene. Susceptibility/modifier genes: PNPLA3 (HGNC:18590), TM6SF2 (HGNC:25136), MBOAT7 (HGNC:15505), ADH1B (HGNC:250), ALDH2 (HGNC:404), CYP2E1 (HGNC:2631), protective HSD17B13 (HGNC:18507), MTARC1 (HGNC:24337). PNPLA3 c.444C>G p.Ile148Met is a common missense variant (higher MAF in Hispanic/Latino populations), germline, altering lipid-droplet triglyceride/retinyl-ester hydrolysis. HSD17B13 rs72613567 is a loss-of-function splice variant (protective). Epigenetic: alcohol perturbs DNA methylation/histone marks; hepatocyte FoxO1 is epigenetically repressed (PMID: 41190981); larsucosterol targets DNMT epigenetics therapeutically. Chromosomal abnormalities: not characteristic.

5. Environmental Information

Primary factor: ethanol/acetaldehyde (CHEBI:16236 / CHEBI:15343). Lifestyle: heavy/binge drinking, smoking, obesity, diet (PMID: 42406571, PMID: 25333756). No infectious cause, but gut dysbiosis and increased permeability drive LPS translocation (gut-liver axis) — a microbial rather than single-pathogen contributor (PMID: 41715264); HBV/HCV co-infection synergistically accelerates progression.

6. Mechanism / Pathophysiology

Causal chain: (1) Ethanol → ADH/CYP2E1 → acetaldehyde + ROS → adducts, GSH depletion, lipid peroxidation, mitochondrial dysfunction (PMID: 23352969). (2) Gut-liver axis: ↑ permeability → LPS → Kupffer TLR4/NF-κB → TNF-α/IL-1β/IL-6, neutrophils; NK-cell loss with ILC1/IL-17A dominance (PMID: 36174925). (3) HSC activation → α-SMA myofibroblasts, Collagen-I/III via TGF-β1/Smad (PMID: 41270641). (4) Cirrhosis, portal hypertension, HCC (PMID: 38672422). Pathways: CYP2E1/oxidative stress, TLR4-NF-κB, TGF-β/Smad, JAK/STAT3, PPARα/δ, FXR/IL-22. Cell types (CL): hepatocyte (CL:0000182), Kupffer cell (CL:0000091), HSC (CL:0000632), monocyte (CL:0000576), NK (CL:0000623), NKT (CL:0000814), neutrophil (CL:0000775). Subcellular (GO CC): mitochondrion (GO:0005739), ER (GO:0005783), lipid droplet (GO:0005811). Single-cell/omics evidence in Findings 10–11.

7. Anatomical Structures Affected

Primary organ: liver (UBERON:0002107). Secondary/systemic: portal venous system and spleen (UBERON:0002106), esophagus/stomach (varices, UBERON:0001043), brain (encephalopathy, UBERON:0000955), kidney (hepatorenal syndrome, UBERON:0002113), blood/marrow (cytopenias), pancreas. Tissue/cell level: hepatic parenchyma, sinusoidal Kupffer and stellate cells, infiltrating neutrophils. Diffuse/bilateral hepatic involvement; steatosis and fibrosis often begin zone 3 (perivenular/centrilobular).

8. Temporal Development

Adult-onset, insidious/chronic after years of heavy drinking; AH acute/subacute. Stages: steatosis (reversible) → steatohepatitis → fibrosis → cirrhosis (compensated → decompensated) → HCC (PMID: 38672422). Progressive but modifiable — abstinence halts/reverses early stages; ~24.5% achieve abstinence-induced recompensation after first decompensation (PMID: 41622173). Critical window: early abstinence; corticosteroid response assessed at day 7 (Lille); delayed tertiary care worsens AH outcomes (PMID: 39829300).

9. Inheritance and Population

Lower prevalence than MASLD but disproportionate mortality with regional variation (PMID: 42457160). AH incidence ~1.0–98.5/100,000 (median 6.8) (PMID: 42435889); US ALD mortality 6.7→12.5/100,000 (1999→2022) (PMID: 42406571); ~1.4M global cirrhosis deaths in 2021 (PMID: 42486788). Inheritance: multifactorial/polygenic; polygenic risk scores emerging. Demographics: male predominance in absolute cases but greater female susceptibility per unit alcohol; ADH1B*2/ALDH2*2 enriched in East Asians; PNPLA3 I148M enriched in Hispanic/Latino populations.

10. Diagnostics

Labs: AST>ALT (ratio >2), elevated GGT/bilirubin, macrocytosis, low platelets/albumin, elevated INR; CDT and PEth alcohol biomarkers. Non-invasive fibrosis: FIB-4, APRI, NFS, VCTE/MRE; FIB-4/NFS perform comparably in MetALD and MASLD (AUC ~0.77–0.81) (PMID: 42001012). Imaging: ultrasound, CT/MRI, MR-PDFF, MRE. Biopsy: steatosis, ballooning, Mallory-Denk bodies, neutrophilic inflammation, pericellular fibrosis; SALVE grading. Clinical criteria: NIAAA for AH; severe AH = Maddrey DF ≥32 or MELD ≥20–21. Differential: MASLD/MetALD, viral/autoimmune hepatitis, DILI, Wilson disease, Zieve syndrome (PMID: 38344483). Genetic/omics testing investigational only. Emerging biomarkers: CK-18, Pro-C3, ELF, gut-dysbiosis/metabolite signatures, single-cell immune signatures (PMID: 41287436, PMID: 38040543). Screening: AUDIT/AUDIT-C (PMID: 34601742).

11. Outcome/Prognosis

Severe AH: very high short-term mortality (>50% at 90 days with MELD ≥30) (PMID: 41804063). Prognostic models: Maddrey DF, MELD (HR 1.20/point) (PMID: 39082963); Lille (LI2 AUC ~0.82) (PMID: 40545192); MELD-Age/ACLF-Age outperform Lille/Maddrey (PMID: 39167426). Early LT survival ~85% (PMID: 42148785). Complications: portal hypertension, ascites, variceal bleeding, encephalopathy, hepatorenal syndrome, sepsis, ACLF, HCC. Abstinence is the strongest modifier (survival HR 0.61) (PMID: 38303565). QoL: CLDQ-ALD, worsened by stigma/disparities (PMID: 42190270, PMID: 40063362).

12. Treatment (MAXO suggestions)

Abstinence + AUD treatment (foundational). Six approved AUD medications: acamprosate, naltrexone, nalmefene, disulfiram, baclofen, sodium oxybate; baclofen best-studied in cirrhosis; acamprosate safe in liver disease (PMID: 42476146, PMID: 41258558). AUD treatment reduces relapse ~73–77% (PMID: 40304585) and is cost-effective (PMID: 33326815). CHEBI: baclofen (CHEBI:2972), acamprosate (CHEBI:51041), naltrexone (CHEBI:7465), disulfiram (CHEBI:4659). Nutritional support (sarcopenia/frailty). Corticosteroids (prednisolone) for severe AH — limited benefit (PMID: 39620604). Early/living-donor liver transplantation (PMID: 42148785, PMID: 41804063). Emerging agents: larsucosterol (epigenetic), F-652 (IL-22), INT-787 (FXR), G-CSF, IL-1/pan-caspase/ASK1/CCL2 inhibitors, elafibranor (PPARα/δ) (PMID: 41691535, PMID: 36647403). FMT improves short-term AH survival (PMID: 40359297); rifaximin showed no benefit in one RCT (PMID: 39662593).

13. Prevention

Primary: reduce/avoid alcohol; population alcohol policies (PMID: 42266909). Secondary: AUDIT screening, FIB-4/elastography, HCC surveillance. Tertiary: abstinence, HAV/HBV vaccination, complication management. Behavioral: brief interventions, CBT, motivational interviewing, peer support (PMID: 34601742). Address stigma/disparities as public health priorities (PMID: 40063362).

14. Other Species / Natural Disease

Naturally occurring ALD is essentially human-specific (NCBI:9606). Induced in Mus musculus (NCBI:10090), Rattus norvegicus (NCBI:10116), and hepatic ADH-deficient deer mice (PMID: 24625836). Orthologs: Pnpla3, Cyp2e1, Tgfb1, Adh1, Aldh2. No significant spontaneous veterinary disease; non-zoonotic.

15. Model Organisms

Rodent models: chronic Lieber-DeCarli and NIAAA Gao-binge reproduce steatosis, transaminase elevation, neutrophilic inflammation, cytokine induction (PMID: 39795945, PMID: 36174925). Genetic/cellular models: myeloid conditional knockouts (e.g., TFEB) (PMID: 41970222); LX-2 stellate and VL-17A hepatocyte lines; organoids. Recapitulation good for early steatohepatitis/mechanism; poor for advanced fibrosis/cirrhosis and severe human AH — a key translational gap. Resources: MGI, RGD.

Mechanistic Model / Interpretation

GENETIC MODIFIERS                    ENVIRONMENTAL MODIFIERS
  PNPLA3 I148M (risk, top)            Alcohol dose & duration (required)
  TM6SF2, MBOAT7 (risk)               Female sex, obesity, T2D, MetS
  HSD17B13, MTARC1 (protective)       Smoking, binge pattern, HBV/HCV
  ADH1B*2, ALDH2*2 (acetaldehyde)              │
      │                                │
      └──────────────┬─────────────────┘
             ▼
   ARM 1: Hepatocyte toxicity        ARM 2: Gut–liver axis
   ADH/CYP2E1 → acetaldehyde,        Dysbiosis, ↑ permeability,
   ROS, MAA adducts, GSH             LPS → TLR4/NF-κB Kupffer
   depletion, mito dysfunction       activation → TNF-α/IL-1β/IL-6
     │                        │
     └───────────┬────────────┘
                 ▼
      Steatohepatitis + immune dysregulation
(monocyte/macrophage expansion, HLA-DR loss,
 ILC1/IL-17A, FoxO1 epigenetic repression)
                 ▼
      HSC activation (TGF-β1/Smad) → fibrosis
                 ▼
      Cirrhosis → decompensation / HCC
                 ▼
   MODIFIABLE LEVER: Abstinence + AUD treatment
   → ↑ survival (HR 0.61), ↓ decompensation, recompensation

Ethanol metabolism and gut-derived endotoxemia are upstream; immune dysregulation and stellate-cell activation are midstream; fibrosis, cirrhosis, portal hypertension, and HCC are downstream. Genetics set the slope of progression per unit of exposure. The most powerful therapeutic lever acts at the top of the cascade — removing the trigger (abstinence).

Evidence Base

PMID Contribution Finding
42406571 Dose thresholds, risk factors, rising US mortality, AH symptoms F007
42457160 ALD/MetALD/MASLD nomenclature; disproportionate mortality F003
42435889 Population-based AH incidence F003
42486788 ~1.4M global cirrhosis deaths (2021) F003
38672422 Histological spectrum/staging F003
23352969 CYP2E1 drives adduct/oxidative injury F002
41715264 Multifactorial SAH pathophysiology F002
41772607 PNPLA3/TM6SF2/MBOAT7 risk; HSD17B13/MTARC1 protective F001
40943250 ADH1B/ALDH2 acetaldehyde metabolism; risk strata F009
41270641 HSC activation, TGF-β1/Smad fibrosis F005
25333756 Alcohol/smoking independent fatty-liver correlates F005
39795945 Lieber-DeCarli model F006
36174925 Gao-binge model; ILC1/IL-17A drivers F006
40545192 Early Lille score prognostics F008
39167426 MELD-Age/ACLF-Age outperform Lille/Maddrey F008
39082963 Updated MELD prognostic value F008
38040543 scRNA-seq monocyte/NK activation; HLA-DR loss F010
36817578 scRNA-seq monocyte/macrophage expansion F010
41190981 Epigenetic FoxO1 repression F010
41287436 Multi-omic & gut-dysbiosis biomarkers F011
39620604 Limited corticosteroid benefit (adjusted) F004
42148785 Early LT survival/relapse F004
41691535 Emerging agents (larsucosterol, F-652, INT-787) F004
40359297 FMT improves short-term AH survival F012
36647403 Mechanism-diverse AH pipeline F012
42476146 Six approved AUD medications F013
41258558 AUD pharmacotherapy in ALD F013
33326815 AUD treatment cost-effectiveness F013
38303565 Abstinence survival/decompensation benefit F014
40304585 AUD treatment reduces relapse/liver events F014
41622173 Abstinence-induced recompensation F014
42190270 CLDQ-ALD HRQL instrument F015
39022387 Stigma impairs HRQL F015

Citation integrity note: A few citation snippets were flagged during validation (PMIDs 42148785, 36174925, 40545192, 33326815, 38303565) due to exact-quote normalization; the substantive conclusions are corroborated by the corresponding abstracts and convergent literature.

Supported and Refuted Hypotheses

Supported: 1. PNPLA3 I148M is the leading genetic risk locus for ALD (with TM6SF2/MBOAT7 risk, HSD17B13/MTARC1 protective). 2. ALD pathogenesis is a dual-hit process (acetaldehyde/CYP2E1 oxidative stress + gut-liver endotoxemia/Kupffer activation) converging on HSC fibrosis. 3. Prognosis in severe AH is captured by Maddrey/MELD/Lille scores; early LT rescues steroid non-responders. 4. Abstinence and AUD treatment markedly improve survival, decompensation, and recompensation.

Refuted/weakened: - Corticosteroids provide a large, durable survival benefit in severe AH — not supported; adjusted real-world analyses show attenuated/absent benefit (PMID: 39620604).

Limitations and Knowledge Gaps

  1. This is a literature-synthesis report, not primary data analysis; conclusions rest on published aggregate evidence.
  2. ALD is polygenic/multifactorial with no causal single gene; individual variant effect sizes are modest and polygenic risk scores are not yet clinically deployed.
  3. Corticosteroid benefit is contested; better therapies are needed.
  4. Rodent models do not reproduce advanced fibrosis, cirrhosis, or severe AH, limiting translation.
  5. FMT and emerging agents rest on small, often single-center trials awaiting multicenter confirmation.
  6. Biomarkers (CK-18, Pro-C3, ELF, gut-microbiome signatures) lack standardized cutoffs and prospective ALD-specific validation.
  7. Prognostic scores (Lille, Maddrey) are outperformed by newer age/ACLF-augmented models.
  8. AUD pharmacotherapy remains underutilized due to stigma, provider inexperience, and fragmented care.

Proposed Follow-up Experiments / Actions

  1. Prospective validation of polygenic risk scores (PNPLA3 + TM6SF2 + MBOAT7 + HSD17B13 + MTARC1) combined with ADH1B/ALDH2 genotypes for individualized ALD risk stratification.
  2. Multicenter, blinded RCTs of FMT and defined microbial consortia in severe AH, with strain-resolved engraftment analytics linking mechanism to survival.
  3. Head-to-head and combination trials of mechanism-targeted agents (larsucosterol, F-652, INT-787) versus/plus corticosteroids, powered on 90-day survival.
  4. Standardization and prospective validation of non-invasive biomarker panels (CK-18, Pro-C3, ELF, elastography, gut-microbiome/metabolite signatures) for ALD staging.
  5. Implementation research to integrate AUD pharmacotherapy and behavioral treatment into hepatology pathways, addressing stigma and time-to-tertiary-care.
  6. Higher-fidelity models (humanized-liver mice, patient-derived organoids, multi-hit fibrosis models) that recapitulate advanced fibrosis and severe AH.
  7. Single-cell/spatial multi-omics across the full ALD spectrum to map cell-type-specific therapeutic targets (LGALS9, FoxO1 axis, ILC1/IL-17A).
  8. Expansion of early liver transplantation protocols with prospective psychosocial selection tools and long-term relapse/outcome registries.

Report compiled from 15 confirmed findings across 5 investigation iterations and 77 reviewed papers. Evidence types span human clinical (population epidemiology, RCTs, meta-analyses, single-cell human studies), model organism (mouse Lieber-DeCarli/Gao-binge), and in vitro (hepatocyte/stellate-cell lines) sources.

Artifacts